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INTRODUCTION 
 Siddha system of medicine is an ancient, and holistic medical system among all system 
of medicine in the world, it was founded by siddhars who were spiritual and efficient scientists. 
The term siddha comes from the word siddhi which means attainment of perfection. 
   Medicine is all about preventing and treating ailments thus postponing death. An 
interesting aspect of siddha system of medicine is its view about death. Thirumoolar defines the 
ailments of the body and mind as diseases. In the same breath he defines death as disease and 
hence could be prevented. 
               ÁÚôÀÐ ¯¼ø §¿¡ö ÁÕó¦¾ÉÄ¡Ìõ 
       ÁÚôÀÐ ¯Ç§¿¡ö ÁÕó¦¾Éîº¡Öõ 
       ÁÚôÀÐ þÉ¢ §¿¡ö Å¡Ã¡¾¢Õì¸ 
       ÁÚôÀÐ º¡¨ÅÔõ ÁÕó¦¾ÉÄ¡§Á 
                                       - ¾¢ÕãÄ÷ 
                One that cures physical ailment is medicine 
                One that cures psychological ailment is medicine 
                One that prevents ailment is medicine and 
                One that bestows immortality is medicine 
- Thirumoolar 
         
   A perfect health is the first step towards greater intellectual pursuits. According to 
Siddhars it is achieved by adhering to a very strict personal discipline. 
 
  Siddha system is the true knowledge of natural laws and remains forever. 
 
The human body is made up of five elements of nature namely Mann (Earth), Neer 
(water), Thee (Fire), Vayu (air), and Aagasam (Space).  
 
             The physiological function of the body is mediated by three vital humours namely 
Vatham, Pitham, Kabam. According to the siddha system of medicine, diet and life style play a 
major role not only in health but also in curing diseases. 
 
        Á¢¸¢Ûõ Ì¨ÈÂ¢Ûõ §¿¡ö ¦ºöÔõ á§Ä¡÷  
        ÅÇ¢Ó¾Ä¡ ±ñ½¢Â ãýÚ.             -ÌÈû 941 
          
     Excess or deficit of any action which produces more or less of the three humours 
beginning with Vali (wind) is reckoned by the authors of medical science to cause disease.   
 
              When the normal equilibrium of 3 humours is disturbed disease is caused. The factors 
which affect this equilibrium are environment, climatic conditions, diet, physical activities and 
emotions. 
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              Vellai noi (leucorrhoea) is one, which affects the women commonly and frequently. The 
natural vaginal discharge may vary considerably, especially under differing hormonal influences 
such as puberty, pregnancy or prescribed contraception. A sudden or recent change in discharge, 
especially if associated with alteration of color and smell, or vulval itch/ irritation is more likely 
to indicate an infective cause than gradual or long- standing change.  
 
Local epidemiology is particularly important when assessing possible causes. In the UK, 
most cases of vaginal discharge are not sexually transmitted, being due to either candidal 
infection or bacterial vaginosis. World-wide, the most common treatable Sexually Transmitted 
Infection causing vaginal discharge is trichomoniasis; other possibilities include gonorrhoea and 
Chlamydia. Herpes Simplex Virus may cause increased discharge, although vulval pain and 
dysuria are usually predominant symptoms. Non-infective causes include retained tampons, 
malignancy and/ or fistulae. 
 
Trichomoniasis is a cosmopolitan disease usually transmitted by sexual intercourse. It is 
estimated that 3 million women in the United States and 180 million worldwide acquire this 
disease annually, and 25% of sexually partners are also parasitized at least transiently. 
  
Trichomoniasis tends to cause a profuse yellow or green discharge and is usually 
associated with significant vulvo-vaginal inflammation. Diagnosis is made by observing motile 
flagellate protozoa on wet mount microscopy slide of vaginal material.  
 
  Vaginitis is the second most common gynaecological problem after menstrual disorders. 
It is a physical, social, emotional and economical problem. It is observed that 15-20% of vaginal 
infection is due to Trichomonas vaginalis (a protozoon). 
 
     Women must be educated to lead a healthy life. Then only they can make their family 
healthy.  
          
                  Women in reproductive age group and even young girls are commonly affected by 
vellai noi. 
 
                  As per siddha literature Agasthiyar gunvagadam (pgno; 269, poem 1081) Vellai noi 
(syn; Piramiyam, Piramegam) has been enumerated as per the following symptoms lower 
abdominal pain, purulent white discharge can be correlated with LEUCORRHOEA in modern 
science.   
                   Vaginal Infection is more common in women of childbearing age & in older women 
(post menopausal period). The factors like increasing age, illiteracy, low socioeconomic status, 
high parity, induced abortion & place of delivery are all contributing factors for occurrence of 
vaginal discharge. 
                   Siddha formulations not only treat this disease but also strengthen the entire female 
genital tract. We are receiving more number of Vellai noi cases in our OPD which is the driving 
force behind to select this topic for my dissertation study.  
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                    As preparation of the trial drug is cost effective efficacious & easily available. I 
have chosen Mega rajanga kirutham for the treatment of “VELLAI NOI 
(LEUCORRHOEA)‟‟.The below ingredients of MEGA RAJANGA KIRUTHAM(Internal), 
Athimathuram (Root of Glycyrrhiza glabra Linn),Naval pattai (stem bark of Lannea 
coromandelica Houtt), Karumbu rasam (Juice of Saccharam indicum Linn),Nellikai charu (Juice 
of Embelica officinalis Linn),Elumichai rasam (Juice of Citrus lemon Linn),Gingely oil, Ealam 
(Seed of Elettaria cardamomum Maton),Kirambu (Flower bud of Syzygium aromaticum 
Linn),Sathikai (Seed of Myristica fragrans Houtt),Citrarathai (Rhizome of Alpinia officinarum 
Linn), Nilapanai kizhangu(Root tuber of Curculigo orchioides Goertn), are found to cure Vellai 
noi as per Gunapadam Mooligai vaguppu. No clinical documentation on Mega rajanga kirutham 
in the treatment of Vellai noi has been found yet. So there is a need to evaluate the therapeutic 
efficacy of this classical Siddha formulation “MEGA RAJANGA KIRUTHAM” mentioned in 
Sigicha rathna deepam for scientific validation. 
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 AIM & OBJECTIVES 
  
 AIM  
              To find out the efficacy of Mega rajanga kirutham in the treatment of vellai noi. 
 
OBJECTIVES 
PRIMARY OBJECTIVE: 
             To evaluate the therapeutic efficacy of MEGA RAJANGA KIRUTHAM in the 
treatment of VELLAI NOI (LEUCORRHOEA) by using Wet test. 
  
 SECONDARY OBJECTIVE: 
 
  Reduction of clinical symptoms     
 To study the cofactors related to the disease (i.e., age, socioeconomic status) 
  To prepare the trial drug as per SOP drug preparation. 
 To evaluate the anti inflammatory activity. 
 To evaluate the anti microbial activity. 
 To evaluate the physico chemical analysis.  
 To evaluate the antioxidant activity. 
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SIDDHA ASPECTS 
 
       VELLAI NOI 
SYNONYMS: 
                       Pramiyam, pramegam, ozhukku vellai, Vettai noi, ven theettu. 
 
DEFINITION: 
                "¦º¡øÖ¸¢ýÈ §Å¨Ç ¾ýÉ¢ÄÊ ÅÂ¢üÈ¢ø ¾¡Ûõ 
                         ¦ºÂÄ¡¸ §Å¾¨É¨Â Ôñ¼¡ìÌõ À¡Õ 
                  Á¸ò¾¡É ¬ÏìÌ ¿£÷¾¡¨ÃÂ¢É¢ýÚõ  
                          
                          Á¸ò¾¡É ¦ÀñÏìÌ ƒÉÉ þó¾¢Ã¢Âó ¾ýÉ¢ø 
                  ¦¾¡øÖÄ¸¢ø º£ô§À¡Ä ¦ÅÙò¾ ¿£Ã¡ö  
                         ¦¾¡ôÀÉ§Å ÅÊ¸¢ýÈ §Á¸ ¿£ÕìÌ  
                  «øÄø¦ºöÔõ ¦Åû¨Ç¦ÂýÚõ ¦º¡øÅ¡÷ §Á§Ä¡÷" 
-  Agasthiyar Gunavagadam 
Lower abdominal pain, Pus like pale watery discharge from vaginal orifice in female & from 
urethral orifice in male is called as “Meganeer” or Leucorrhoea or Vellai noi. 
AETIOLLOGY: 
     I. ACCORDING TO AGASTHIYAR GUNAVAGADAM 
       "§¸Ç¼¡ À¢Ã§Á¸ ¯üÀò¾¢ ¾ý¨É 
         ¦¸½¢¾Ó¼ý ¦º¡øÖ¸¢ý§Èý ¿ýÈ¡ö §¸Ù 
     ¿¡É¼¡ ŠòÃ£§À¡¸õ «¾¢¸Ã¢ò¾¡Öõ 
         ¿ý¨ÁÔ¼ý §Á¡¸Ó¼ý ÀðÊÉ¢Â¡Öõ 
     Å¡Ç¼¡ Š¾õÀÉí¸û ¦ºöÅ¾¡Öõ 
         À¡Æ¼¡ «¾¢¸Á¡ö Òº¢ôÀ¾¡§Ä 
     À¡í¸¡É À¢Ã§Á¸ó §¾¡Ïõ À¡§Ã" 
1) Repeated sexual act 
2) Lustfulness with starvation 
3) Restraining the ejaculation of semen during sexual intercourse 
4) High intake of salty, spicy &astringent foods. 
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II. ACCORDING TO THIRUMOOLAR KARUKKADAI VAITHYAM 600 
               
'' «ýÉõ À¢Èó¾Ð «¨ÉòÐ Å¢¨¾Â¢Öõ 
  ÁýÉ¢Â ¦Åð¨¼ Á¸¡º£¾õ þÃñÊÉ¡ø 
  ÀýÉ¢ «È¢ó¾¢¨¾ô À¡÷À¡÷ ¦ÀÃ¢§Â¡÷¸û 
  ¸ýÉ¢ ÁÂì¸ò¾¡ø ¸ñÊÎõ §Á¸§Á'' 
''§Á¸õ À¢Èó¾ Å¢¾ó ¦º¡ýÉ¡ ¦Ãó¿ó¾¢ 
 ¬õÁ¢Çò¨¾ô ÀÕÅÁ¾¢ø §Á¡¸¢òÐõ 
 §À¡¸ó¾¢Éï ¦ºöÂ¢üÒ¸ú Áó¾ò§¾ ÜÊø 
 Å¡¸ô Àº¢Â¡ø ÅÆí¸ï ¨º§Â¡¸§Á'' 
''¨º§Â¡¸õ ¦ºöÂò ¾É¢ò¾ ÍÆ¢§Â¡Îõ 
 ³Â¡ «Á¢÷¾õ «¼ì¸¢ì ¸É§ÄÚõ 
 ¦ÁöÂ¡¸ Å¢óÐÅ¢Æô Òñ½¡Ìõ 
 ¨ÁÂ¡É §Á¸õ ÅÇÕí ¸¢Ãó¾¢§Â'' 
III. ACCORDING TO AGASTHYAR VAITHYA KAAVIYAM 1500: 
                    ''§¸ÇôÀ¡ ¦Åð¨¼ À¢ò¾õ ¦¸ÊÂ¡É Å¡¾õ Å¡ö×  
                Å¡ÇôÀ¡ ¨ÅÂïº£¾õ ÅÇ÷ó¾¢Îõ «ýÉò¾¡§Ä  
            À¡ÇôÀ¡ «ýÉó¾¡Ûõ À¨¸Ô¼ý ÀÆ¢Ôõ ¦¸¡ûÙõ 
 §ÅÇôÀ¡ «ýÉò¾¡§Ä §Á¸í¸û À¢Èô¨À §¸Ù''-Poem35 
   §Á¸ ¯üÀò¾¢:            
            ''§Á¸í¸û À¢ÈóÐ ¿¢ýÈ Å¢¾í¸¨Ç Å¢ÇõÀì §¸Ù 
     ¬¸í¸û þ¸úó¾§À¡Ð «ôÀ§É ¾¢ÉÓõ ¦ºýÈ  
§À¡¸í¸û ¦ºöÔõ §À¡Ðõ Ò¸úÁó¾õ ÜðÎõ§À¡Ðõ 
     À¡¸í¸û Àº¢ÂëÎõ ÀÕÌï ¨º§Â¡¸ó¾¡§É 
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¨º§Â¡¸ï ¦ºöÔõ §À¡Ðõ ¾É¢¿¢ýÈ ÍÆ¢§Â§Â¡Î 
     ¨ÁÂ§Å¡ «Ó÷¾ó¾ý¨É «¼ì¸¢§Â «Éø¾¡ý 
¦ÁöÂ¼¡ Å¢óÐ¸¡½¢ø Å¢ÆÅ¢Æô ÒñÏó¾¡Û 
      ¨ÁÂ¼¡ §Á¸ò¾¡§Ä ÅÇ÷ó¾Ð ¸¢Ãó¾¢À¡§Ã'' – Poem 36 
              Insulting and reticulating the sacred books, Excessive sexual act, having sex 
during indigestion & hungry and suppressing the ejaculating of semen during sexual act cause 
Mega noi. 
IV. ACCORDING TO YOOGIMUNI:  
''þÂõÀ§Å ±Ç¢§Â¡¨Ã Â¢¸úîº¢ ¦º¡øÄø 
     ²üÈÁ¡õ ¦ÀÃ¢§Â¡¨Ã ²Åø ¦¸¡ûÇø  
ÒÂõÀ§Å ¦À¡ýÈ¨É§Â §º¡Ãï ¦ºö¾ø 
     ¦À¡Õû¾¨É§Â À¸¢÷ò¾ø ¦ÀÕ¨Á ¦º¡øÄø 
¿ÂõÀ§Å ¿õÀ¢É¡÷ìÌ ¿ð¼ï ¦ºö¾ø 
     ¿¡ð¼Á¡ ±ó§¿ÃÓõ ¦Àñ §À¡¸¢ò¾ø 
ÀÂõÀ§Å ÀÂóÐ Åó¾ §À¨Ãì ¸¡ð¼ø 
     ÀÆ¢ò¾ §À¡÷ À¢ÃÁ¢Âò¾¢ü À¡¼¡§Á 
À¡¼¡¸ ¦Àñ §À¡¸ Á¢¸Å¢ÕõÀ¢ô 
     ÀÂ¢ýÈ¢ðÎô ÀðÊÉ¢§Â Á¢¸Å¢Õò¾ø 
¾¡¼¡¸ò ¾ý À¡¾ò¾¢ø ÝÎ ¾¡í¸ø  
     ºÃºÁ¡öì ¸¡Ãò¨¾ Á¢¸ô ¦À¡º¢ò¾ø 
°¼¡¸ ¯ôÒ¨ÃôÒò ÐÅ÷ôÒ Á¢ïºø 
     ¯ì¸¢ÃÁ¡õ ÀÄÀÄÅ¡õ Å¢§º¼õ ¦ºö¾ø 
¸¡¼¡É ÁÉì¸¢§Äºõ ¸¡ÃÁ¡É 
     ¨¸ò¾§Ä¡Î Á¢Õì¸Ä¢Ð¸¡Ïí ¸¡§½''  
                        -Yoogimuni vaidya chinthamani 800 
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1. Riduculating the downtrodden. 
2. Commanding elders  
3. Filching gold 
4. Filfering others things 
5. Self boasting 
6. Bringing loss to others 
7. Being thoughts of sexual intercourse always 
8. Starvation for longtime 
9. Walking without foot wear 
10. Increased intake of spicy food, salty food, and astringents, pungents and bitter tasty foods. 
 
V. According to T.V. Sambasivam pillai the chief causes of disease is 
o Venereal disorder,  
o Intemperate habits,  
o Improper dietary Habits,  
o Conceptional Defects, 
o Any accidental Happening, 
o Prostitution. 
VI. According to Magalir Maruthuvam (pg No.124) 
1. Due to Physiological factors, 
2. Altered Sexual Indulgence causes Vellai noi. 
TYPES AND CHARACTERS OF VELLAI NOI  
ACCORDING TO AGASTHIYAR VAITHYA KAAVIYAM 1500: 
 
Å¡¾ §Á¸õ ÁüÚõ §ºòÐÁ §Á¸õ: 
 
               ''Å¢ÕõÀ¢Â º¢¨Ä¾¡Ð×õ ¦ÅÙò¾¢Êø Å¡¾§Á¸õ 
                    ÁÕõÀ¢Â ¯‰½ó¾¡Ûõ ÁÂ¢Ä¾ý ¿¢È§ÁÂ¡É¡ø  
               ¾¢ÕõÀ¢Â ¨ÅÂò¾¡§Ä §º÷ó¾¢Îõ §Á¸Á¡Ìõ 
                   ÍÕõÀ¢Â ãýÈ¡ÄôÀ¡ §¾¡ýÈ¢Îõ Ì½í¸û §¸§Ç.’’ 
-    Poem 51  
 
10 
 
  À¢ò¾ §Á¸õ:  
                ‘’¬îºôÀ¡ §Á¸õ §¸Ù «ôÀ§É ÀÂ¢ò¾¢Â §Ã¡¸õ  
                    ¿£îºôÀ¡ §Á¸ó¾ý¨É ¿¢ºï ¦º¡ý§Éý ¸¡Ï 
    ¸¡îºôÀ¡ Áïºû §À¡Äì ¸Å£½Æó¾ý¨É ¸ñ¼¡ø 
Å£îºôÀ¡ À¢ò¾§Á¸õ Å¢ÇõÀ¢É¡÷ Å¢ÕõÀ¢ì ¸¡§½’’ 
- Poem 50 
According to the color of vaginal discharge Mega noi divided in to three types. In Vaatha 
megam the discharge is white in color. In Pitha megam the discharge is yellow in color. In 
Sethuma megam the discharge is greenish blue in color.  
 
À¢ò¾ Å¡ö× §Á¸ò¾¢ø §º÷ó¾¡ø:  
  
               ''§¸ÇôÀ¡ À¢ò¾Å¡ö× ¦¸ÊÔ¼ý §ºÕÁ¡¸¢ø 
                    ¾¡ÇôÀ¡ »¡ÉÁ¡É ¾ÁÃ¢§Ä ¦ÂÃ¢òÐ§ÅÌõ 
               Å£ÇôÀ¡ ¿£¨Ãì¸ðÎõ Å¢Øõ¦À¡º¢ó ÐÇ¢ÔÁ¡Úõ  
À¡ÇôÀ¡ º¢Ä§¿Ãí¸û ÀÇ¢î¦ºÉ þÈíÌó¾¡§É.''- 
            Poem 52 
   In Mega noi, if there is pitha added then the symptoms are Burning sensation of vagina, 
absence of urination, drippling of urine, and sometimes pricking pain associated with 
micturition. 
Å¡ö× ´Ðí¸¢É¡ø:  
                ''¾¡¦ÉýÈ Å¡ö× ´Ðí¸¢É¡ø ¾ñÊ§Ä §¿¡×¾¡É¡õ 
                    Å¡¦ÉýÈ Áó¾ò¾¡§Ä Å¡ÔÅ¢ø ÒÌó§¾º¡Îõ 
                ¸¡¦ÉýÈ ±Ã¢îºø ¸¡Ïõ ¸øÄ¨¼ôÀ¡Ìõ À¢ý¨É  
                    Á¡¦ÉýÈ Å¡ÐÅ¡ö× ÁÕÅ¢Êø ¦Åû¨Ç ¸¡§½.'' – 
Poem 53 
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¦Åû¨Ç Á¢Ì¾¢Â¡É¡ø þÄðº½õ:  
 
            ‘’¦Åû¨Ç¾¡ý ¦Áò¾Å£Æ¢ø §ÁÉ¢Ôõ ¦À¡ÕÁ¢ì¸¡Ïõ 
                    ¸ûÇ§Á ºÃ£Ã¦ÁøÄ¡õ ¸ÚôÒ¼ý ¿ÃõÒ §Á¡Îõ 
              ¾ûÇ§Å ¾¡Ð¿ð¼ó §¾¸Ó Á¢Ì¾¢Ôñ¼¡õ 
¯ûÇÐ ¦º¡ý§É¡ ¿¡Ó ÓüÚ½÷óÐ «È¢óÐ ¦¸¡û§Ç.'' 
       –Poem 54 
          If the Vaginal discharge is increased, then the symptoms are Body pain, blackening 
of skin, prominent veins on the skin, infertility present.  
MUKKUTRAIYAL (PATHOLOGY): 
       Certain extrinsic and intrinsic factors are said to be causative factors, which alter the 
equilibrium of tridosha and produce the disease. Among the mukkutram, Pitham is the chief 
factor. 
According to Theraiyar 
                  
   "À¸÷À¢ò¾ Å¢ó¨¾ÂÄ¡Ð §Á¸õ ÅÃ¡Ð" 
     Ref. Noinadal Noimuthal nadal Part 1. 
         It denotes that alteration of pitham causes Mega diseases. Altered pitham affects Abanan, 
viyanan and devadhathan  
        Affected abanan alters the theyu pootham so it produces burning micturition, purulent 
discharge in the vagina, low back pain lower abdominal pain and constipation. 
        Affected viyanan and devadhathan alters the akaya pootham and leads to loss of appetite, 
fatigue, emaciation, itching on vulval region, sleep disturbances, and mental stress. 
 Diagnosis mainly related to three components namely  
1) Poriyalarithal 
2) Puzhanalarithal 
3) Vinathal 
Poriyalariyhal:  
“Pori” means Organ of Perception namely  
1) Skin  
2) Tongue 
3) Eyes 
12 
 
4) Ears 
5) Nose 
Pulanalarithal: 
“Pulan” means Object of Sense namely 
1) Touch 
2) Taste 
3) Vision 
4) Hearing 
5) Smell respectively. 
“Pori” and “Pulan” with that of Physician‟s “Pori” and “pulan”. 
Vinathal:    It is a method of enquiring about the details of the patient‟s complaints from his own 
words or from their attenders. 
These three components can be compared with that of interrogation and inspection. 
Besides this “Thottuparthal” (palpation) and Thattiparthal (percussion) are also used to examine 
the patients. 
Another important diagnostic method is “Envagai thervugal” 
  
"¿¡Ê ŠÀÃ¢ºõ ¿¡ ¿¢Èõ ¦Á¡Æ¢ Å¢Æ¢  
 ÁÄõ ãò¾¢ÃÁ¢¨Å ÁÕòÐÅÃ¡Ô¾õ" 
According to Agasthiyar 
 
"¦¾¡Ìì¸ÖüÚ «ð¼Å¢¾ô ÀÃ¢ð¨º ¾ý¨É 
 ÐÄì¸ÓÚõ ÀñÊ¾§É ¦¾Ç¢Å¡¸ô 
 ÀÌò¾È¢Â ¿¡Ê¨Â ¿£ À¢ÊòÐô À¡Õ 
 À¸¢÷¸¢ýÈ Å¡÷ò¨¾ô À¡÷ ¿¡¨Å À¡Õ 
 ÅÌì¸Ã¢Â §¾¸¦ÁÉò ¦¾¡ðÎô À¡Õ 
 ÅÇÁ¡É ºÃ£Ãò¾¢ý ¿¢Èò¨¾ô À¡Õ  
 º¸¢ì¸Ã¢Â ÁÄò¨¾ô À¡÷ ºÄò¨¾ À¡Õ 
 º¡÷ó¾ Å¢Æ¢¾¨Éô À¡÷òÐ ¦¾Ç¢Å¡ö ¸¡§½"  
–Agasthiyar vaithiya vallathi-600 
According to Agasthiyar Gunavagadam: 
  
 "¾Ã½¢ÔûÇ Å¢Â¡¾¢¾ý¨É Âð¼¡í¸ò¾¡ø 
   ¾¡ÉÈ¢Â §ÅñÎÅÐ Â¡§¾¡ ¦ÅýÉ¢ø 
 ¾¢Ã½¢Â§¾¡÷ ¿¡Ê ¸ñ¸û ºò¾ò§¾¡Î 
 §¾¸ò¾¢ÉÐ ŠÀÃ¢ºõ ÅÕ½õ ¿¡ìÌ  
   Â¢Ã½ ÁÄ ãò¾¢Ã Á¢¨Å¸ ¦ÇðÎõ 
      ½ÕÇ¡ø ¦ÀÃ¢§Â¡÷¸û À¡¾õ §À¡üÈ¢ô  
   ÀñÒ ¾ÅÈ¡Áø ÀñÊ¾ï ¦ºöÅ£§Ã" 
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According to Theraiyar: 
 
 "¦ÁöìÌÈ¢ ¿¢Èõ ¦¾¡É¢ Å¢Æ¢¿¡ 
 þÕ ÁÄõ ¨¸ìÌÈ¢" 
1) Naadi  
2) Sparism 
3) Naa 
4) Niram 
5) Mozhi 
6) Vizhi 
7) Malam 
8) Moothiram 
1.  Naadi:  
 Naadi is the main diagnosis scale of the siddha system. It can be felt at one inch below 
the wrist on the radial laterally by means of palpation with the tip of index, middle and ring 
finger corresponding to vatham, pitham and kabam. Normally these three vital forces exist in the 
ratio 1:1/2:1/4.  Derangement of this ratio leads to various disease entities. 
In Vellai Noi the following Naadi nadai are seen commonly Vatham, Pitham, Vathapitham, Pitha 
vatham and sometimes Kaba pitham may be present. 
 
According to sathaga naadi padalgal: 
 
Pitha naadi: 
 
"¯Ú¾¢ÔûÇ À¢ò¾ÁÐ §¾¡ýÈ¢ø ¦ÅôÒ 
  ¯ð½Å¡Ô Åò¾¢ÍÃ Á¾¢º¡Ãí¸û 
 ÁÈ¾¢Ô¼ý ¸¢Ú¸¢ÚôÒ ÀÂ¢ò¾¢Â §Ã¡¸õ  
  ÅÇ÷§º¡¨¸ ÂÆ¦ÄÃ¢× ¸¡ó¾ø ¨¸ôÒ 
 þÕ¾Âò¾¢ø ¸Äì¸ÁÐ ÁÈôÒ ¾¡¸õ 
  ±Øí¸É× §ÁÂ¨É× ÁÂì¸ ã÷î¨º  
 º¢È¢Ð¦ÀÕõÀ¡Î Ãò¾õ À¢Ã§Á ¸í¸û  
§º÷óÐ Á¢ÌÀ¢½¢ ÀÄ×ï º¢ÈìÌó ¾¡§É" 
 
Vaatha naadi: 
 
 "Å¡¾¦ÁÛõ ¿¡ÊÂÐ §¾¡ýÈ¢ø  
  º£¾Áó¾¦Á¡Î ÅÂ¢Ú ¦À¡ÕÁø ¾¢Ãðº¢ Å¡ö× 
 º£¾ÓÚí ¸¢Ã¡½¢ Á§¸¡¾Ãõ ¿£Ã¡¨Á 
  ¾¢ÃûÅ¡ö× Ý¨Ä ÅÄ¢¸ÎôÒò ¾£¨Ã 
 ¿£¾ÓÚí ¸¢ÕÁ¢ ÌýÁõ «ñ¼Å¡¾õ 
  ¿¢¨ÄÔõ ¿£÷ì¸¢Ã¢îºÃí¸û ¾óÐ§Á¸õ  
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 §À¾¸Á¡õ ¯¾Ãô À¢½¢ ãÄ§Ã¡¸õ 
  §Àº¦ÅÌÀ¢½¢¸Ù§Á ¦À¡ÕÇ¾¡§Á" 
 
Vaatha pitha naadi: 
 
 "¦À¡ÕÇ¡É Å¡¾ò¾¢ø À¢ò¾õ §º÷óÐ 
  ¦À¡ÕóÐ Ì½í¸Ç¡ Óð½Å¡Ô ºì¾¢ 
 ¦ºÃ¢Â¡¨Á ÒÇ¢ò§¾ôÀõ ¦À¡ÕÁø ¿£Ã¢ø  
  º¢ÅôÒÁÄõ À¢Êò¾ÖÕó ¾¡Ð ¿ð¼õ  
 ¸ÕÅ¡É §¾¸Á¾¢ø ¯¨Çîºø §º¡õÀø 
  ¨¸¸¡ø ¾È¢ôÒ ¿¡¸ºìÌ ÁýÉõ  
 ÀÃ¢Å¡É °ñÌ¨È¾ø Õº¢§¸¼¡¾ø  
  ÀÄ§¿¡Ôõ ÅÕò¾¢ ¨ÅìÌõ À¡íÌ¾¡§É" 
2. Sparisam:  
 Sparisam means touch. By touching the skin body temperature will be noted.  
In Vellai noi body temperature is slightly increased and maintained as low grade fever. 
3. Naa:   
  To rule out the color, coating and ulceration of the tongue.  
In Vellai noi the tongue may be dry and coated. If anaemia present then the color of the tongue is 
pallor. 
4. Niram:  
To rule out the color of the tongue, eyes face and skin etc. 
5. Mozhi: 
 To rule out the high or low pitched voice, Slurred speech or Incoherent speech, nasal 
speech, hoarseness of voice. 
 In vellai noi speech is normal and voice is medium pitched. 
6. Vizhi:  
 Both motor & sensory functions of eye will be noted. Burning sensation of eyes 
Lacrimation, irritation, colour are also noted under this heading.  
 In vellai noi sometimes burning sensation of eyes will be noted. 
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7. Malam:  
 Quantity, colour, odour, constipation, diarrhea, presence of blood and undigested matter 
in the stools can be find out. In vellai noi Constipation may be noted.   
8. Moothiram:  
"Åó¾¿£÷ì ¸Ã¢±¨¼ Á½õ Ñ¨Ã ±ïº¦Äý 
¨Èó¾¢ÂÖÇÅ¨Å Â¨ÈÌÐ Ó¨È§Â"   
-Theraiyar Neerkuri Neikuri Nool 
 Moothiram consists of Neerkuri (Niram, Manam, Edai, Nurai, and Enjal) and Neikuri. 
Neerkuri: 
 Niram  - It indicates colour of urine 
 Manam - It indicates the smell of urine 
 Edai  - It indicates specific gravity of urine 
 Nurai  - It indicates frothy of urine 
 Enjal  - It indicates quantity of urine  
In addition frequency of micturition, burning micturitions, any abnormalities and 
associated vaginal discharge can be found out. 
In vellai noi Burning micturition and painful micturition, and associated with purulent 
discharge can be noted. 
Neikuri: 
  "«ÕóÐÁ¡È¢Ã¾Óõ «Å¢§Ã¡¾Á¾¡ö 
 «·¸ø «Ä÷¾ø «¸¡Äçý ¾Å¢÷ó¾Æü 
 ÌüÈÇÅÕó¾¢ ¯Èí¸¢ ¨Å¸¨È  
 ¬Êì¸Äºò ¾¡Å¢§Â ¸¡Ð ¦ÀöÐ 
 ´ÕÓÜ÷ò¾ì ¸¨ÄìÌðÀðÎ ¿£Ã¢ý  
¿¢ÈìÌÈ¢ ¦¿öìÌÈ¢ ¿¢ÕÁ¢ò¾ø ¸¼§É"  
Ref: Theraiyar Neerkuri Neikuri Nool. 
 
Method: 
Prior to the day of urine examination the patient is advised to take a balanced diet and the 
quantity of food must be proportionate to his appetite and should have a good sleep. 
After waking up in the morning the first urine voided by the patient is collected in a glass 
container and is subjected to analysis with in 1 ½ hours. 
A drop of gingley oil is dropped in to container without shake. The nature of the neikkuri 
should be noticed in direct sunlight. 
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Observation 
 
I. Vatha neer :  
"«Ã¦ÅÉ ¿£ñÊý «·§¾ Å¡¾õ" 
 
When the drop of oil spreads like a snake it indicates Vatha neer. 
 
II. Pitha neer: 
"¬Æ¢§À¡ü ÀÃÅ¢ý «·§¾ À¢ò¾õ" 
 
When the drop of olil spreads like a ring it indicates pitha neer. 
 
III. Kaba neer: 
"Óò¦¾¡òÐ ¿¢ü¸¢ý ¦Á¡Æ¢Å¦¾ý ¸À§Á" 
 
When the drop of oil remains as that of pearl it indicates kabaneer.  
   
IV. Thontha neer: 
 
"«ÃÅ¢Ä¡Æ¢Ôõ ¬Æ¢Â¢ø «Ã×õ «ÃÅ¢ø ÓòÐõ ¬Æ¢Â¢ø ÓòÐõ 
    §¾¡üÈ¢ø ¦¾¡ó¾ §¾¡¼í ¸Ç¡§Á" 
 
 When the drop of oil shows two shapes enclosed within one another it indicates thontha 
neer. 
In vellai noi the neikuri spreads like a ring.  
 
Thinai (Land & Place):  
  
 The geographical distribution of the land is classified into five regions.  
 
1. Kurinji  -  Mountain and its surroundings. 
2. Mullai  - Forest and its surroundings. 
3. Marutham - Fields and its surroundings. 
4. Neithal  - Sea and its surroundings. 
5. Palai  - Desrt and its surroundings. 
 
Each region has its own character, which influence the inhabitants, physical, 
mental, economic, occupational and cultural activities. In each region some ailments are 
endemic based on the clinical features. Preventions and curative measures for these 
ailments are stated in medical literature. 
 
Kalam (Seasons):  
 
 With reference to the position of sun, the year is divided into six seasons as follows. 
 
1. Karkalam   - Aavani and Puratasi  (Aug-15 to Oct-14)                                                                  
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2. Koothir kalam   - Aypasi and Kaarthigai (Oct-15 to Dec-14)  
3. Munpani kalam   - Margazhi and Thai (Dec-15 to Feb-14) 
4. Pinpani kalam  - Maasi and Panguni (Feb-15 to April-14)    
5. Elavenil kalam  - Chithrai and Vaikasi (April-15 to June-14) 
6. Muthuvenil kalam  - Aani and Aadi  (June-15 to Aug-14) 
According to climatic conditions in every season changes will occur in the land water, 
plants, animals, and human beings which will modify the physiology and make them susceptible 
to certain specific diseases into account of these changes, siddhars have advised to follow certain 
measures in the form of diet, purgation, exercise etc. to avoid the onset of this disease.  
Udal vanmai:  
 Smartness, strength, vitality constitutes udal vanmai. It is classified into 3 types.  
1. Iyarkai vanmai  - Inherited immunity by birth. 
2. Kala vanmai   - Vitality that is generally found in different age 
3. Cheyarkai vanmai - Improvement of vitality obtained by good habits, physical 
exercise and proper diet. 
Mukkutrangal:  
 The anatomical and physiological units of the body that is vatham, pitham, and kabam are 
known as three vital forces. When they are affected then it is called as Mukkutrangal. Vatham is 
described as ten forms. Pitham and Kabam have been classified into five forms. 
Vatham: 
 The word vatham not only implies wind but also comprehensive all the phenomenawhich 
comes under the functions of the central and sympathetic nervous system. Ten types of vatham 
are 
1. Pranan 
2. Abanan  
3. Uthanan 
4. Viyanan 
5. Samanan 
6. Nagan 
7. Koorman 
8. Kirugaran 
9. Devathathan  
10. Dhanajayan 
In Vellai noi AbananViyanan and samanan are affected. 
 Affected Abanan produces burning sensation in the urethra, burning micturition, purulent 
discharge, pain in the lower abdomen, low back pain and constipation. 
 Affected Viyanan produces pain all over the body, loss of appetite, loss of weight, 
fatigue, itching, and altered sleep rhythm. 
 Affected Samanan produce loss of appetite. 
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Pitham: 
 Pitham does not essentially mean bile but signifies the function of the thermo genesis of 
heat production and metabolism, comprehensing in its scope. The process of digestion, 
colouration of blood and formation of various secretion and excretions which are either the 
means or the ends of tissue combustion. 
Five types of Pitham: 
1. Analagam 
2. Ranjagam 
3. Prasagam  
4. Alosagam 
5. Santhigam 
In Vellai noi Anarpitham, Rantagam were affected. Affected anarpitham produces loss of 
appetite. Affected Ranjagam produces pallor of eyes, skin and nail buds. 
Kabam: 
 Five types of Kabam are  
1. Avalambagam, 
2. Kilethagam,  
3. Pothagam, 
4. Tharpagam, 
5. Santhigam 
In Vellai noi Kilaethagam, tharpagam, and santhigam are affected. Avalambagam also 
affected due instability of other kabam. 
Affected Kilethagam causes loss of appetite. 
Affected tharpagam causes burning eyes. 
Affected Santhigam causes low back pain. 
Seven udal thathukal: 
They are the basic principles, which constitute entire body. 
1. Saram  
2. Senner 
3. Oon 
4. Kozhuppu 
5. Enbu 
6. Moolai 
7. Suronitham. 
In Vellai noi Saram, seneer, oon, kozhuppu, Moolai, suronitham are affected. 
Saram  -Loss of appetite, fatigue, dryness of skin. 
Senner  -Weakness of the bidy, Anaemia. 
Oon  -Back pain 
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Kozhuppu -Emaciation  
Moolai  -Oliguria, Burning sensation. 
Suronitham -Yellowish or white vaginal discharge. 
Differential diagnosis: 
Chronic cervicitis:  
By the use of contraceptive devices for longtime, inflammation occurs. 
Symptoms: 
Vaginal discharge, low back pain, dysuria, polyuria. 
 
Oopherities: 
Vaginal discharge, Lower abdominal pain, constipation, Increased Body 
temperature, coated tongue, Menorrhagia. 
 
 
 
MARUTHUVAM: (LINE OF TREATMENT) 
  
 "¯üÈ¡ý «Ç×õ À¢½¢ÂÇ×í ¸¡ÄÓí 
  ¸üÈ¡ý ¸Õ¾¢î ¦ºÂø" -ÌÈû 
 
The treatment should be based on the age; body built of the patient, the severity of the 
diseaseand the period of the ailment. In Siddha system of medicine, treatment is not onlyfor cure 
of disease, but also the prevention and improving the body condition after treatment. 
This is said as,  
o Kappu (Prevention) 
o Neekamn (Treatment) 
o Niraivu (Restoration of wellbeing) 
 
KAPPU (Prevention):  
  
 Siddha system has unequivocally stated that even during the time of conception. Some 
defects creep into fertilized embryo, which forms certain disease. Those diseases may be cured 
not only by medicine but by teaching the following habits. 
1. Teaching good moral habits. 
2. Avoid excessive sex indulgence. 
3. Avoid pre and extra marital sex. 
4. Avoid sex after taking oil bath and curd rice. 
5. Avoiding stress and anxiety. 
6. Always have good mental thoughts by doing meditation. 
7. Avoiding the use of unhygienic undergarments. 
8. Always wash the undergarments in a soap plus disinfectant solution. 
9. Avoid urinary infection by taking more water.  
10. Avoid increased intake of spicy, sour and salty foods. 
11.  Taking oil bath regularly. 
12. Taking laxatives once in 6 months. 
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13. Always do yoga practice and prnayamam according to their physical and mental 
conditions. 
 
Neekam:  
 According to Noi nadal and Noi muthal nadal a good physician should know the 
deranged kuttram and should treat the patient on the basis of altered kuttram. 
 
"ÓôÀ¢½¢ ÁÕÅ¢ÓÈ¢×¦¸¡û ÌÈ¢ô¨À 
  ¾ôÀ¡¾È¢Ôõ ¾ý¨ÁÔõ Å¡¾À¢ò¾¨ÅÂô À¢Ã¢¨ÅÔ Á¨Å¾¡õ 
  ²È¢Â¢Èí¸¢ þ¨½óÐ ¸ÄóÐ 
  Á¡È¢ Á¡È¢ ÅÕóÐ ¦ºö¨¸Â¡ü À¢½¢ 
  §¿÷¨ÁÂÈ¢óÐ ¿£ðÎ ÁÕó§¾ 
  º£Ã¢Â¾¡ ¦ÁÉî ¦ºôÒÅ÷ º¢ò¾§Ã" 
      -Ref: Noi naadal Noi muthal naadal part-1. 
The aim of treatment is based on  
   To bring the Tridosham to normal 
   To treat the disease according to the symptoms by internal drugs. 
For Regulating Tridosham: 
 
 "Å¢§ÃºÉò¾¡ø Å¡¾õ ¾¡Øõ 
  ÅÁÉò¾¡ø À¢ò¾õ ¾¡Øõ 
  ¿º¢Â «ïºÉò¾¡ø ¸Àõ ¾¡Øõ" 
 Vatha diseases can be brought down by “viraesanam”. For this laxatives and purgatives 
are given according to patient‟s tolerance to drug and also the severity of the disease should be 
assessed. 
 Pitha diseases can be brought down by giving “vamanam” (Emetics) and kabha diseases 
can be brought down by “Anjanam” and “Nasiyam”. 
 In vellai noi Vatham and pitham is affected. So purgative medicine will be administered 
on the first day or before starting the specific treatment. 
 
Medicine:  Mega rajanga kirutham - 4ml twice a day before food for a period of 9 days twice a 
month. 
 
Pathiyam:  
During the course of treatment, the patient is advised to follow certain precautions 
regarding diet and physical activities. This form of medical advice in siddha system of medicine 
is termed as “PATHIYAM” which is very important in sidha system of medicine. 
Pathiyam has been classified into itchapathiyam and kadum pathiyam 
Itchapathiyam:  
§¾¨ÃÂ÷ ¦ÅñÀ¡ 
"¯Ä¸¢Ä¢îº¡ Àò¾¢Âí¸ñ Ë÷ÜÃ Á¡í¸¡ 
ÂÄ¸¢É¨Áì ¸¡ö¦¸¡ò ¾Å¨Ã-¸Ä¸ÓÉ¢ 
Áó¾Å¨¸ ÜúôÀ¡ñ¼ Á¡¸Î¦¸û ¦Çý§È¡Ð 
Á£ó¾Å¨¸ Â£òÐñÀ §¾" 
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Íó¾Ã¡óó¾÷ ¬Ôû§Å¾ ¦À¡Ð Äì„½õ 
"¸Î¸¢¿üÈ¢Äò ¦¾ñ¦½öÜúô À¡ñ¼í¸û ¸¼¨Ä 
ÅÊÅ¾¡¸¢Â ¦¾íÌÁ¡ ÅÕì¨¸¿ü ¸¡Âõ 
ÁÊÅ¢Ä¡¾¦Åû ÙûÇ¢¦¸¡û Ò¨¸Â¢¨Ä ÁÐ¦Àñ 
þ¼ÐÀ¡¸§Ä¡ ¼¸ò¾¢¿£ì ¸¢¼Ä¢îº¡ Àò¾¢Âõ” 
    (Ref- Theraiyarvenba, suntharananthar ayul vetha pothu lakshanam in sigicharathna 
deepam pg 319,320). 
Kadum pathiyam:  
 "¸Î¨Á ¦ÂýÈ¢Î Àò¾¢Âõ ãÅ÷ÅÚò Ðñ¼ø  
  ¬¨¼Å¢Ä¡ ÁÚÀò¾¢ò ÐÅ÷ ÅÚò¾Õò¾ø 
  ¦¸¡Î¨Á ¦ºöÒÇ¢ ¾¨ÉîÍðÎ ÜðÊ¼ ÄýÈ¢ô 
  ÀÊÂ¢ø ¸ò¾Ã¢ º¢ìÌÃô À¢ïº¢¨Éô ÀÕ¸ø"   
Pathiyam (diet) for Pitha disease: 
Pathiyam for pitha disease as mentioned in pathartha guna chinthamni is as follows. 
 
"¦¸¡õÁðÊ Å¡¨ÆôÀýÉí ¦¸¡Øò¾¢Â ¸Ã¢Â¢§É¡§¼ 
 Å¢õÁ¢Â ¾ñ½£÷Å¢ð¼¡ý §Å¦ÃÛí ¸¢ÆíÌ º¡ó¾ï 
 ¦ºõ¨Á§º÷ ¦¿øÄ¢ÓûÇ¢ §ºÕÁ¢ø ÁÕó¦¾øÄ¡§Á 
 ¸õÁ¢Â Á¢ò¾¾¢üÌ ¸¡Ä¦Äý §È¡Ð Å¡§Ã" 
Niraivu (Restoration): 
 
1. Reassurances of recovery were given to every patient. 
2. Every patient was advised to follow strick diet restrictions, good moral behavior 
Diet and Advice:  
The following diet to be taken:  
  
 Drink adequate water 
 Leafy greens & vegetables 
 Lady‟s finger  
 Onion  
 Ginger  
 Steamed vegetables & vegetable salads 
 Riped bananas 
 Lemon or orange juice 
 Pears Black plums  
 Apple 
 Gooseberry 
 Dates  
 Fig fruit 
 Pomegranate 
 Grapes 
 Guava 
 Whole wheat 
 Brown rice 
 Milk 
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 Butter milk 
 Ghee 
  Fenugreek 
 Coriander seeds 
 Cumin seeds 
 
The following food should be avoided: 
 
 Bitter gourd 
 Chicken 
 Meat 
 Coconut 
 Jack fruit 
 Asafoetida 
 Mango 
 Brinjal 
 Sesbanian leaves 
 Mustard 
 Sesame 
 Tamarind 
 Eggs 
 Mushrooms 
 Bread 
 Sweets 
 White sugar 
 Tea 
 Coffee 
 Preserved cool drinks 
 Oily & fried foods 
 Sour foods 
 
Avoid: 
 
o Tobacco 
o Alcohol 
o Excessive lust 
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MODERN ASPECT  
ANATOMY OF THE FEMALE GENITAL TRACT  
 The female genital tract may be divided into the external and internal genitalia. The 
external genital organs are vulva and the vagina. The internal genital organs are uterus, cervix, 
fallopian tubes, ovaries and other supporting structures. 
The vulva:  
 The vulva comprises the following structures. 
1. The Mons Pubis 
2. The Labia Majora 
3. The Labia Minora  
4. The Clitoris 
5. The Vestibule 
6. The External Meatus 
7. Bartholin‟s glands 
8. The Hymen 
The Mons pubis:  
Mons pubis is a rounded eminence present in in front of the pubic symphysis. It is formed 
by accumulation of subcutaneous fat. It is covered with pubic hair. The hair bearing area has a 
nearly horizontal upper limit. 
The Labia majora:  
 Labia majora are two thick folds of skin enclosing fat. They form the lateral boundaries 
of the pudendal cleft. Their outer surfaces are covered with hair, and inner surfaces are stutted 
with large sebaceous glands. The larger anterior ends are connected to each other below the 
mons pubis to form the anterior commisure. The area between the posterior commisure and the 
anus which is about 2.5 cm long constitutes the gynaecological perineum. 
The Labia minora: 
 Labia minora are two thin folds of skin, which lie within the pudendal cleft. Anteriorly, 
each labium minus splits into two layers; the upper layer joins the corresponding layer of the 
opposite side to form the prepuce of the clitoris. Similarly the lower layers of the two sides join 
to form the frenulum of the clitoris.  Posteriorly the two labia minora meet to form the frenulum 
of the labia minora. The inner surface of the labia minora contains numerous sebaceous glands. 
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The clitoris:   
 The clitoris is an erectile organ, homologous with the penis. However, it is not traversed 
by the urethra. It lies in the anterior part of the pudendal cleft. The body of the clitoris is made up 
of two corpora cavernosa enclosed in a fibrous sheath and partly separated by an incomplete 
pectiniform septum. The surface of the glans is highly sensitive and plays an important role in 
sexual responses. 
The Vestibule:  
 The vestibule of the vagina is the space between the two labia minora. The external 
urinary meatus opens into it. The boat shaped Navicular fossa is situated in front of the 
fourchette and bounded in front by the hymen. 
Bulbs of the vestibule: 
 These are two oval bodies of erectile tissue that correspond to the two halves of the bulb 
of the penis. The bulbs lie on either side of the vaginal and urethral orifices, superficial to the 
perineal membrane. The tapering anterior ends of the bulbs are united in front of the urethra by a 
venous plexus, called the bulbar commisure. The expanded posterior ends of the bulbs partly 
overlap the greater vestibular glands. 
Greater vestibular glands of Bartholin: 
 Greater vestibular glands are homologous with the bulbourethral glands of Cowper in the 
male, but unlike them these lie in superficial perineal space at the vaginal orifice. They are 
overlapped by the posterior ends of the bulbs of the vestibule. Each gland has a long duct about 2 
cm long which opens at the side of the hymen, between the hymen and the labium minus. 
Hymen:  
 This is a membrane found in the lower part of vagina. An intact hymen is a sign of 
virginity. It has an opening for the menstrual flow. If the opening is absent in the hymen it is 
called imperforate hymen. Hymen is torn or ruptured during sexual act. 
The Vagina:  
 Synonyms: kolpos = vagina  
The vagina is a fibromuscular canal, forming the female copulatory organ. The term 
vagina means a sheath. The vagina extends from the vulva to the uterus, and is situated behind 
the bladder and the urethra, and in front of the rectum and anal canal.  
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Direction: 
 In the erect posture, the vagina is directed upwards and backwards with a slight 
forward convexity, making an angle of about 45 degrees with the uterus. However, these 
angulations vary with the condition of the bladder and rectum.  In the supine position, it makes 
an angle of about 75 degrees with the horizontal plane. 
Size and shape  
 The anterior wall of the vagina is about 8 cm and the posterior wall about 10 cm 
long. The diameter of the vagina gradually increases from below upwards. The upper end of 
vault is roughly 5 cm twice the size of the lower end (2.5cm). However, it is quite distensible and 
allows passage of the head of the foetus during delivery. The lumen is circular at the upper end 
because of the protrusion of the cervix into it. Below the cervix, the anterior and posterior walls 
are in contact with each other, so that the lumen is a transverse slit in the middle part, and is H – 
shaped in the lower part. In the virgin, the lower end of the vagina is partially closed by a thin 
annular fold of mucous membrane called the hymen. In married women the hymen is represented 
by rounded elevations around the vaginal orifice, the caruncular hymenale.  
Fornices of vagina:    
 The interior of the upper end of the vagina or vaginal vault is in the form of a 
circular groove that surrounds the protruding cervix. The groove becomes progressively deeper 
from before backwards and is arbitrarily divided into four parts called the vaginal fornices. The 
anterior fornix lies in front of the cervixand is shollowest. The posterior fornix lies behind the 
cervix and is deepest. The lateral fornices lay one on each side of the cervix. 
Arterial supply: 
 The vagina is a very vascular organ, and is supplied by the following arteries: 1) 
the main artery supplying it is the vaginal branch of the internal iliac artery. 2) In addition, the 
upper part is supplied by the uterine artery. The lower part by the middle rectal and internal 
pudendal arteries. Branches of these arteries anastomose to form anterior and posterior midline 
vessels called the vaginal azygos arteries. 
Venous drainage: 
 The rich vaginal venous plexus drains into the internal iliac veins through the 
vaginal veins which accompany the vaginal arteries.  
Lymphatic drainage:  
 Lymphatics from the upper one-third of the vagina drain into the external iliac 
nodes; from the middle one-third into the internal iliac nodes; and from the lower one-third into 
the medial group of superficial inguinal nodes. 
26 
 
Nerve supply:  
1) The lower one-third of the vagina is pain sensitive and is supplied by the 
pudendal nerve through the inferior rectal and posterior labial branches of the 
perineal nerve. 
2) The upper two-thirds of the vagina are pain insensitive and are supplied by 
sympathetic L1, L2 and parasympathetic segments S2, S3 nerves derived from 
the inferior hypogastric and uterovaginal plexuses. Sympathetic nerves are 
vasoconstrictor and parasympathetic nerves vasodilator. The fibers which 
accompany the vaginal arteriesc form the vaginal nerves.  
Structure of vaginal wall:  
The vaginal wall consists of 
1) Mucosa – Nonkeratinized stratified squamous epithelium 
2) Submucosal layer – Lamina propria- loose connective tissue. 
3) A Mucosal layer – Outer longitudinal & an inner circular layer 
4) Outer fibrous coat is the usual connective tissue. 
The Vaginal secretion:  
 The vaginal secretion is small in amount in healthy women, and consists of white 
coagulated material. The top layers are rich in glycogen and some of these squamous cells are 
shed and acted on by the gram positive Dodrelein bacilli present in the vagina, converting this 
glycogen into lactic acid. This action is responsible for maintaining the PH of the vagina around 
4.5 and preventing the growth of pathogenic organisms. Because of its protective function, the 
doderline bacillus is considered a vaginal police man. However with menopause and also prior to 
puberty and vaginal mucosa is thin and devoid of glycogen due to the absence of oestrogenic 
stimulus, and hence the PH of the vagina is alkaline.  
Normal vaginal flora: 
   The microflora of normal vaginal secretions is characterized by a predominance of lacto 
bacilli, primarly acidophilic lacto bacilli.  Usually an additional 5 to 15 bacterial species are also 
normally cultured from the vagina.  G.vaginalis can be found in >50% of normal healthy women. 
 The vaginal flora can be divided in to aerobic and anaerobic organisms. Common aerobic 
facultative organisms found include lacto bacilli, staphylococcus epidermis, streptococcal and G. 
vaginalis. The anaerobic organism commonly found includes bacteroides species, B.bivius and 
peptostreptococcus.  Mycoplasma hominis can be found in 20%- 50% and Ureaplasma 
urealyticum can be found in 50% to 70% of sexually active women.  In women with normal 
vaginal flora, lactobacillus species account for >95% of the total organisms present. 
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The Uterus: 
 
 The uterus is pyriform in shape. And it measures about 7.5cm×5cm×2.5cm.  It weighs 
about 30 to 40gms.  It is divisible in to upper expanded part called the body and a lower 
cylindrical part called the cervix.  The junction of these two parts is marked by a circular 
constricition.  The body forms the upper two thirds of the organ, and the cervix forms the lower 
one third.   
Normal position and angulation: 
 Normally, the long axis of the uterus forms an angle of about 90 degrees with the long 
axis of the vagina.  The angle is open forwards.  The forward bending of the uterus related to the 
vagina is called ante version.  The uterus is also slightly flexed on itself: this is referred to as ante 
flexion.  The angle of ante flexion is 125 degree.  Roughly the long axis of the uterus 
corresponds to the axis of the pelvic inlet, and the axis of the vagina to the axis of the pelvic 
cavity and of the pelvic outlet.   
Communications: 
 Superiorly, the uterus communicates of each side with the uterine tube, and inferiorly 
with the vagina. 
Body of the uterus: 
 The body has a fundus, two surfaces, anterior or vesicle. And posterior or intestinal; and 
two lateral borders.   
 The fundus is formed by the free upper end of the uterus.  The fundus lies above the 
openings of the uterine tubes.  It is convex like a dome.  It is covered with peritoneum and is 
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directed forward when the bladder is empty.  The fertilized oocyte is usually implanted in the 
posterior wall of the fundus. 
 The anterior or vesicle surface is flat and related to the urinary bladder.  It is covered with 
peritoneum and forms the posterior or superior wall of the uterovesical pouch. 
 The posterior intestinal surface is convex and is related to coils of the terminal ileum and 
to the sigmoid colon.  It is covered with peritoneum and forms the anterior wall of the recto 
uterine pouch. 
 Each lateral border is rounded and convex.  It provides attachment to the broad ligerment 
of the uterus which connects it to the lateral pelvic wall. The uterine tube opens into the uterus at 
the upper end of this border. This end of the border gives attachment to the round ligament of the 
uterus, anteroinferior to the tube; and to the ligament of the ovary posterinferior to the tube. The 
uterine artery ascends along the lateral border of the broad ligament. 
 In sagittal section, the cavity of the body of the uterus is seen as a mere slit because the 
uterus is compressed anteroposteriorly. In coronal section, the cavity is seen to be triangular in 
shape, the apex being directed downwards. At the apex, the cavity becomes continuous with the 
canal of the cervix.   The junction is called internal os.  
Cervix of the uterus: 
 The cervix is the lower cylindrical part of the uterus. It is about 2.5cm long. The lower 
part of cervix projects into the anterior wall of the vagina which divides it into supravaginal and 
vaginal parts. 
 The supravaginal part of the cervix is related a) Anteriorly to the bladder; b) Posteriorly 
to the rectouterine pouch, containing coils of intestine and to the rectum and c) on each side, the 
ureter and to the uterine artery, embedded in parametrium. 
 The vaginal part of the cervix projects into the anterior wall of the vagina. The cervical 
canal opens into the vagina by an opening called external os. In nulliparous women the external 
os is small and circular. However, in multiparous women, the external os is bounded by anterior 
and posterior lips, both of which are in contact with the posterior wall of the vagina.  
 The cervical canal is fusiform shape. The walls of cervical canal shows mucosal folds 
which resemble the branches of a tree called the arborvitae uteri. The folds in the anterior and 
posterior walls interlock with each other and close the canal. 
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Ligaments of the uterus: 
Peritoneal ligaments  
 These are mere peritoneal folds which do not provide any support to the uterus. 
1) The anterior ligament consists of the uterovesical fold of peritoneum. 
2) The posterior ligament consists of the rectovaginal folds of peritoneum. 
3) The right and left broad ligaments are folds of peritoneum which attach the 
uterus to the pelvic wall. 
The broad ligament contains the following structures.  
1) The uterine tube. 
2)  The round ligament of the uterus.  
3) The ligament of the ovary. 
4)  Uterine vessels near its attachment to the uterus. 
5) Ovarian vessels in the infundibulopelvic ligament. 
6) The uterovaginal and ovarian nerve plexuses. 
7) Epooophoron.  
8) Paroophoron. 
9) Some lymph nodes and lymph vessles. 
10) Dense connective tissue or parametrium present on the sides of the uterus. 
Fibro muscular ligament  
 The fibro muscular ligaments are: 1) Round ligaments of the uterus, 2) transverse 
cervical ligaments 3) Utero sacro ligaments.  
Arterial supply: 
The uterus is supplied by two uterine arteries and the ovarian arteries. The uterine artery 
is a branch of the anterior division of the internal iliac artery. Apart from the uterus the artery 
also gives branches to vagina, medial two thirds of the uterine tube the ovary the ureter and the 
structures present in the broad ligament.  
Venous Drainage:  
The veins form a plexus along the lateral border of the uterus. The plexus drains through 
the uterine, ovarian and vaginal veins into the internal iliac veins. 
Lymphatic drainage: 
 Lymphatics of the uterus begin at three inter communicating networks, endometrial, 
myometrial and subperitoneal. These plexuses drain into lymphatics on the side of the uterus. Of 
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these, the upper lymphatics from the fundus and upper part of the body drain mainly into the 
aortic nodes, and only partly to the superficial inguinal nodes along the round ligament of the 
uterus. The lower lymphatics from the cervix drain into the external iliac, internal iliac and sacral 
nodes. The middle lymphatics from the lower part of the body drain into the external iliac nodes. 
Nerve supply: 
 The uterus is richly supplied by both sympathetic and para sympathetic nerves, through 
the inferior hypogastric and ovarian plexuses. Sympathetic nerves from T12, L1 segment of 
spinal cord produce uterine contraction and vasoconstriction. The parasympathetic nerves (S2, 
S3, and S4) produce uterine inhibition and vasodilatation. Pain sensation from the body of the 
uterus passes along sympathetic nerves, and from the cervix, along the parasympathetic nerves. 
The structure of the uterus:  
The wall of the uterus consists of 3 layers. 
1) Outer peritoneal coverings or Perimetrium. 
2) The middle muscular layer or Myometrium. 
3) The inner mucosa or Endometrium.  
Perimetrium: 
 It is incomplete. Anteriorly the whole body of the uterus is covered with peritoneum. The 
peritoneum is reflected on the bladder at the level of the internal os.  
 Posteriorly the whole of the body is covered by peritoneum. Laterally peritoneum is 
incomplete because of the insertion of the fallopian tubes, the round and ovarian ligaments into 
the uterus. 
Endometrium:  
 The endometrium is the special epithelial lining. The surface of the epithelium is made up 
of glands and stroma. The endometrium varies in thickness during menstrual cycle and forms 
decidua during pregnancy in response to the hormones. The endometrium of the body of the 
uterus can be divided into two zones; a superficial termed the functional layer, and a deeper one 
termed the basal layer, which lies adjacent to the myometrium.  
 The vascular system of the endometrium is of great importance. Two types of arteries 
supply the endometrium. One of these is restricted to the basal third and consists of small straight 
and short arteries. The superficial two thirds of the endometrium are supplied by coiled arteries.  
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Myometroium: 
 It is the thickest of the 3 layers of the wall of the uterus. It again consists three layers.  
1) Outer longitudinal layer, which has a detrusor action during labour.  
2) The middle thick vascular layer which by virtue of its being arranged in a figure of 
eight around the vessels has a haemostatic effect to prevent post-partum hemorrhage. 
3) The inner circular layer, which is seen mostly around the tubal orifices, the internal 
and external os and probably, has a sphincteric action. 
Supporting structures of the uterus:  
1) Broad Ligament:  
It stretches the lateral border of uterus wall of pelvis, they encloses the uterus. 
Along the upper border of broad ligament and fallopian tubes are situated to the 
posterior wall of ligament the ovaries are attached. Lower border of ligament is 
related to the floor of the pelvis. 
2) Round Ligament: 
One on each side of the uterus. They pass to the side of pelvis through the 
inguinal canal to end by fusing the majora. 
3) Two uterosacral ligament: 
Originate from the posterior part of cervix and vagina pass backward one on each 
side of rectum to the sacrum. 
4) Transverse cervical or cardinal or Mackendrort‟s ligament: 
Originate from side of the cervix and vagina pass to the side of pelvic wall. 
 
5) Pubocervical Fascia:  
It extends forward from transverse cervical ligaments on each side of the 
bladder to the posterior surface of pubic bone. 
Blood supply of Uterus: 
 Uterus is supplied by uterine arteries and branch of internal iliac artery. Venous plexus of 
uterus drain into internal iliac vein. Deep and superficial lymphoid of uterus open into aortic 
lymphnodes. 
Fallopian tubes or Oviducts: 
 It lies in the free border of broad ligament. This part is called as mesosalpinx. It is 10 cm 
in length. Its lateral end opens into peritoneal cavity through its abdominal ostium. 
Parts:  
 It consists of four portions. 
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1) Infundibulum:  
Lateral end of the uterine tube is funnel shaped is called as infundibulum. It has a 
finger shaped process called fimbriae. One of the fimbriae is longer than other fimbriae 
are attached to the ovary. It is known as ovarian fimbriae. 
2)  Ampulla: 
The part, medial to the infundibulum is called ampulla. It is the longest and 
largest part of the uterine tube. Fertilization normally occurring in ampulla. After that the 
zygote moves towards the fundus of uterus within 72 hours. 
3) Isthumus:  
The part, medial to the ampulla is called as isthumus. It is narrow rounded part. It 
forms medial one third of uterine tubes. 
4) Intramural part:  
It is 1 cm long, lies within the uterine wall. It opens into uterine cavity by uterine 
ostium. 
Functions of the tube: 
1) Conduction of ovum from ovary. 
2) Conduction of sperm 
3) Fertilization and formation of zygote occurs in the tube. 
4) Migration of zygote.  
If the tube is blocked by disease or ligation leads to sterility. Sometimes the block 
may be partial and the fertilized ovum may get arrested in the tube or sometimes 
fertilized ovum does not reach the uterus within72 hours. So the zygote develops in the 
tube, resulting in tubal pregnancy. It may leads to rupture of the tube. 
Blood supply of the tube:  
 Supplied by uterine artery and lateral part of tube is supplied by branches of ovarian 
artery. Lymph nodes are drain in to pre aortic nodes. 
The ovary: 
 Ovaries are female gonads. They correspond with testis of male. The ovaries are two in 
number. They lie on either sides of the uterus. The ovaries are attached to the broad ligaments of 
the uterus. Each is an ovoid structure about 3.5cm×2cm×1.5cm. 
Structure and functions of the ovary: 
 The ovary is covered by germinal epithelium. It consists of cortex and medulla. The 
cortex has ovarian follicle. One follicle matures every month and this matured ovarian follicle is 
known as graffian follicle. The ovum is released by the rupture of the follicle. Liberation of an 
ovum from the ovary is called ovulation. It occurs on or about the 14
th
 day of a 28
th
 day 
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menstrual cycle. After the ovum is liberated the ovarian follicle is converted into a 
structurecalled the corpus luteum. 
 The hormone oestrogen is secreted by the cells present in wall of the ovarian follicles. 
Another hormone, progesterone is produced by the corpus luteum. 
 The medulla of the ovary is vascular and it has soft tissue and blood sinusoids. 
 
 LEUCORRHOEA  
DEFINITION:   
The term leucorrhoea should be restricted to those conditions when the normal vaginal 
secretion is increased in amount. In such patients there will be no excess of leucocytes present 
when the discharge is examined under the microscope, and the discharge is macroscopically and 
microscopically non-purulent. 
 Leucorrhoea is strictly defined as an excessive normal vaginal discharge.  The symptom 
of excessive is a subjective one with individual variations, while to declare it to be normal and 
not an infective one, requires clinical and laboratory investigations. 
               The term Leucorrhoea should fulfil the following criteria:  
The excess secretion is evident from persistent vulval moistness or staining of the undergarment 
(brownish yellow or drying) or need to wear a vulvalpad.                                                                                                                                                                         
It is a non-purulent and non-offensive. It is non-irritant   and never causes purities. 
PATHO PHYSIOLOGY:  
           Normal vaginal secretion:  
                             The origin and nature of the normal vaginal secretion during the reproductive 
period has been described below. 
                          The physiologic basis involved in normal vaginal secretion is dependent on the 
endogenous estrogen level.  With the rising estrogen level, there is abundant secretory activity of 
the endo cervical glands and the superficial vaginal epithelium becomes rich in glycogen. 
                            The mucoid secretion from the cervical glands is normally small in amount. 
The carbohydrate radicle of the glycoprotein mucin is split off and fermented into lactic acid. 
If however, the mucus is secreted in excess, it pours out at the vulva. 
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The excessive secretion is due to: 
 Physiological excess 
 Cervical cause (Cervical leucorrhoea) 
 Vaginal cause (Vaginal leucorrhoea) 
Physiologic excess: 
During puperty:     Due to increased level of endogenous oestrogen. 
During Menstrual cycle: Around ovulation- peak rise of oestrogen-increase in secretory activity 
of the cervical glands.  Premenstrual pelvic congestion and increased mucus secretion from the 
hypertrophied endometrial glands.  
Pregnancy: There is hyperoestrinism with increased vascularity. This leads to increased vaginal 
transudate and cervical gland secretion.  
During sexual excitement: When there is abundant secretion from the Bartholin glands. 
CERVICAL CAUSE:  
Mucous discharge from the endocervical glands increases in such conditions as chronic 
cervicitis, cervical erosion, mucous polyp, and ectropion (cervical glands are exposed to the 
vagina). When the mucous secretion of the cervix is produced in excess, it undergoes little 
change in the vagina, and appears as mucoid discharge at the vulva. 
VAGINAL CAUSE: 
This form of leucorrhoea is seen when the discharge originates in the vagina itself as a 
transduction through the vaginal walls. Almost all the lactic acid of the healthy vagina is formed 
from the glycogen contained in the keratinized cells of the vaginal mucosa and the vaginal 
portion of the cervix.  
These cells are constantly being desquamated, when their glycogen liberated is fermented 
by Doderlein‟s bacilli, which produces lactic acid. This process is under the control of oestrogen, 
the level of which determines the PH of the vagina.  
Local congestive states of the pelvic organs such as pregnancy, acquired retroversion and 
prolapsed congested ovaries, chronic pelvic inflammatory disease and even chronic constipation 
associated with a sedentary occupation are all reasonable causes of an increased vaginal 
secretion. 
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DIAGNOSIS: 
Vulval inspection reveals: 
                               White or creamy discharge and No evidence of pruritus  
Bimanual including a speculam examination reveals: 
                                  Either a negative pathology 
                                 Associated pelvic lesions mentioned earlier causing cervical or vaginal 
leucorrhoea. 
                                 To exclude the infective nature, the discharge is subjected to microscopic 
examination for detection of pus cells. If the pus cell is not detected, it is considered as a case of 
true leucorrhoea. If however pus cells are detected, further investigations are   to be carried out to 
identify the organism from the discharge provided neoplasm and foreign body are excluded  
These examinations include: 
 Hanging drop preparation 
 Clue cells  
 Gramstain 
 Culture 
SPECIFIC VAGINAL INFECTIONS 
 If the strict definition of leucorrhoea is accepted as an excessive vaginal secretion in 
which the primary cause is not infective, any vaginal discharge which is frankly purulent and 
contains pus cells and form which the causative organisms can be isolated and cultured should be 
considered as due to specific vaginal infection. 
Specific vaginal infection comprises 
1) Gonococcal 
2) Trichomonal 
3) Monilial 
4) Chlamydial and  
5) Bacterial vaginosis 
It is observed that 50% vaginitis is due to bacterial vaginosis, 20-25% vaginitis due to monilial 
infection and 15-20% due to trichomonal infection. Since most of these are sexually transmitted. 
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TRICHOMONIASIS   
                 Vaginal trichomoniasis is the most common and important cause of vaginitis in the 
child bearing period. In clinical practice, this is amongst the most common. Nearly half the 
patients who complain of pruritus vulvae harbour this organism. It is almost entirely a disease of 
childbearing era, though young girls and postmenopausal women are not at all immune.  
 There is no doubt that this infection is sexually transmissible but, in some instances, it 
can be acquired by an inadequate hygiene or the use of an infected person‟s towels, bath or 
clothes. Its ingress to the vagina is favoured by a low general resistance and when the PH is 
raised as during a menstrual period (pH 5-6). It is not uncommon during pregnancy and is often 
associated with gonococcal infection.   
Epidemiology:  
 Trichomoniasis is a cosmopolitan disease usually transmitted by sexual intercourse.  
 It is estimated that 3 million women in the United States and 180 million worldwide. 
Acquire this disease annually and 25% of sexually partners are also parasitized at least 
transiently. 
 Infection is rare in adult virgin, where as rates as high as 70% are seen among prostitutes, 
sexual partners of infected patients and individuals with other venereal diseases. 
 In women, the peak incidence of trichomoniasis is between 16 and 35 years of age, but 
there is still a relatively high prevalence in the 30 to 50 year age group.  
 Non venereal transmission is uncommon. Transfer of organisms on shared wash clothes, 
may explain, in part the high frequency of infection seen among institutionalized women. 
AETIOLOGY         
                                 TRICHOMONAS VAGINALIS 
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             The causative organism is Trichomonas vaginalis. It is a pear shaped unicellular 
flagellate protozoa. It is actively motile, slightly larger than a leucocyte and is anaerobic.  
Three types of trichomonas are known, namely, Tr.buccalis, which is a normal inhabitant 
of the mouth; Tr.hominis, a normal inhabitant of the anal canal and rectum; and Tr.vaginalis, 
which is found in the vagina. It has been shown by transplantation experiments that Tr.buccalis 
and Tr.hominis are unable to survive in the human vagina.   
Tr.vaginalis measures 20 micron long and 10 micron wide. It has got four anterior 
flagellae and a spear like protrusion at the other end with an undulating membrane surrounding 
its anterior two-third. It is actively motile.  
MODE OF TRANSMISSION:  
               The organism is predominantly transmitted by sexual contact. The male harbours the 
infection in the urethra and prostate. The transmission may also be possible by toilet articles 
from one woman to the other or through examining gloves. The incubation period is 3 to 28 
days.  
                In women the organism is found in the vagina, urethra, and para-urethral glands. While 
the urinary tract is the sole site of infection in less than 5% of cases, urethral infection is present 
in 90% of episodes. In adults, transmission is almost exclusively sexual. Due to site specificity, 
infection can only follow intra vaginal or intra urethral inoculation of the organism. 
 CLINICAL FEATURES: 
 Twenty percent remain asymptomatic; others develop symptoms 4-28 days following 
sexual contact with an infected partner, or infected material, like towel or toilet.  
  There is sudden profuse and offensive vaginal discharge often dating from the last 
menstruation. There is presence of urinary symptoms such as dysuria and frequency of 
micturition  
 10 to 50% of infected women are asymptomatic. In those with symptoms, these include 
vaginal discharge, vulval itching, dyspareunia, or offensive odour. Occasionally, the 
presenting complaint is lower abdominal discomfort. 
 Vaginal discharge occurs in up to 70% of case, varying in consistency from thin and 
scanty to profuse and thick.  
 The classical frothy yellow discharge occurs in 10 to 30% of women. Approximately 2% 
of patients will have strawberry cervix appearance to the naked eye.  
 Higher rates are seen on colposcopic examination. No abnormalities will be seen in 5 to 
15% of women on examination. 
 There is increasing evidence of that Trichomonas vaginalis infection can have a 
detrimental outcome on pregnancy, and is associated with preterm delivery and low birth 
weight.  
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PATHOLOGY: 
               In about 25% of women in the reproductive period, the parasite harbour in the vagina in 
asymptomatic state. When the local defense is impaired during and after menstruation, after 
sexual stimulation and following illness the pH of the vagina is raised to 5.5 -6.5. At this level of 
pH the trichomonads thrive. The organisms usually lie in between the rugae and produce surface 
inflammatory reaction when the defense is lost. In about 75% of cases the organism can be 
isolated from the urethra, skene‟s tubules or even from the Bartholin‟s glands. 
ON EXAMINATION:  
 There is thin, greenish yellow and frothy offensive discharge per vagina. 
 The vulva is inflamed with evidences of pruritus. 
 Vaginal examinations may be painful.  The vaginal walls become red and inflamed with 
multiple punctuate haemorrhagic spots. 
  Similar spots are also found over the mucosa of the portio vaginalis part of the cervix on 
speculum examination giving the appearance of straw berry. 
Complications: 
                   Some of the complications of T. vaginalis in women include: preterm delivery, 
low birth weight, and increased mortality as well as predisposing 
to HIV infection, and cervical cancer T. vaginalis has also been reported in the urinary 
tract, fallopian tubes, and pelvis and can cause pneumonia, bronchitis, and oral lesions.  
                  Trichomonas vaginalis infection in males has been found to cause asymptomatic 
urethritis and prostatitis. It has been proposed that it may increase the risk of prostate cancer. 
DIAGNOSIS:   
o Direct observation by wet mount or acridine orange staining is approximately 
70% sensitive compared with culture in females. Microscopy T.vaginalis should 
be performed as soon as possible after the sample is taken, as motility diminishes 
with time. 
o Identification of the trichomonads is done by hanging drop preparation. If found 
negative even on repeat examination, the conformation may be done by culture. 
o Culture of the discharge collected by swabs in Kupferberg‟s or Feinberg 
Whittington medium. 
o Culture techniques are still regarded as the most sensitive and specific. Culture 
media is varying in efficiency, but diamond TYM medium (Medium Tripticase, 
Yeast extract maltose) or modified version is among the best. 
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o PCR based diagnostic test s have been developed recently, and sensitivities and 
specificities approaching 100% have been reported. No PCR assay for T.vaginalis 
is currently on the market.  
o Trichomonads are sometimes reported on cervical cytology, however, a Meta 
analysis has shown that while it has good specificity, the weighted mean 
sensitivity was only 58%. In such cases it is prudent to confirm the diagnosis, 
preferably by culture of vaginal secretions. 
IDENTIFICATION OF ORGANISM IN SLIDE:  
                  The material is dropped over a slide and then mixed with one drop of normal saline. It 
is then covered with a coverslip. Actively motile trichomonas can be seen under microscopic 
easily. It can be effectively visualized after staining with 1% of brilliant cresyl violet, lucicytes 
and other bacteria will not take up the dye.  
  TRICHOMONAS VAGINALIS 
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CANDIDAL VAGINITIS 
 It is caused by yeast like micro organism called Candida or Monilia. The most common 
species causing human disease is Candida albicans, which is gram positive and grows in acid 
medium. It may be sexually transmitted. Almost 25% women harbour Candida in the vagina, 
these are often asymptomatic.   
CANDIDA ALBICANS 
 
Risk factors: 
 These include promiscuity, immunosuppression, and pregnancy, steroid therapy, 
following long-term broad spectrum antibiotic therapy, oral contraception pills, diabetes 
mellitus, poor personal hygiene and obesity. 
Clinical features: 
 Pruritus vulva is the cardinal symptom. It is often accompanied by vaginal irritation, 
dysuria, or both, and passage of thick curdy or flaky discharge.  
Speculum examination reveals vaginal wall congestion with curdy discharge often visible 
at the vulval mucocutaneous junction and in the posterior fornix.  
Diagnosis: 
 It is essentially based on clinical findings. But the diagnosis can be confirmed on 
microscopic examination of a smear of the vaginal discharge treated with 10% KOH solution 
which dissolves all other cellular debris, leaving the mycelia and spores of the candida in bold 
relief.  
Gram staining of the discharge or Pap smears may also reveal presence of candida. 
 Culture on Sabouraud‟s agar or Nickerson‟s medium helps to identify Candida.   
41 
 
BACTERIAL VAGINOSIS  
Bacterial vaginosis is termed vaginosis rather than vaginitis, because it is associated with 
alteration in the normal vaginal flora rather than due to any specific infection.       
BACTERIA ON CULTURE 
   
 
There is a considerable decrease in the number of lactobacilli in the vaginal discharge 
with 100 fold increase in growth of other anaerobic bacteria. Since lactobacilli release hydrogen 
peroxide toxic to other bacteria, reduction in their number allow other bacteria, i.e. aerobic and 
anaerobic bacteria to grow.  
These are Haemophilus vaginalis, Gardnerella, Mobiluncus and Mycoplasma hominis. 
The Mobiluncus is a gram-positive curved rod with a characteristic corkscrew spinning anaerobe. 
The bacterial vaginosis is therefore a Polymicrobial condition.   
It is not sexually transmitted with a variable incubation period. About 50% women are 
asymptomatic carriers of infection, but majority complain of vaginal discharge without itching.  
The characteristic of vaginal discharge are: 
 White, milky, non-viscous discharge adherent to the vaginal wall.  
 PH of the discharge is more than 4.5. 
 Fishy odour when mixed with 10% KOH is due to amino-metabolites 
from various organisms (amine or whiff rest).  
 Presence of clue cells-the epithelial cells have fuzzy border due to 
adherence of bacteria. 
 Increased number of Gardnerella vaginalis and other organisms and 
reduced number of lactobacilli, and leucocytes.  
 The woman has minimal vulval irritation.  
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Diagnosis: 
The diagnosis is based on wet smear and culture. 
 The smear reveals clean background with few inflammatory cells and other organisms, 
but scanty lactobacilli.  
Many epithelial cells present a granular cytoplasm caused by small gram-negative bacilli   
adhering on their surface, so called clue cells.  
Free floating clumps of Gardnerella are seen.  
Complication: 
 This infection can cause PID, Chorioamnionitis, premature rupture of membrane 
(PROM), and preterm labor. 
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MATERIALS AND METHODS 
TITLE: 
Clinical evaluation of Siddha drug “Mega Rajanga kirutham” (internal) in the 
treatment of VELLAI NOI ( Leucorrhoea). 
BACK GROUND 
 The development of nation lies in the empowerment of women. A Healthy mother brings 
forth a healthy baby. Women in India make approximately 50% of the population. Their 
socioeconomic and health statuses are considerably very low. Vellai noi (Leucorrhoea) is one of 
the sexually transmitted disease which affects women commonly and frequently.  
Trichomoniasis is a cosmopolitan disease usually transmitted by sexual intercourse.  
 It is estimated that 3 million women in the United States and 180 million worldwide. 
Acquire this disease annually and 25% of sexually partners are also parasitized at least 
transiently. 
 Infection is rare in adult virgin, where as rates as high as 70% are seen among prostitutes, 
sexual partners of infected patients and individuals with other venereal diseases. 
 In women, the peak incidence of trichomoniasis is between 16 and 35 years of age, but 
there is still a relatively high prevalence in the 30 to 50 year age group.  
 The signs and symptoms of Vellai noi can be correlated with Leucorrhoea in modern 
science. The incidence of velai noi was found in women irrespective of their socio- economic 
status.  More number of cases is recorded in OPD of Ayothidoss pandithar hospital, NIS. So I 
have decided to choose Leucorrhoea (Vellai noi) as my dissertation topic. 
 I have chosen Mega rajanga kirutham (Ref.Sigicha rathna deepam) to treat the vellai noi. 
As per literature evidence the ingredients of the trial drug possess anti microbial & anti 
inflammatory activity which cures vellai noi.  
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Aims  
a. Primary Aim:  
To estimate the efficacy of Mega rajanga kirutham in the treatment of 
vellai noi (Leucorrhoea) 
 
b. Secondary Aim:  
 To study the siddha co factors related to the disease. 
 To study the pharmacological activity of the trial drug  
 To study the physico chemical analysis of the trial drug 
STUDY DESIGN AND CONDUCT OF STUDY: 
Study type: An open Clinical trial 
 Study place: OPD and IPD of Dept of Maruthuvam and Dept of Magalir maruthuvam, 
National institute of siddha, Tambaram –sanatorium, Chennai-47. 
 Study period: 12 months.  
 Duration of drug administration: 9 days twice a month (18 days). 
Study population: The patient who are attending the OPD & IPD of Department of 
Maruthuvam and Department of Magalir Maruthuvam, Ayothidoss pandithar hospital, National 
institute of siddha, Tambaram- sanatorium, Chennai-47. 
Sample size: 40 patients 
Study drug: Mega rajanga kirutham 
Dosage: 4 ml, twice a day before food. 
STUDY SUBJECT SELECTION:  
 When patients reporting at OPD of dept of Maruthuvam & Magalir maruthuvam, 
Ayothidoss pandithar hospital who satisfies the inclusion and exclusion criteria will be subjected 
to screening test & documented by using screening proforma.  
INCLUSION CRITERIA: 
o Age: 21-45 years 
o Married female 
o Vaginal smear for Trichomonas vaginalis positive & negative 
o Whitish / yellowish discharge per vagina. 
o Pruritis Vulva 
o Vulval irritation. 
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o Lower abdominal pain 
o Dysuria 
o Low back pain 
o Patient willing to sign the informed consent. 
o Patient who are willing to subject herself for vaginal swab sample collection, as 
well as to undergo routine laboratory investigation. 
EXCLUSION CRITERIA: 
o Non specific Leucorrhoea 
o Gonorrhoea/ syphilitic infection 
o Diabetes mellitus 
o Pregnancy/ Lactation 
o  Fistula/ trauma of genitalia 
o Malignancy 
o Organic Lesion of Genito-urinary tract 
o Hypertension/Any other systemic illness  
o Prolapse of uterus 
o Bacterial vaginosis 
o Vulvovaginal candidiasis 
WITHDRAWAL CRITERIA: 
o Intolerance to the drug & development of adverse reactions during drug trial. 
o Poor patient compliance & defaulters 
o Patient turned unwilling to continue in the course of clinical trial. 
o Increase in severity of symptoms. 
TEST & ASSESSMENTS 
o Clinical assessment 
o Siddha assessment  
o Routine investigation 
o Specific investigation. 
Clinical Assessment: 
 Whitish or yellowish discharge per vagina 
 Pruritis Vulva 
 Vulval irritation 
 Lower abdominal pain 
 Low back pain 
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 Dysuria 
 Dyspareunia 
Siddha Assessment: 
 Siddha way of investigation 
 Envagai Thervu: 
1. Naadi(Pulse perception) 
2. Naa(Tongue) 
3. Niram( complexion) 
4. Vizhi(Eyes) 
5. Mozhi(Voice) 
6. Sparisam(Palpatory perception) 
7. Malam( Bowel habit) 
8. Moothiram(Urine) 
Neer kuri- Niram, Manam, Nurai, Edai, Enjal. 
Neikuri – Vatham, pitham, kabam, thontham, or other fasions. 
Routine Blood investigations: 
o Hb (gms/dl) 
o Total RBC(million/cu.mm) 
o Total WBC( million/cu.mm) 
o Differential count (%)  
 Polymorphs 
 Lymphocytes 
 Monocytes 
 Eosinophils 
 Basophils 
o ESR 
o Blood sugar level- fasting(mg/dl) , Postparandial(mg/dl) 
o Lipidprofile-Totalcholesterol,HDL(mg/dl),LDL(mg/dl),VLDL(mg/dl) 
o VDRL 
o Liver function test: Total bilirubin(mg/dl), (direct & indirect),SGOT, 
SGPT,Alkaline phoaphatase, Total protein(mg/dl), Serum Albumin(mg/dl), 
Serum globulin(mg/dl), Serum fibrinogen(mg/dl). 
o Renal function test: Blood urea (mg/dl), Sr. creatinine(mg/dl). 
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Urine Examination: 
o Albumin 
o Sugar (fasting& post parandial) 
o Deposits 
Vaginal Smear: Wet test for Trichomonas vaginalis 
STUDY SUBJECT ENROLLMENT 
 In this clinical trial, patients reporting at the OPD of Dept of Maruthuvam & Dept of 
Magalir maruthuvam, Ayothidoss pandithar hospital, National institute of siddha, who satisfies 
the inclusion and exclusion criteria, will be enrolled for this study.  
 After ascertaining the patient‟s willingness, informed consent would be obtained in 
writing from them in the consent form (Form IV). 
 The patients who are to be enrolled would be informed (Form V) about the study, trial 
drug, possible outcome and the objectives of the study in the known language and terms 
understandable to them.  
If the patient give consent to the trial, then the (Form I) screening form should be filled 
and the ID NO for the patient should be given. 
Complete clinical history, complaints and duration, examination findings all would be 
recorded in the Case record form (Form II). Patient adviced to take blood and urine investigation 
and the result would be noted in Form III. 
Patient would be advised to take the trial drug and appropriate dietary advice would be 
given according to the patient‟s perfect understanding. 
Conduct of the study: 
 The day before starting trial drug “Mega rajanga kirutham” purgation will be given with 
“Meganatha kuligai -1 in ginger juice at early morning”. The next day rest will be given to the 
patients. Third day onwards the trial drug Mega rajanga kirutham -4 ml twice a day before food 
will be given continuously for 9 days followed by 9 days drug holidays , then 9 days medicine. 
The patients will be asked to have regular treatment in the OPD once in 9 days. In every visit the 
clinical assessment f will be recorded in the prescribed Proforma (Form-II). The laboratory 
investigation will be done before and after treatment and recorded in the prescribed proforma 
(Form III). For IP patient the drug has been provided & prognosis is noted daily. Routine 
laboratory investigations & vaginal smear will be done on 0
th
 day and 28
th
 day.  
 At the end of the trial the patient will be advised to come for follow up for 2 months for 
observation. 
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Data management:  
o After enrolling the patient in the study, a separate file for each patient will be 
opened and all forms will be filled in the file. Study NO and patient NO will be 
entered on the top of file for easy identification. Whenever the study patient visits 
OPD during the study period, the respective patient file will be taken and 
necessary recordings will be made at the assessment form or other suitable forms. 
o Screening forms will be filled separately. 
o The data recordings will be monitored for completion by guide, (HOD, Dept. of 
Maruthuvam), SRO (statistics) and the adverse event will be monitored by the 
members of the phrmacovigilance department of NIS. All forms will be further 
scrutinized in presence of investigator & Sr. Research officer (statistics) for 
logical errors and incompleteness of data to avoid any bias. No modification in 
these results is permitted for unbiased reports.  
OUT COME:   
 The Good outcome is mainly assessed by the vaginal smear when Wet test becomes 
negative for T. vaginalis and complete relief from clinical symptoms after treatement. 
The Moderate outcome is assessed by reduction of clinical symptoms such as white 
discharge, pruritis vulva, Low back pain and lower abdominal pain. 
The Poor outcome is mainly assessed by the vaginal smear when wet test becomes 
positive for T.vaginalis with clinical symptoms slightly reduced.     
STATISTICAL ANALYSIS:  Paired t- test for changes in objective parameters. 
ASSESSMENT FORMS 
FORM I  Screening & selection Proforma 
FORM II  Case record form 
FORM III Laboratory investigation form 
FORM IV Drug compliance form 
FROM V Patient information form 
FORM VI Informed Consent form 
FORMVII Withdrawal form/ adverse reaction form (pharmacovigilance form) 
FIRM VIII Dietary advice form  
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DRUG REVIEW 
1) ATHI PATTAI 
 
Name   : Athi  
Botanical Name : Ficus racemosa. Linn. 
English Name  : Country fig, Cluster fig, gular fig. 
Family   : Moraceae 
Synonyms  : Atham, athavu, uthumbaram, koli, supirathashtam. 
Part used  : Bark 
Taste   : Astringent 
Quality  : Coolant 
Division  : Sweat 
Action   : Astringent 
Ì½õ (character) : Å£Ú ¸ÎôÀ¢Ãò¾õ ¦Åñº£¾ Ãò¾¦Á¡Î 
                 ¿¡ÚÅ¢Ã ½í¸¦ÇÄ¡õ ¿¡¼¡Å¡õ- ÜÚí¸¡ø 
                 «ò¾¢¾Õ §Á¸õ§À¡õ ¬Â¢¨Æ§Â! ±ï»¡ýÚõ  
 «ò¾¢ôÀ¡ü Àð¨¼ì ¸È¢.  
–Ref Gunapadam Mooligai vaguppu pg   no-21 
 
Activity : Astringent, Anti inflammatory, Anti oxidant, Hypoglycemic, 
Anti nocioceptive, Anti bacterial, 
 
Chemical constituents : β-sitosterol, glanol, lupeol acetate, α- amyrin acetate, tetra cyclic 
tri terpine gluanol acetic acid, β-sitosterol-D-glucoside and 
friedellin glycoside β-D- glucosyloxy benzoic acid along with 
sterols, hydrocarbons, sugars and amino acids. 
2) NAVAL PATTAI 
 
Name    : Naval  
Botanical Name  : Syzygium cumini. Linn.  
English Name   : Jambul 
Family    : Myrtaceae  
Synonyms : Navval, nambu, sambu, satuvalam, sambal, surabipathirai, 
Aarugatham, sathavam, neraedu, neraedam. 
Part used   : Bark 
Taste    : Astringent 
Quality   : Coolant 
Division   : Pungent 
Action    : Astringent 
Ì½õ (character)  : Å¡¾ ÁÚí¸ÃôÀ¡ý Á¡Úõ Å¢Ã½¦Á¡Î  
               µ¾ÓÚ ¿£Ã¢Æ¢× ÓóÐÃò¾- º£¾Óí¸¡ö 
               Á¡Åý ÍÃÓõ ÅÇ÷§Á¸Óõ §À¡Ìõ   
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  ¿¡ÅÄý §ÅÃ¾¨É ¿¡Î.  
Ref -Gunapadam Mooligai vaguppu pg   no-571 
 
Chemical constituents  : Myricetin-3-L-arabinoside, dihydromyricetin. 
 
Activity : Astringent, Anti oxidant, Antiinflammatory, Anti 
bacterial, Anti HIV, Anti fungal, Anti diabetic. 
 
3) OOTHIYAM PATTAI 
 
Name   : Oothiyam  
Botanical Name : Lannea coromandelica. Merr. 
English Name  : Rhus olina 
Family   : Anacardiaceae 
Synonyms  : Uthimaram, moothagam. 
Part used  : Bark 
Taste   : Astringent 
Quality  : Hot 
Division  : Pungent. 
Action   : Astringent, Tonic, Anti septic, styptic. 
Uses   : Bark decoction used for leucorrhoea and menorrhagia.  
 
Ref- Gunapadam Mooligai vaguppu pg no-173. 
  
Chemical constituents: Quercetin, Aralia cerebroside, β-sitosterol palmitate, myricadiol, 
protocatechuic acid, Isovallin, transcinnamic acid, Palmitic acid, stearic acidP hydroxybenzoic 
acidethyl ester. 
 
Activity : Anti inflammatory, Astringent, Tonic, Disinfectant, and Styptic.  
 
4) KARUMBU RASAM 
 
Name   : Karumbu 
Botanical Name : Saccharam officinarum. Linn.  
English Name  : Sugar cane, Noble cane 
Family   : Poaeceae 
Synonyms  : Punar poosam, ekku, vaei. 
Part used  : Juice 
Taste   : Sweat 
Quality  : Coolant 
Division  : sweat 
Action : Demulcent, antiseptic, coolant, Laxative, Diuretic.  
 
Ì½õ (character) : ¸ÕõÀ¢Ã¾ ¦Áò¾×ñ¼¡ü ¸¡Ïí ¸À§¿¡ö 
Å¢ÕõÀ¢¦ÅøÄ ¦Áò¾×ñ¼¡ø §Á¸õ ¾ÕÁÐ¿£÷ 
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            ¯ñ¼¡Á¨¾Á¢¾Á¡ Ôñ¼¡ø§Á¸õ À¢ò¾õ 
Á¢ñ¼¡Áü º¡ó¾ÓÚõ Å¢û. 
 Ref- Gunapadam Mooligai vaguppu pg   no- 237. 
 
Chemical constituents : 5-o-Methyl apigenin, 3‟, 4‟, 5, 7 tetra hydroxyl-3, 6-dimethoxy 
flavox. 
Activity : Anti inflammatory, Anti thromboitic, Anti hepato toxic, 
Analgesic, Demulcent, Antiseptic, Cooling, Laxative, Diuretic, 
Nutrient, Anti oxidant.  
5) NELLIKKAI CHARU 
 
Name   : Nelli 
Botanical Name : Emblica officinalis. Linn.  
English Name  : Indian goose berry 
Family   : Euphorbiaceae 
Synonyms : Amalagam, Aalagam, aambal, aamarigam, thaththari, thaththiri, 
korangam, miruthupala, meethunthu. 
Part used  : Juice 
Taste   : sour, astringent, sweat. 
Quality  : Coolant 
Division  : Sweat 
Action   : Astringent, coolant, diuretic, laxative. 
Ì½õ (Character) :    ¦¿øÄ¢ì¸¡öì ÌôÀ¢ò¾õ ¿£íÌ Á¾ýÒÇ¢ôÀ¡ø 
          ¦ºøÖ§Á Å¡¾Á¾¢ü §º÷ÐÅÃ¡ø-¦º¡øÖ¨ÁÂõ  
          µÎÁ¢¨¾î º¢ò¾ò¾¢ø ¯ýÉ «ÉÖ¼§É 
     ÜÎÀ¢È §Á¸Óõ §À¡í ÜÚ.  
- Ref- Gunapadam Mooligai vaguppu pg no-621. 
 
Chemical constituents  : Linoleic acid closely related to linseed oil, ellagic acid, 
lupeol. 
 
Activity : Anti inflammatory, Anti oxidant, Analgesic, Anti-
ulcerogenic, Anti diabetic, Anti mutagenic, Hypo 
lipidemic, Anti coagulant, Anti bacterial, wound healing. 
6) ELUMICHAI CHARU  
 
Name   : Elumichai 
Botanical Name : Citrus lemon. Linn.  
English Name  : Lime 
Family   : Rutaceae 
Part used  : Lemon juice 
Taste   : Sour. 
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Quality  : Hot 
Division  : Pungent  
Action   : Coolant. 
Ì½õ (character) : "º¾¡ÀÄì ¸É¢¸¡Â ºãÄÓ Ó½§Å 
   ¿¢¾¡ÉÁ¡ö ÀÂ¢ò¾¢Â ¿¢ó¨¾Â¡ö «¸Ö§Á"  
  
±ÖÁ¢î¨º ÀÆõ, ±ÖÁ¢î¨º ¸¡ö, ±ÖÁ¢î¨º §Å÷, þ¨Ä 
þ¨Å¸¨Ç ¦¸¡ûÇ¢ý ¾£ìÌüÈò¾¡ø ¯ñ¼¡É §¿¡ö¸Ùõ, 
¦ÅÈ¢ §¿¡Ôõ §À¡õ.  
Ref- Gunapadam Mooligai vaguppu pg no-159. 
 
Chemical constituents\   : Hesperidin, Narigin, Poncirin. 
Activity                           : Anti fungal, Anti microbial, Refrigerant, Carminative. 
7) GINGELI OIL 
 
Name   : Ell 
Botanical Name : Sesamum indicum. Linn.  
English Name  : Gingeli oil 
Family   : Pedaliaceae 
Synonyms  : Thilam 
Part used  : Oil 
Taste   : Sweat 
Quality  : Hot 
Division  : Sweat 
Action : Coolant, Laxative, tonic, Demulcent, Emollient. 
 
Chemical constituents : Lignans, sesamolin, sesamin, pinoresinol, lariciresinol. 
Activity           : Anti oxidant, Emmenagogue, Stimulant, Tonic, Diuretic, 
Galactogogue, Laxative. 
8) GHEE 
Name   : Cow‟s ghee 
Activity  : Anti inflammatory, Anti viral, Antioxidant, Tonic. 
ÀÍ ¦¿öÂ¢ý Ì½õ:  ¾¡¸ÓÆ ¨ÄÍð¸õ Å¡ó¾¢ À¢ò¾õ Å¡ÔÀ¢Ã 
    §Á¸õ ÅÂ¢ü¦ÈÃ¢× Å¢ì¸ÄÆø-Á¡¸¡ºí 
    ÌýÁõ ÅÈðº¢ Ì¼üÒÃð¼ ÄŠ¾¢Íð¸ï 
  ¦º¡ýãÄõ §À¡ìÌ¿¢¨Èò ÐôÒ. 
Ref- Gunapadam thathu jeeva vaguppu-pg no-702 
 
Uses : Cow‟s ghee is used for thirst, pitha diseases, vomiting, Poisons, 
ulcer, Sexually transmitted diseases, hiccough, cough, burning 
sensation of stomach, Bone diseases, haemorrhoides. 
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Chemical constituents of Ghee:  
 It contains approximately 8% saturated fatty acids which make it 
easily digestible. The  digestibility co efficient or the rate of 
absorption is 96% which is better than any other animal or 
vegetable fat. It contains triglycerides, di-glycerides, mono-
glycerides, phospholipids, beta carotene 600IU and vitamin E 
which are known anti-oxidants. 
9) ELAM 
 
Name   : Elam 
Botanical Name : Elettaria cardamomum. Maton. 
English Name  : Cardamomum seeds 
Family   : Zingiberaceae 
Synonyms  : Aanji, korangam, thudi. 
Part used  : seed 
Taste   : Pungent. 
Quality  : Hot 
Division  : Pungrent 
Action : Stimulant, Carminative, Stomachic 
Ì½õ (character):   
¦¾¡ñ¨¼ Å¡ö¸×û ¾¡ÖÌ ¾í¸Ç¢ø 
                 §¾¡ýÚõ §¿¡Â¾¢ º¡ÃõÀý §Á¸ò¾¡ø  
             ¯ñ¨¼ §À¡¦ÄØí ¸ðÊ ¸¢Ã¢îºÃõ  
            ................................................................... 
                  ¬Ä Á¡í¸Áú ²Ä ÁÕó¾§¾. 
Ref- Gunapadam Mooligai vaguppu pg   no-166. 
 
Chemical constituents: α- Pinene, β- Pinene, Sabinene, myrcene, D- Limonene, 1, 8 
Cineole. 
 
Activity : Anti cancer, Immuno modulatory, Stimulant, Carminative, 
Stomachic. 
10) THALISA PATHIRI 
 
Name   : Thalisapathiri 
Botanical Name : Taxus buccata 
English Name : flaurtia calaphracta, many spiked flacortia, east Himala fir yans 
silva. 
Family   : Taxaceae 
Part used  : Leaf 
Taste   : Pungent. 
Quality  : Hot 
Division  : Pungrent 
Action : Tonic, Carminative, Stomachic, Exopectorant. 
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Chemical constituents: Taxine, Taxol. 
  
Activity : Anti inflammatory, Anti nocioceptive, Stomachic, Carminative, 
Expectorant, Tonic. 
11)  KIRAMBU 
 
Name   : Lavangam 
Botanical Name :  Syzygium aromaticum. Linn. 
English Name  : Cloves 
Family   : Myrtaceae 
Synonyms : Anjugam, urkadam, karuvai kirambu, sosam, thirali, varangam. 
Part used  : Flowerbud. 
Taste   : Pungent. 
Quality  : Hot 
Division  : Pungrent 
Action : Carminative, Anti spasmodic, Stomachic. 
 
Chemical constituents: Caryophyllane, Eugenol, Naphthaene, Eugenine 
 
Activity  : Anti fungal, Anti spasmodic, Carminative, Stomachic. 
 
12) SATHIKKAI 
 
Name   : Sathikkai 
Botanical Name : Myristica fragrans. Houtt. 
English Name  : Nut Meg 
Family   : Myristicaceae. 
Synonyms  : Kulakkai,  
Part used  : Ripe 
Taste   : Astringent. 
Quality  : Hot 
Division  : Pungent 
Action : Stimulant, Carminative, Narcotic, Aromatic, Aphrodisiac, Tonic. 
 
Chemical constituents : Seven new dimeric phenyl propanoides, neolignan, 
erythrosurinamensin and a diaryl phenyl proponoid, virolane.  
 
Activity : Anti inflammatory, Stimulant, Carminative, Narcotic, Aromatic, 
Aphrodisiac, And Tonic. 
13) CHITRARATHAI 
 
Name   : Chitrarathi 
Botanical Name : Alpinia officinarum.Hance. 
English Name  : Galangal the lesser 
Family   : Zingiberaceae 
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Part used  : Root 
Taste   : Pungent. 
Quality  : Hot 
Division  : Pungrent 
Action   : Expectorant, Stomachic, Febrifuge. 
Chemical constituents: Galangin, Kaempferide, Kaempferol. 
Activity : Anti inflammatory, Anti oxidant, Anti biotic, Anti- ulcer, 
Expectorant, Stomachic, Febrifuge. 
14) ATHIMATHURAM 
 
Name   : Athimathuram 
Botanical Name : Glycirrhiza glabra.Linn. 
English Name  : Jequitity, Indian or Jamaica Liquorice. 
Family   : Fabaceae 
Synonyms  : Athingam, atti mathugam, kunri ver.  
Part used  : Root 
Taste   : Sweat, 
Quality  : Coolant 
Division  : Sweat. 
Action   : Febrifuge, Emollient, Demulcent, Expectorant, Laxative, Tonic. 
Ì½õ   :      Òò¾¢ìÌ Å¢ò¾¡Ìõ ºó¾¡Àó ¾£÷ìÌõ  
Ò¨¸ó¦¾ÎìÌõ §ºðÎÁò¨¾ô À¢ò¾§Ã¡¸ò¨¾ 
«ò¾¢ô ÀüÈ¢É §Á¸ó¾ý¨É Å¡¾ò¾¢¨É 
ÂÚò¾¢Îõ Åîº¢Ãõ ±ýÀ¡÷ «¾¢ÁÐÃó¾¨É§Â. 
   Ref- Gunapadam Mooligai vaguppu- pgno- 14. 
  
Chemical constituents : Glycyrrhizin, Anethole, Iso flavane glabrene, Iso flavane    
glabridin, Phyto oesrigens. 
Activity : Anti inflammatory, Anti oxidant, Emollient, Anti cancer, Anti 
microbial, Anti viral, Demulcent, Mild Expectorant, Laxative, 
Tonic, Immuno modulator. 
15) NILAPANAI KIZHANGU 
 
Name   : Nilapanai kizhangu 
Botanical Name : Curculigo orchioides. Gaertn. 
English Name  :  Black Musale 
Family   : Hypoxidaceae.  
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Synonyms : Varagi, Musali, Thiralaram, Thiragaththaru, Thiranarasan, 
Sagiyam, Thalamooli, Thalaithathu, Nilavizhumi, Naeyam, 
Kuraththi, sithi. 
Part used : Root tuber 
Taste : Sweat. 
Quality : Coolant, 
Division : Sweat. 
Action : Emollient, Laxative, Tonic, Carminative, diuretic, Astringent. 
Ì½õ (character : §Á¸ ÅÉø¾½¢Ôõ ¦ÅñÌð¼ó ¾¡ýÅ¢ÄÌõ 
                 §À¡¸ Á¢¸×ÓÚõ ¦À¡ü¦¸¡Ê¦Â!-§À¡¸¡¾ 
                 Ý¨Ä§Á¸í ¸¦Ç¡Î ÐýÛ¸Õõ ÒûÇ¢Ôõ§À¡ï  
                 º¡Ä ¿¢ÄôÀ¨ÉìÌò ¾¡ý. 
  Ref- Gunapadam Mooligai vaguppu pg no- 576. 
 
Chemical constituents : 5.7, dimethoxy-dihydro myrcetin- 3-0-α-L-xylopyranosyl (4-1) 
B-D glycophyrranoside. 
Activity : Anti cancerous activity, Anti inflammatory, Anti bacterial, Anti 
oxidant, Emollient, Laxative, Carminative, Tonic, Astringent. 
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   ELUMITCHAI CHARU    THENGAI PAAL 
    
COW‟S GHEE     GINGELY OIL 
    
       MEGA RAJANGA KIRUTHAM 
 
 
Dosage: 4 ml, twice a day before food. 
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RESULTS AND OBSERVATIONS 
Results of the study were observed with respect to the following criteria;  
1. Sex distribution 
2. Age distribution 
3.  Gunam 
4. Paruva kaalam 
5. Family history 
6. Diet 
7. Thinai 
8. Socioeconomic status 
9. Kaalam 
10.  Thegi 
11.  Educational status 
12.  Body built 
13.  Habit 
14.  Occupation 
15.  Treatment history 
16.  Derangement of Vatham 
17.  Derangement of Pitham 
18.  Derangement of Kabam 
19.  Derangement of envagai thervugal 
20.  Neikkuri analysis 
21.  Derangement of udal thathukal 
22.  Clinical features distribution 
23.  Improvement after treatment.  
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Results and Observation 
1. Sex distribution: 40 female cases were selected for this dissertation. 
 
2. Age distributon:  
Age(years) No of cases Percentage 
21-30 20 50% 
31-40 18 45% 
41-45 2 5% 
 
 
 
    Figure: 1 
Observation: Among 40 cases, most of the patients were observed in the age group 
between 21-30 (50%) and the second most age group was 31-40 (45%). 
GUNAM 
       GUNAM NO of CASES PERCENTAGE 
Sathuva gunam 0 0 
Rastha gunam 40 100% 
Thamo gunam 0 0 
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    Figure: 2 
 
Observation: All the 40 cases (100%) were found to posses‟ Rasatha gunam 
Food habit:  
  
 
 
    Figure: 3  
Observation: Among 40 cases most of the cases were under Non-vegetarian diet. 
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PARUVA KAALAM (Season):  
Season  NO of Cases Percentage 
1. Kaarkaalam 0 0 
2. Koothir kaalam 0 0 
3. Munpani kaalam 26 65% 
4. Pinpani kaalam 14 35% 
5. Ilavenil kaalam 0 0 
6. Muthu venil kaalam 0 0 
 
 
    Figure: 4 
Observation: Among the 40 patients, 65% were suffered in Munpani kaalam and 35% in 
Pinpanikaalam. 
Family History: 
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Present 4 10 
Absent 36 90 
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    Figure: 5 
Observation:  
Among 40 cases only 10 % of cases had Family history of vellai noi. 
Socio economic status: 
  
 
 
   
     Figure: 6 
Observation: Among 40 patients 47.5% were poor, and 40% were middle, and only 12.5% were 
had high socio- economic status. 
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THINAI: 
  
 
 
 
 
 
     Figure: 7 
Observation:  
 72.5% 0f patients were belongs to Neithal nilam. 
 25% of patients were belongs to Marutha nilam. 
 2.5 % of patients were beongs to Kurinji nilam 
Kaalam distribution:   
Kaalam No of cases Percentage 
Vatha kaalam 29 72.5 
Pitha kaalam 11 27.5 
Kaba kaalam 0 0 
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Palai 0 0 
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    Figure: 8 
Observation: 
 Among 40 cases, 72.5% of cases were in vaatha kaalam (age up to 33 years). 
 27.5% of cases were in Pitha kaalam (age from 34 to 66 years). 
Habit: 
All the 40 cases do not have any bad habits, like pan, snuff etc. 
Thegi: 
Thegi No of cases Percentage 
Vaatha thegi 12 30 
Pitha thegi 15 37.5 
Kaba thegi 0 0 
Thontha thegi 13 32.5 
 
  
    Figure: 9 
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Observation: 
 Among 40 cases, 37.5% of patients were Pitha thegi. 32.5% of patients were Thontha 
thegi. And 30% of patients were Vaatha thegi. 
Educational status: 
                          Literate Illiterate 
 Middle school 
completed 
High school 
completed 
Degree 
holder 
 
No of cases 11 8 5 16 
Percentage 27.5 20 12.5 40 
 
  
    Figure: 10 
Observation: 
 Among 40 cases, 40% of cases were illiterate, 27.5% of patients were middle school 
completed, and 20% of patients were High school completed. Only 12.5% of patients were 
degree holder. 
Body built:  
Body built No of cases Percentage 
Lean 22 55 
Moderate 11 27.5 
Obesity 7 17.5 
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   Figure: 11 
Observation: 
  Among 40 cases, 55% of patients were under weight. 27.5% were Normal weight 
and 17.5% were Obese. 
Occupation:   
Occupation No of cases Percentage 
House wives 15 37.5 
Sedentary work 5 12.5 
Daily wages 20 50 
  
 
    Figure: 12 
Observation: 
 Among 40 cases, 50% of patients are doing field work. 37.5% of patients are housewives. 
Only 12.5% of patients are doing sedentary work 
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Treatment history: 
Treatment history No of cases Percentage 
Allopathy 18 45 
Sidhha 7 17.5 
Ayurvedha 3 7.5 
Homeopathy 4 10 
No treatment history 8 20 
 
  
    Figure: 13 
Observation: 
 Among 40 cases, 45% of patients had allopathic treatment for leucorrhoea. 20% of 
patient‟s dose not had any treatment. 17.5% of patients had siddha treatment, 7.5% had 
Ayurvedhic and 10% had Homeopathic treatment for the same illness. 
Disturbances of Vatham: 
Disturbances of vatham Before Treatment (%) After Treatment (%) 
Piranan 0 0 
Abanan 100 20 
Uthanan 0 0 
Viyanan 100 12.5 
Samanan 100 25 
Nagan 0 0 
Koorman 5 5 
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Kirugaran 0 0 
Devathathan 100 2.5 
Dananjeyan 0 0 
 
 
     Figure: 14 
Observation:  
 Among 40 cases, before treatment, 100% of patients were affected with Abanan, 
Viyanan, Samanan and Devathathan. After treatment the abanan was affected in 20%, Viyanan 
was affected in 12.5%, Samanan was affected in 25%, and devathathan was affected only in 
2.5% of patients. 
Disturbances of Pitham:  
Disturbances of pitham Before treatment (%) After treatment (%) 
Anarpitham 50 10 
Ranjaga pitham 20 20 
Sathaga pitham 0 0 
Pirasaga pitham 0 0 
Alosaga pitham 5 5 
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      Figure: 15 
Observation:  
 Among 40 cases, 50% of patients were affected Anarpitham in before treatment, and it 
was affected only in 10% in after treatment.  
Disturbances of Kabam: 
Disturbances of Kabam Before treatment (%) After treatment (%) 
Avalambagam 100 20 
Kilethagam 0 0 
Pothagam 0 0 
Tharpagam 0 0 
Santhigam 100 20 
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     Figure: 16 
Observation: 
 Among 40 cases, 100% of patients were affected with Avalambagam and santhigam in 
before treatment and after treatment; both were affected only in 20% of patients.  
Changes in Kosangal:  
Kosangal Before treatment (%) After treatment (%) 
Annamaya Kosam 100 20 
Piranamaya kosam 80 7.5 
Manomaya kosam 100 7.5 
Vingnanamaya kosam 5 2.5 
Ananthamaya kosam  55 0 
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     Figure: 17 
Observation:   
 Among 40 cases, 100% of cases were affected with Annamaya kosam in before 
treatment, and after treatment, it was affected only in 20%of patients. 
 Among 40 cases, 80% of cases were affected with Piranamaya kosam in before 
treatment, and after treatment, it was affected only in 7.5% of patients. 
 Among 40 cases, 100% of cases were affected with Manomaya kosam in before 
treatment, and after treatment, it was affected only in 7.5% of patients. 
 Among 40 cases, only 5% of cases were affected with Vignanamaya kosam in before 
treatment, and after treatment, it was affected only in 2.5% of patients. 
 Among 40 cases, 55% of cases were affected with Ananthamaya kosam in before 
treatment, and after treatment, the Ananthamaya kosam was Normal in all 40 cases. 
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Changes in Udal thathukkal: 
Udal thathukkal Before treatment (%) After treatment (%) 
Saaram 100 5 
Senneer 20 20 
Oon 0 0 
Kozhuppu 0 0 
Enbu 30 2.5 
Moolai 0 0 
Suronitham 100 22.5 
 
 
     Figure: 18 
Observation:  
 Among 40cases, 100% of cases were affected with Saaram and after treatment it was 
reduced in to 5%.  
 Among 40 cases, 100%of cases were affected with Suronitham and it was reduced into 
22.5%.  
 Among 40 cases, 20% of patients were affected with senneer in before and after 
treatment. 
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 Among 40 cases, 30% of patients were affected with Enbu in before treatment. And it 
was affected only in 2.5% of cases. 
Improvement of signs and symptoms: 
  
 
  
    Figure: 19 
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Clinical symptoms Before treatment (%) After treatment (%) 
Profuse, thin, creamy whitish 
/ yellowish discharge per 
vagina. 
100 37.5 
Pruritus vulva 97.5 17.5 
Vulval irritation 100 10 
Dysuria 75 12.5 
Abdominal pain 95 37.5 
Low back pain 100 42.8 
Dyspareunia 100 - 
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Observation: 
Among 40 cases, 100% of patients had Profuse thin or thick, whitish or yellowish 
discharge per vagina, and after treatment the above symptoms were present only in 37.5% of 
patients. 
 Among 40 cases, 97.5% of patients had Pruritus vulva in before treatment, and after 
treatment it was present only in 17.5% of cases. 
 Among 40 cases, 100% of patients had Vulval irritation in before treatment, and after 
treatment it was present only in 10% of cases. 
 Among 40 cases, Dysuria was present in 75% of cases in before treatment and after 
treatment it was present only in 12.5% of cases. 
 Among 40 cases, abdominal pain was present in 95% of patients, and after treatment it 
was present in 37.5% of patients. 
 Among 40 cases, Low back pain and Dyspareunia was present in 100% of cases, and 
after treatment low back pain was present in 42.5% of cases. Dyspareunia is not elicited due to 
Itcha pathiyam.  
WET test positive for Trichomonas vaginalis 
WET test NO of cases Before treatment (%) After treatment (%) 
Positive 15 37.5 12.5 
Negative 25 62.5 87.5 
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    Figure: 20 
Observation: Among 15 Wet test positive cases, 10 cases were negative in after treatment i.e. 
66% of cases were negative in after treatment.  
RESULTS: 
Improvement after 
treatment 
GOOD MODERATE POOR 
50% 40% 10% 
 
 
     Figure: 21 
Observation: 
 50% of patients showed good result, 40% showed moderate result and only 10% showed 
poor prognosis. 
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Results of Pharmacological study: 
1) In vitro anti inflammatory activity by protein (albumin) denaturation assay :  
The test drug Mega rajanga kirutham was effective in inhibiting heat induced 
albumin denaturation. Maximum percentage inhibition of about 69.54% was observed 
at 500 µg/ml when compare to that of the Diclofenac sodium, a standard anti-
inflammatory agent with the maximum inhibition 89.22 % at the concentration of 
100µg/ml 
2) Anti microbial activity by Disc diffusion method: 
The trial drug Mega rajanga kirutham was effective aginst Trichomonas vaginalis, 
Staphylococcus aureus, E.coli, Candida albicans and not active against Aspergillus 
niger. 
3)  Anti oxidant activity by using DPPH(2,2-Diphenyl 1-2 picrylhydrazyl Assay, 
Nitric Oxide Radical Scavenging Assay and ABTS assay: 
From the results of the present investigation it was concluded that the siddha 
formulation Mega rajanga kirutham has promising anti-oxidant activity in the 
estimated test. 
4) Physico-chemical evaluation: 
Parameter Observation 
Color Yellowish 
Smell Characteristic 
Touch Greasy 
Appearance Turbid 
 
S.No Parameter Mean(n=3) SD 
1. Loss on Drying at 105ºc(%) 8.03±1.09 
2. Total Ash(%) 0.788±0.37 
 
S.No Specific test Mega rajanga kirutham 
1. pH 6 
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2. Refractive index 1.48 
3. Iodine value(mg12/g) 101 
4. Saponification value(mg of KOH to 
saponify 1 gm of fat) 
205 
5) Phytochemical analysis: 
In this evaluation Flavonoids, Steroids, Sugar, Triterepnoids, Coumarins, Phenols, 
and Proteins are identified. 
6) Quantitative estimation of phytoconstituents of Mega rajanga kirutham: 
Phyto-constituents Mega rajanga kirutham 
Total phenols 
(GAE mg/gm) 
0.934±0.04 
Total flavanoids 
(Quercetin mg/gm) 
2.82±0.42 
Mean with 3 replicates±SD 
7) GCMS Analysis of Mega rajanga kirutham: 
 19 components were detected inthis analysis. They are following; 
1) Oxiranemethanol, 3-propyl-c1s-$$ (3-Propyl-2-oxiranyl) methanol 
#$$ (3-propyl-2-oxiranyl) methanol $$. 
2) 1, 5-Anhydro-6-deoxyhexo-2, 3 Diulose $$ 4H-pyran-4-ON, 2-3 
dihydro-3, 5-dihydrxy-6-methyl. 
3) Benzofuran, 2, 3-dihydro-$$ 2, 3 Dihydrobenzofuran $$2, 3-dihydro-
1-benzofuran # $$ 1- benzofuran $$23-D. 
4) 4-Hepten-3-one, methyl, $$ (4f)-4-methyl, 4-hepten-3-one # $$ 1-
Benzofuran $$ 23-D. 
5) 2-furancarboxaldehyde, 5-(hydrxymethyl)-$$2=furaldehyde, 5-
(hydroxymethyl)-$$2-furadehyde-5. 
6) Ethyl4-amino-1H-imidazole, 5-carboxylate=$$ 1H-imidazole, 5-
carboxylate=$$ 1H-imidazole4-carboxylic acid, 5-amino, ethyl ester 
$$E. 
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7) 2-Nonenal, 2-phenyl, $$2-pentylon-2-enal$$(2z)-2-pentyl, 2-
nonenal#$$(2z)-2-pentyl-2-nonenal $$(2z)-2p. 
8) 2, 4-Diisopropenyl-1-methyl-1-vinylcyclohexane $$ beta-etemen-(2). 
9) 8,11,14 Eicosatrienoic acid, (z, z, z)-$$(8E,11E,14E)-8,11,14-
icosatrienoic acid# $$(8E,11E,14E)-8,11,14-icosatrienol. 
10) 1-Naphthalenol, Decahydro, (1-alpha, 4A, beta-8A alpha) - $$-1-
Naphthal, 1, alpha-2, 3, 4, 4A-Alpha-5, 6, 7, 8, 8A, BE. 
11) 2H-pyran, 2-(7-heptodecynyloxy) tetrahydro-$$2-(7-heptadecynyloxy) 
tetra hydro-2-H-pyran# $$ 2(hepta]. 
12) Cyclooctanol $$cyclooctyl alcohol $$EINECS 211-800-6$$ NSC 
60162. 
13) 2, 4- Ditert-butylphenol $$2, 4-ditert-butylphenol. 
14) 9- Octadecenoic acid (z)-$$ octadec-9-Enioc acid $$(9E)-9-
octadecenoic acid # $$(9E)-9-octadecenoic acid. 
15) 2-Aminobenzoyl fluride $$2-amino-benzoyl fluride. 
16) 1, 2- Benzenedicarboxylic acid, 3-nitro-$$3- Nitrophthalic acid $$ 
A13-02074$$ AIDS-019415$$ Einecs 210-030-8$. 
17) 9- Octadecenoic acid (z)-$$ octadec-9-Enoic acid $$(9E) -9-
Octadecenoic aciod # $$ (9E)-9-Octadecenoic acid. 
18) Hexanedioic acid, BIS  (2-Ethylhexyl) Ester $$ Hexanedioic acid, 
dioctyl ester $$ adipic acid BIS (2-ethylhe) 
19) 9, 12-Octadecadienoic acid (z, z) –$$(9E, 12E)-9, 12-octadecadienoic 
acid # $$(9E, !@E)-9, 12-octadecadienoic acid. 
8) TLC and HPTLC analysis: Peak Table of HPTLC finger printing of MRK 
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BLOOD INVESTIGATION (Haematology) 
S. 
NO 
OP NO NAME A/S      TC  
Cells/cumm 
                                    DC (%) 
P P L L M M E E 
    BT AT BT AT BT AT BT AT BT AT 
1 I28105 B.Anjali 38/f 11800 5500 77 62 19 31 2 3 2 4 
2 I04794 A.Ramadevi 38/f 7700 7000 60 57 34 36 3 3 3 4 
3 G70637 S.Sasikala 29/f 10900 8100 68 70 29 28 0 0 3 2 
4 I38185 S.Saritha 30/f 13100 8900 60 45 28 33 2 2 10 20 
5 I44538 P.Anjala 31/f 5600 5500 53 50 41 44 3 3 3 3 
6 I41415 A.Suseela 30/f 9300 8900 69 60 26 30 3 5 2 5 
7 I1860 M.Jayasree 35/f 5600 7200 62 65 33 30 2 3 2 3 
8 I31972 V.Shema 30/f 4600 5600 52 50 44 42 0 4 4 4 
9 I34742 S.Radhika 30/f 6500 6600 60 69 35 29 0 0 5 2 
10 I37025 B.Jeyalakshmi 34/f 8200 7900 54 55 41 40 0 0 5 5 
11 I46385 S.Sridevi 21/f 5200 4700 58 65 35 30 0 0 7 5 
12 I41931 Lakshmi 37/f 7700 6900 61 58 30 31 5 3 4 8 
13 I29619 N.Mythili 30/f 7100 7800 58 60 36 35 3 2 3 5 
14 I35655 Vijayasree 30/f 9100 9400 65 63 30 32 0 0 5 5 
15 I50296 Vijayalakshmi 26/f 6000 5700 51 50 43 44 3 3 3 3 
16 I24039 L.Vijaya 32/f 4600 5400 62 58 31 35 0 0 7 7 
17 I31958 K.Srimathy 32/f 8000 8300 56 55 40 40 2 2 2 3 
18 I56390 M.Selvi 27/f 5000 4400 56 50 37 44 3 3 4 3 
19 I36211 V.Valliamma 32/f 9500 8500 45 63 35 21 1 5 19 11 
20 I28243 M.Kujila 30/f 7600 6600 42 33 44 55 1 2 13 10 
21 I36215 B.Rose 32/f 5500 4800 48 54 48 42 2 2 2 2 
22 I58375 P.Amara 24/f 8500 8100 59 51 33 39 4 2 4 8 
23 I36214 S.Vasantha 45/f 6300 4700 52 52 34 38 3 2 11 8 
24 I50527 V.Amuthini 27/f 9200 9200 59 51 33 44 3 3 3 2 
25 I55449 Rathanavathy 31/f 6100 8500 60 69 35 28 3 2 2 1 
26 I54714 J.Anitha 29/f 8800 8200 65 60 30 38 3 1 2 1 
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27 I43262 Rajeswari 31/f 5700 6800 52 55 43 41 3 1 2 2 
28 I60109 M.Vimala 30/f 5600 6200 50 52 46 44 2 2 2 2 
29 I53755 G.Ammatchi 36/f 10200 9200 60 60 36 38 0 0 4 2 
30 F82273 V.Jayasree 33/f 10100 9800 50 55 45 40 3 3 2 2 
  
S. 
NO 
OP NO NAME A/S      TC                                     DC 
P P L L M M E E 
    BT AT BT AT BT AT BT AT BT AT 
31 H66126 S.Shanthi 31/f 9800 9200 70 70 23 28 3 1 4 1 
32 I48333 S.Bridgetmary 45/f 10300 9200 55 50 41 43 2 4 2 3 
33 I47675 Suganthi.N 27/f 8900 8500 60 50 31 41 0 1 9 8 
34 G39746 H.Gomathi 37/f 4700 5800 40 40 53 51 1 0 7 8 
35 I00923 G.Yuvarani 35/f 8700 8800 60 56 35 41 0 0 5 3 
36 I66325 L.Manju 27/f 7300 5000 54 35 34 60 4 0 8 5 
37 H96938 J.Maheswari 27/f 6400 5500 50 55 39 38 1 0 10 7 
38 II68998 K.Prasanna 32/f 7200 7600 49 58 44 37 0 0 7 5 
39 I60605 G.kala 26/f 6700 7000 61 60 35 38 0 0 4 2 
40 I63726 A.Manimegalai 22/f 9300 8700 60 56 34 36 3 3 3 5 
 
S. 
N
O 
OP NO NAME A/S      ESR 
mm/1 hr 
      Hb 
gm/dl 
Bldsug(F) 
mgs% 
Bldsug(PP) 
mgs% 
VDRL 
BT AT BT AT BT AT BT AT BT AT 
1 I28105 B.Anjali 38/f 52 24 12.8 13.3 110 107 120 99 NR NR 
2 I04794 Ramadevi 38/f 22 22 10.1 9.8 76 102 82 112 NR NR 
3 G70637 Sasikala 29/f 22 12 13.8 13 99 97 120 110 NR NR 
4 I38185 Saritha 30/f 16 12 13.9 13.9 58 81 110 126 NR NR 
5 I44538 Anjala 31/f 4 26 12.7 12.8 63 92 110 120 NR NR 
6 I41415 Suseela 30/f 16 28 10 10.6 77 94 110 134 NR NR 
7 I01860 Jayashree 35/f 34 42 9.5 10.2 110 78 128 128 NR NR 
8 I31972 Shema 30/f 8 40 12.9 13.5 60 85 101 91 NR NR 
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9 I34742 Radhika 30/f 12 4 13.7 13.3 65 97 128 124 NR NR 
10 I37025 Jeyalakshmi 34/f 28 6 8.7 8.8 79 103 112 112 NR NR 
11 I48385 Sridevi 21/f 12 12 13.3 14 75 104 76 84 NR NR 
12 I41931 Lakshmi 37/f 12 8 13.6 12.6 72 99 98 118 NR NR 
13 I29619 Mythili 30/f 18 44 12.3 13 73 100 108 154 NR NR 
14 I35655 Vijaya 30/f 8 36 12.5 12.7 87 110 108 117 NR NR 
15 I50296 Vijayalakshmi 26/f 8 6 12.3 13.3 62 99 50 102 NR NR 
16 I24039 Vijaya 32/f 32 16 11.3 11.4 82 106 81 140 NR NR 
17 I31958 Srimathy 32/f 8 16 13.8 13.9 92 97 111 115 NR NR 
18 I56930 Selvi 27/f 8 6 11.9 11.2 92 97 82 102 NR NR 
19 I36211 Valliamma 32/f 18 22 12.5 12.6 92 94 110 120 NR NR 
20 I28243 Kujila 30/f 20 6 12.8 12.7 83 95 102 108 NR NR 
21 I3245 Rose.B 32/f 16 6 13.1 12.5 84 110 112 122 NR NR 
22 I58375 Amara.p 24/f 12 4 11.3 11.5 83 94 112 120 NR NR 
23 I36214 Vasantha 45/f 42 32 6.5 5.9 94 90 110 110 NR NR 
24 I50527 Amuthini 27/f 42 12 12.8 12.8 87 86 138 101 NR NR 
25 I55449 Rathnavathy 31/f 22 40 11.1 11.3 97 105 88 90 NR NR 
26 I54714 Anitha 29/f 24 6 9 9.2 99 110 117 125 NR NR 
27 I43262 Rajeswari 31/f 8 4 11.5 11.9 101 87 124 110 NR NR 
28 I60109 Vimala 30/f 46 18 13.9 13.9 124 110 95 120 NR NR 
29 I53755 Ammatchi 36/f 12 8 12.7 12.6 110 105 127 115 NR NR 
30 F82273 Jayasree 33/f 12 6 14.6 14.2 100 110 150 128 NR NR 
31 H66126 Shanthi 31/f 62 8 13 13.2 88 92 110 120 NR NR 
32 I48333 Bridjetmary 45/f 110 50 10.5 10.2 107 100 142 115 NR NR 
33 I47675 Suganthi 27/f 34 32 13.1 12.8 107 84 106 91 NR NR 
34 G39746 Gomathi 37/f 12 22 8.6 8.3 92 86 93 95 NR NR 
35 I00923 Yuvarani 35/f 42 10 13.3 12.8 104 84 133 120 NR NR 
36 I66325 Manju 27/f 22 42 11.6 11 111 103 111 93 NR NR 
37 H96938 Maheswari 27/f 40 70 12.5 11.6 100 89 131 98 NR NR 
38 I68998 K.Prasanna 32/f 32 20 13.2 12.2 97 83 110 94 NR NR 
39 I50605 G.kala 26/f 34 12 13 13.2 94 84 107 93 NR NR 
40 I63726 Manimegalai 22/f 4 6 12.5 12.7 104 110 135 127 NR NR 
 
88 
 
S. 
N
O 
OP NO NAME A/S                                     Liver function test( mg/dl) 
T.bilirubin 
(mg/dl) 
Dir 
mg/dl 
 
Ind 
mg/dl 
 
SGOT 
Iu/l 
 
 
SGPT 
Iu/l 
ALK 
phos 
Iu/l 
Total 
Protein 
g/dl  
    BT AT BT AT BT AT BT AT B
T 
AT BT AT BT AT 
1 I28105 B.Anjali 38/f 0.3 0.3 0.1 0.2 0.2 0.1 14 15 11 09 51 40 7.0 6.6 
2 I04794 A.Ramadevi 38/f 0.3 0.4 0.1 0.1 0.2 0.3 22 20 12 13 56 58 7.4 7.1 
3 G70637 S.Saaikala 29/f 0.5 0.5 0.2 0.2 0.3 0.3 29 14 42 17 97 95 7.6 7.0 
4 I38185 S.Saritha 30/f 0.5 0.5 0.2 0.2 0.3 0.3 18 17 15 18 48 35 7.0 6.8 
5 I44538 P.Anjala 31/f 0.6 0.7 0.3 0.3 0.3 0.4 25 23 17 18 48 47 7.9 7.0 
6 I41415 A.Suseela 30/f 0.2 0.4 0.1 0.2 0.1 0.2 22 21 11 14 70 65 7.2 7.4 
7 I1860 M.Jayasree 35/f 0.2 0.3 0.1 0.1 0.1 0.2 16 24 11 18 51 47 7.4 7.8 
8 I31972 V.Shema 30/f 0.8 0.8 0.4 0.4 0.4 0.4 22 20 24 24 59 61 6.7 7.1 
9 I34742 S.Radhika 30/f 0.4 0.7 0.2 0.3 0.2 0.4 14 11 10 10 30 27 6.9 6.5 
10 I37025 B.Jeyalakshmi 34/f 0.5 0.7 0.2 0.3 0.3 0.4 13 07 11 13 84 66 6.7 6.8 
11 I46385 S.Sridevi 21/f 0.3 0.4 0.1 0.2 0.2 0.2 15 16 16 16 49 61 7.2 7.1 
12 I41931 Lakshmi 37/f 0.9 0.9 0.3 0.4 0.6 0.5 15 13 10 06 58 55 7.7 7.2 
13 I29619 N.Mythili 30/f 0.6 0.8 0.2 0.3 0.4 0.5 20 17 17 13 48 52 7.4 7.3 
14 I35655 Vijayasree 30/f 0.4 0.3 0.2 0.2 0.2 0.1 19 17 22 21 64 52 7.8 7.3 
15 I50296 Vijayalakshmi 26/f 0.7 0.6 0.4 0.3 0.3 0.3 18 16 15 15 45 43 7.7 7.5 
16 I24039 L.Vijaya 32/f 0.6 0.5 0.3 0.2 0.3 0.3 19 13 16 11 50 39 7.6 7.3 
17 I31958 K.Srimathy 32/f 0.6 0.8 0.3 0.4 0.3 0.4 17 15 24 15 61 68 7.1 7.4 
18 I56390 M.Selvi 27/f 0.6 0.9 0.3 0.5 0.3 0.4 14 12 12 20 42 44 7.0 6.8 
19 I36211 V.Valliamma 32/f 0.5 0.6 0.2 0.3 0.3 0.3 14 15 13 18 52 65 7.2 7.2 
20 I28243 M.Kujila 30/f 0.3 0.2 0.1 0.1 0.2 0.1 13 15 14 13 42 65 6.9 6.7 
21 I36215 B.Rose 32/f 0.9 0.9 0.4 0.4 0.5 0.5 19 20 11 25 58 78 7.0 7.0 
22 I58375 P.Amara 24/f 0.3 0.2 0.2 0.1 0.1 0.1 26 23 27 22 41 43 7.0 7.0 
23 I36214 S.Vasantha 45/f 0.2 0.2 0.1 0.1 0.1 0.1 18 18 07 18 36 39 7.4 7.2 
24 I50527 V.Amuthini 27/f 0.7 0.4 0.3 0.2 0.4 0.2 20 17 09 14 59 60 7.5 7.2 
25 I55449 Rathanavathy 31/f 0.3 0.4 0.1 0.2 0.2 0.2 14 15 12 12 52 51 6.7 6.8 
26 I54714 J.Anitha 29/f 0.2 0.2 0.1 0.1 0.1 0.1 10 10 11 14 84 85 6.6 6.4 
27 I43262 Rajeswari 31/f 0.3 0.3 0.1 0.1 0.2 0.2 14 20 10 30 75 55 6.6 6.5 
28 I60109 M.Vimala 30/f 1.0 1.2 0.4 0.5 0.6 0.6 13 15 12 28 49 69 8.0 7.4 
29 I53755 G.Ammatchi 36/f 0.3 0.2 0.1 0.1 0.2 0.1 13 12 17 18 69 83 7.3 7.2 
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30 F82273 V.Jayasree 33/f 1.1 1.0 0.4 0.4 0.7 0.6 17 28 15 24 75 79 7.8 7.2 
31 H66126 Shanthi 31/f 0.3 0.2 0.1 0.1 0.2 0.1 16 18 20 25 80 86 7.2 7.4 
32 I48333 Bridjetmary 45/f 0.2 0.2 0.1 0.1 0.1 0.1 16 19 16 20 78 79 7.7 7.6 
33 I47675 Suganthi 27/f 0.3 0.2 0.1 0.1 0.2 0.1 17 17 17 21 49 55 7.4 6.9 
34 G39746 Gomathi 37/f 0.3 0.3 0.1 0.1 0.2 0.2 21 13 14 10 42 50 7.0 7.0 
35 I00923 Yuvarani 35/f 0.5 0.3 0.2 0.1 0.3 0.2 17 17 17 15 60 63 7.5 7.1 
36 I66325 Manju 27/f 0.4 0.3 0.2 0.1 0.2 0.2 13 17 10 08 61 70 7.0 7.1 
37 H96938 Maheswari 27/f 0.8 0.5 0.3 0.2 0.5 0.3 15 22 12 23 52 59 7.9 7.5 
38 I68998 K.Prasanna 32/f 0.4 0.3 0.2 0.2 0.2 0.1 11 15 10 08 53 62 7.0 6.5 
39 I50605 G.Kala 26/f 0.6 0.6 0.3 0.3 0.3 0.3 18 20 26 14 36 45 7.3 7.1 
40 I63726 Manimegalai 22/f 0.4 0.5 0.2 0.2 0.2 0.3 11 18 18 20 43 78 7.7 7.2 
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S. 
N
O 
OP NO NAME A/S     Total 
RBC 
(milli/cumm) 
 
           Renal function test (mg/dl) WET test 
for 
Trichomona
s vaginalis 
 
Blood 
urea 
mg/dl 
Sr. 
creatinie 
mg/dl 
Sr. uric  
Acid mg/dl 
    BT AT BT AT BT AT BT AT BT AT 
1 I28105 B.Anjali 38/f 4.0 4.2 20 23 0.7 0.8 0.9 2.3 + - 
2 I04794 A.Ramadevi 38/f 4.4 4.4 38 15 0.7 0.9 2.4 2.6 + - 
3 G70637 S.Sasikala 29/f 5.2 4.8 13 14 0.7 0.7 3.5 3.1 + - 
4 I38185 S.Saritha 30/f 4.6 4.6 19 18 0.9 0.9 3.5 4.3 + - 
5 I44538 P.Anjala 31/f 4.0 4.1 17 18 0.8 0.7 2.5 2.8 + - 
6 I41415 A.Suseela 30/f 3.9 4.1 17 16 0.8 0.7 2.1 2.2 + - 
7 I1860 M.Jayasree 35/f 3.9 4.6 12 15 0.7 0.8 4.1 4.1 + - 
8 I31972 V.Shema 30/f 4.6 4.8 18 19 0.7 0.7 4.0 4.0 + + 
9 I34742 S.Radhika 30/f 4.7 4.6 13 14 0.8 0.8 3.5 4.2 + + 
10 I37025 B.Jeyalakshmi 34/f 4.0 4.1 21 22 0.9 0.9 4.9 4.3 + - 
11 I46385 S.Sridevi 21/f 4.1 4.4 0.3 0.4 0.1 0.2 0.2 0.2 + - 
12 I41931 S.Lakshmi 37/f 4.9 4.5 16 15 0.9 0.8 4.1 3.2 + + 
13 I29619 N.Mythili 30/f 4.6 4.8 17 17 1.0 0.9 3.7 3.9 + + 
14 I35655 J.Vijayasree 30/f 4.7 4.6 13 11 0.9 0.8 4.4 4.7 + - 
15 I50296 S.Vijayalakshmi 26/f 4.5 4.5 17 09 0.9 0.8 3.6 2.2 + - 
16 I24039 L.Vijaya 32/f 4.4 4.5 12 16 0.9 0.8 2.1 1.9 - - 
17 I31958 K.Srimathy 32/f 4.3 4.3 16 15 0.7 0.7 2.9 3.1 - - 
18 I56390 M.Selvi 27/f 4.5 4.4 24 16 0.9 0.8 2.2 3.2 - - 
19 I36211 V.Valliamma 32/f 4.5 4.6 19 15 0.8 0.7 4.0 4.0 - - 
20 I28243 M.Kujila 30/f 4.2 4.2 12 13 0.7 0.7 2.4 2.4 - - 
21 I36215 B.Rose 32/f 4.5 4.5 28 29 0.7 0.6 2.3 2.3 - - 
22 I58375 P.Amara 24/f 4.1 4.2 21 21 0.8 0.8 3.6 3.6 - - 
23 I36214 S.Vasantha 45/f 3.8 3.6 23 20 0.8 0.8 3.8 3.8 - - 
24 I50527 V.Amuthini 27/f 4.1 4.2 18 18 0.7 0.8 3.0 2.3 - - 
25 I55449 B.Rathanavathy 31/f 4.6 4.1 16 25 0.7 0.8 3.0 5.0 - - 
26 I54714 J.Anitha 29/f 4.6 4.3 17 20 0.8 0.6 3.4 3.2 - - 
27 I43262 S.Rajeswari 31/f 4.1 4.2 16 32 0.8 1.0 4.2 4.4 - - 
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28 I60109 M.Vimala 30/f 4.7 4.7 13 13 0.8 0.8 3.1 3.2 - - 
29 I53755 G.Ammatchi 36/f 4.4 4.3 12 18 0.7 0.8 4.7 4.2 - - 
30 F82273 V.Jayasree 33/f 5.0 5.0 16 17 0.9 0.4 8.2 7.2 - - 
31 H66126 S.Shanthi 31/f 4.3 4.2 17 17 0.7 0.8 4.6 4.3 - - 
32 I48333 S.Bridjetmary 45/f 4.1 4.0 18 17 0.8 0.9 4.6 5.0 + + 
33 I47675 N.Suganthi 27/f 4.6 4.5 15 12 0.7 0.8 2.7 3.1 - - 
34 G39746 H.Gomathi 37/f 4.4 4.2 12 15 0.7 0.8 3.4 2.1 - - 
35 I00923  G.Yuvarani 35/f 4.9 4.6 21 17 0.8 0.8 4.1 2.8 - - 
36 I66325 L.Manju 27/f 4.2 4.1 19 18 0.7 0.7 3.1 3.3 - - 
37 H96938 J.Maheswari 27/f 4.7 4.3 09 14 0.7 0.9 4.2 4.2 - - 
38 I68998 K.Prasanna 32/f 4.6 4.6 12 08 0.8 0.8 2.0 2.0 - - 
39 I50605 G.Kala 26/f 4.5 4.5 22 27 0.8 0.8 4.8 4.3 - - 
40 I63726 Manimegalai 22/f 4.5 4.5 31 30 0.7 0.6 2.9 2.1 - - 
 
S. 
N
O 
OP NO NAME A/S                                            Lipid profile (mg/dl) 
 
 
Total 
cholesterol 
 
HDL LDL VLDL Triglyceride
s 
(Mg/dl) 
    BT AT BT AT BT AT BT AT BT AT 
1 I28105 B.Anjali 38/f 146 117 59 46 76 65 15 10 77 51 
2 I04794 A.Ramadevi 38/f 156 108 49 58 85 98 22 16 110 81 
3 G70637 S.Sasikala 29/f 175 137 45 46 100 74 28 35 209 173 
4 I38185 S.Saritha 30/f 136 131 64 44 76 69 10 13 49 65 
5 I44538 P.Anjala 31/f 121 122 63 54 67 65 08 14 38 73 
6 I41415 A.Suseela 30/f 137 139 58 44 76 74 18 13 89 66 
7 I1860 M.Jayasree 35/f 135 173 60 74 77 91 13 14 63 70 
8 I31972 V.Shema 30/f 79 91 41 43 39 41 18 11 88 54 
9 I34742 S.Radhika 30/f 122 148 51 53 78 81 23 24 114 122 
10 I37025 B.Jeyalakshmi 34/f 124 123 44 46 77 74 16 16 81 81 
11 I46385 S.Sridevi 21/f 143 127 68 59 78 70 11 12 56 63 
12 I41931 S.Lakshmi 37/f 161 149 49 45 102 84 17 20 86 101 
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13 I29619 N.Mythili 30/f 159 190 54 53 101 112 22 22 110 110 
14 I35655 J.Vijayasree 30/f 130 136 60 55 75 76 17 21 86 105 
15 I50296 S.Vijayalakshmi 26/f 120 140 53 59 63 73 12 20 61 101 
16 I24039 L.Vijaya 32/f 136 127 35 40 79 73 17 14 84 69 
17 I31958 K.Srimathy 32/f 115 123 54 54 73 55 59 12 70 62 
18 I56390 M.Selvi 27/f 122 121 51 58 66 63 11 18 52 92 
19 I36211 V.Valliamma 32/f 148 147 44 46 85 85 22 24 111 122 
20 I28243 M.Kujila 30/f 147 128 45 65 82 69 13 09 64 48 
21 I36215 B.Rose 32/f 132 128 53 55 70 70 10 10 50 58 
22 I58375 P.Amara 24/f 140 119 48 51 77 67 14 12 70 60 
23 I36214 S.Vasantha 45/f 104 94 34 40 56 51 19 15 95 76 
24 I50527 V.Amuthini 27/f 148 157 62 68 82 83 13 17 63 87 
25 I55449 B.Rathanavathy 31/f 181 174 61 66 107 102 21 12 102 63 
26 I54714 J.Anitha 29/f 127 132 32 38 77 78 17 12 87 85 
27 I43262 S.Rajeswari 31/f 178 153 50 44 104 98 31 35 152 175 
28 I60109 M.Vimala 30/f 207 208 69 69 106 102 13 14 64 70 
29 I53755 G.Ammatchi 36/f 208 204 65 66 126 128 17 11 85 76 
30 F82273 V.Jayasree 33/f 171 178 59 60 97 98 20 28 100 120 
31 H66126 S.Shanthi 31/f 137 142 50 56 76 72 23 28 114 128 
32 I48333 S.Bridjetmary 45/f 163 161 56 57 95 90 25 24 129 118 
33 I47675 N.Suganthi 27/f 148 143 49 54 75 77 10 12 52 62 
34 G39746 H.Gomathi 37/f 151 136 46 46 86 78 13 12 63 62 
35 I00923  G.Yuvarani 35/f 151 136 56 53 85 75 11 21 57 104 
36 I66325 L.Manju 27/f 127 136 47 46 69 73 11 18 53 93 
37 H96938 J.Maheswari 27/f 159 146 45 43 84 77 13 18 63 93 
38 I68998 K.Prasanna 32/f 176 158 60 47 102 88 21 22 103 111 
39 I50605 G.Kala 26/f 124 128 54 48 68 63 14 14 68 71 
40 I63726 Manimegalai 22/f 134 156 66 63 70 80 10 18 51 62 
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URINE ANALYSIS  
S. 
NO 
OP NO NAME A/S                          URINE ANALYSIS 
Albumin Sugar Deposits 
Pus cells Epi cells 
    BT AT BT AT BT AT BT AT 
1 I28105 B.Anjali 38/f NIL NIL NIL NIL 1-2 2-4 1-2 2-4 
2 I04794 A.Ramadevi 38/f NIL NIL NIL NIL 1-2 6-8 1-2 4-6 
3 G70637 S.Sasikala 29/f NIL NIL NIL NIL 1-2 1-2 1-2 1-2 
4 I38185 S.Saritha 30/f NIL NIL NIL NIL 3-5 2-4 PLENTY 2-4 
5 I44538 P.Anjala 31/f NIL NIL NIL NIL 1-2 2-4 1-2 1-2 
6 I41415 A.Suseela 30/f NIL NIL NIL NIL 3-5 2-3 2-4 4-5 
7 I1860 M.Jayasree 35/f NIL NIL NIL NIL 3-5 1-2 4-6 1-2 
8 I31972 V.Shema 30/f NIL NIL NIL NIL 1-2 2-3 1-2 1-2 
9 I34742 S.Radhika 30/f NIL NIL NIL NIL 1-2 4-5 1-3 2-3 
10 I37025 B.Jeyalakshmi 34/f NIL NIL NIL NIL 4-6 4-5 3-5 1-2 
11 I46385 S.Sridevi 21/f NIL NIL NIL NIL 2-4 1-2 2-4 1-2 
12 I41931 S.Lakshmi 37/f NIL NIL NIL NIL 2-4 2-4 24 2-3 
13 I29619 N.Mythili 30/f NIL NIL NIL NIL 4-6 2-4 4-6 2-4 
14 I35655 J.Vijayasree 30/f NIL NIL NIL NIL 2-4 2-4 2-4 2-4 
15 I50296 S.Vijayalakshmi 26/f NIL NIL NIL NIL 2-3 2-4 2-3 2-4 
16 I24039 L.Vijaya 32/f NIL NIL NIL NIL 2-4 2-4 1-2 1-2 
17 I31958 K.Srimathy 32/f NIL NIL NIL NIL 2-3 2-3 2-3 1-2 
18 I56390 M.Selvi 27/f NIL NIL NIL NIL 3-5 2-4 3-5 1-2 
19 I36211 V.Valliamma 32/f NIL NIL NIL NIL 6-7 1-2 2-4 1-2 
20 I28243 M.Kujila 30/f NIL NIL NIL NIL 4-6 1-2 4-7 1-2 
21 I36215 B.Rose 32/f NIL NIL NIL NIL 1-2 1-2 1-2 3-4 
22 I58375 P.Amara 24/f NIL NIL NIL NIL 2-4 4-6 2-4 2-4 
23 I36214 S.Vasantha 45/f NIL NIL NIL NIL 2-3 1-2 2-3 1-2 
24 I50527 V.Amuthini 27/f NIL NIL NIL NIL 1-2 2-4 1-2 1-4 
25 I55449 B.Rathanavathy 31/f NIL NIL NIL NIL 10-12 4-6 6-7 3-5 
26 I54714 J.Anitha 29/f NIL NIL NIL NIL 1-2 1-2 1-2 2-4 
27 I43262 S.Rajeswari 31/f NIL NIL NIL NIL 2-3 2-4 2-3 2-4 
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28 I60109 M.Vimala 30/f NIL NIL NIL NIL 2-3 1-2 2-3 1-2 
29 I53755 G.Ammatchi 36/f NIL NIL NIL NIL 2-4 1-2 1-2 1-2 
30 F82273 V.Jayasree 33/f NIL NIL NIL NIL 1-2 1-2 1-2 1-2 
31 H66126 S.Shanthi 31/f NIL NIL NIL NIL 1-2 1-2 1-2 2-4 
32 I48333 S.Bridjetmary 45/f NIL NIL NIL NIL PLENTY 1-2 6-7 2-4 
33 I47675 N.Suganthi 27/f NIL NIL NIL NIL 1-2 2-4 1-2 1-2 
34 G39746 H.Gomathi 37/f NIL NIL NIL NIL 1-2 4-5 1-2 1-2 
35 I00923  G.Yuvarani 35/f NIL NIL NIL NIL PLENTY 4-5 2-4 1-2 
36 I66325 L.Manju 27/f NIL NIL NIL NIL 4-5 1-2 2-3 4-5 
37 H96938 J.Maheswari 27/f NIL NIL NIL NIL 1-2 1-2 2-3 2-3 
38 I68998 K.Prasanna 32/f NIL NIL NIL NIL 1-2 1-2 2-4 1-2 
39 I50605 G.Kala 26/f NIL NIL NIL NIL 1-2 2-4 1-2 1-2 
40 I63726 Manimegalai 22/f NIL NIL NIL NIL 1-2 1-2 1-2 2-4 
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ANALYSIS OF TRIAL DRUG 
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CHEMICAL ANALYSIS 
Preparation of extract: 
 25 ml of Mega rajanga kirutham is measured accurately and placed in a 250 ml of clean 
beaker and added with 50ml of distilled water. Then it is boiled well for about 10 minutes. Then 
it is cooled and filtered in a 100ml volumetric flask and made up to 100ml with distilled water.  
S.NO                     EXPERIMENT       OBSERVATION          INFERENCE 
1. Appearance of the sample Straw color  
I. Test For Acid Radicles   
1.  Test for Sulphate: 
           2 ml of the above prepared 
extract is taken in a test tube to this 
added 2ml of 4% ammonium oxalate 
solution. 
No cloudy 
appearance. 
Absence of Sulphate. 
2. Test for Chloride: 
            2 ml of the above prepared 
extract is added with dil. Hno3 till the 
effervescence ceases. Then 2 ml of 
silver nitrate solution is added. 
Cloudy appearance 
present. 
Presence of 
Chloride. 
3. Test for Phosphate: 
          2ml of the extract is treated with 
2ml of ammonium molybdate solution 
and 2ml of con.Hno3. 
No cloudy yellow 
appearance.  
Absence of 
Phosphate. 
4.  Test for Carbonate: 
           2ml of the extract is treated with 
2ml magnesium sulphate solution. 
Cloudy appearance 
present. 
Presence of 
Carbonate. 
5. Test for Nitrate:  
            1 drop of the substance is 
heated with copper turnics and 
concentrated H2SO4 and viewed the test 
tube vertically down.  
No characteristic 
changes. 
Absence of nitrate. 
6. Test for Sulphide:  
            1 ml of the substance is treated 
with 2 ml of con.HCL. 
No rotten egg 
smelling gas evolved. 
Absence of Sulphide. 
7. Test for Fluride & Oxalate: 
             2 ml of the extract is added 
with 2ml of dil. Acetic acid and 2 ml 
calcium chloride solution and heated. 
No cloudy 
appearance. 
Absence of Fluride 
and Oxalate. 
8. 
 
Test for Nitrite: 
             3 drops of the extract is placed 
on filter paper on that 2 drops of acetic 
acid and 2 drops Benzidine solution is 
placed.  
No characteristic 
changes. 
Absence of Nitrite. 
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9. Test for Borate:  
            2 pinches of the substance is 
made into paste by using sulphuric acid 
and alcohol (95%) and introducer into 
the blue flame. 
Bluish green color 
flame not appeared. 
Absence of Borate. 
II.  Test for Basic Radicles   
1. Test for Lead:  
             2 ml of the extract is added 
with 2 ml of Potassium iodide solution. 
No yellow precipitate 
is obtained. 
Absence of Lead. 
2. Test for Copper: 
           One pinch of substance is made 
into paste with con.HCL in a watch 
glass and introduced into the non- 
luminous part of the flame. 
No blue color flame. Absence of copper. 
3. Test for Aluminum:  
           To the 2ml of the extract sodium 
hydroxide is added in drops to excess. 
No characteristic 
changes. 
Absence of 
Aluminium. 
4. Test for Iron: 
a. To the 2 ml of extract add 2 
ml of ammonium thiocynate 
solution. 
b. To the 2ml of extract 2 ml 
ammonium thiocynate 
solution and 2 ml of 
con.HNO3 is added. 
Mild red color 
appeared. 
 
 
Blood red color 
appeared. 
Presence of Iron. 
 
 
 
Presence of Iron. 
5. Test for Zinc:  
             To 2ml of the extract sodium 
hydroxide solution is added in drops to 
excess. 
White precipitate is 
not appeared. 
Presence of Zinc. 
6. Test for Calcium: 
            2 ml of the extract is added with 
2ml of 4% ammonium oxalate solution. 
 
No Cloudy 
appearance.  
Absence of Calcium. 
7. Test for Magnesium: 
              To 2ml of extract sodium 
hydroxide solution is added in drops to 
excess.  
White precipitate is 
obtained. 
Presence of 
Magnesium. 
8. Test for Ammonium: 
             To 2 ml of extract few ml of 
Nessler‟s reagent and excess of sodium 
hydroxide solution are added. 
No brown color 
appeared.  
Absence of 
ammonium. 
9. Test for Potassium: 
              1 ml of substance is treated 
with 2ml of sodium nitrate solution and 
then treated with 2ml of cobalt nitrate 
in 30% glacial acetic acid.  
No yellowish 
precipitate is 
obtained.  
Absence of 
Potassium. 
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10. Test for Sodium:  
            2 pinches of the substance is 
made into paste by using HCL and 
introduced into the blue flame of 
Bunsen burner. 
No yellow color 
flame appeared. 
Absence of sodium. 
11. Test for Mercury: 
             2 ml of the extract is treated 
with 2 ml of sodium hydroxide 
solution. 
No yellow precipitate 
is appeared. 
Absence of mercury. 
12. Test for Arsenic: 
            2 ml of the extract is treated 
with 2 ml of sodium hydroxide 
solution. 
No brownish red 
precipitate is 
obtained. 
Absence of Arsenic. 
III. Miscellanious   
1. Test for Starch: 
           2ml of the extract is treated with 
weak iodine solution. 
No blue color 
developed. 
Absence of starch. 
 
2. Test for Reducing sugar:  
            5 ml of Benedict‟s qualitative 
solution is taken in a test tube and 
allowed to boil for two minutes and 
added 8 to 10 drops of the extract and 
again boil it for 2 minutes. The color 
changes are noted. 
No brick red color 
developed. 
Absence of Reducing 
sugar. 
3. Test for the Alkaloids: 
            2 ml of extract is treated with 2 
ml of picric acid. 
Yellow color 
developed. 
Presence of 
Alkaloid. 
4. Test for Tannic acid:  
           2 ml of extract is treated with 2 
ml of ferric chloride solution. 
Black color 
precipitate is 
obtained. 
Presence of Tannic 
acid. 
5. Test for Unsaturated compound: 
          To the 2 ml of extract 2 ml of 
Potassium permanganate solution is 
added. 
Potassium 
permanganate is not 
decolorized. 
Absence of 
Unsaturated 
compound. 
6. Test for Amino acid:  
         2 drops of the extract is placed on 
a filter paper and dried well. 
No violet color 
developed. 
Absence of amino 
acid. 
7. Test for Type of Compound: 
          2 ml of the extract is treated 2 ml 
of ferric chloride solution.  
No green color 
developed. 
 
No red color 
developed. 
 
 
 
No violet color 
Absence of 
oxyquinole 
epinephrine and pyro 
catechol. 
Anti pyrine, Aliphatic 
amino acids and 
meconic acid are 
absent. 
Apomorphine 
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developed. 
 
No blue color 
developed. 
salicylate and 
Resorcinol are absent. 
Morphine, Phenol 
cresol and hydro 
quinine are absent. 
 
Result:  
The chemical study of the trial drug reveals Calcium, Carbonate, Iron, Zinc, 
Magnesium, Alkaloid and Tannic acid. 
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Physicochemical evaluation of Mega rajanga kirutham 
Project ID  : NRS/AS/0024/02/2017  
Institute  : National Institute of siddha,Chennai 
Sample Name  : Mega rajangakritham 
Sample ID   : MRK 
Percentage Loss on Drying 
10gm of test drug (weight equivalent to oil) was accurately weighed in evaporating dish 
.The sample was dried at 105
o
C for 5 hours and then weighed. 
Percentage loss in drying = Loss of weight of sample/ Wt of the sample X 100 
Determination of Total Ash 
3 g of test drug (weight equivalent to oil) was accurately weighed in silica dish and 
incinerated at the furnace a temperature 400 ºC until it turns white in color which indicates 
absence of carbon. Percentage of total ash will be calculated with reference to the weight of air-
dried drug. 
Total Ash = Weight of Ash/Wt of the Crude drug taken X 100 
Determination of pH 
Sample being oily in nature the direct litmus evaluation method was adopted to check the 
pH of the sample.  
Determination of Iodine value  
About 20 gm of oil was transferred into Iodine flask. To which 10 ml of chloroform  was 
added and warmed slightly and cooled for 10 minutes. Followed by this about 25 ml of Wiji‟s 
solution was added in the same flask and shaken well. The flask was allowed to stand for 30 
mins and refrigerated for anhour.T About 10 ml of KI solution was added to this and titrated 
against 0.1 N Sodium thiosulphate solutions until the appearance of yellow colour. 1 ml of starch 
indicator was added and again titrated against the sodium thiosulphate solution from the burette. 
Disappearance of blue colour indicates end point. Repeat the above procedure without taking 
sample and note the corresponding reading for blank titration. 
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Determination of saponification value  
About 2 gm(weight equivalent to oil) of test sample was transferred into the round 
bottomed flask. To this about 20 ml of 0.5 N alcoholic KOH solutions was added to the round 
bottomed flask. Repeatthe same procedure with out taking the sample for blank titration . Reflux 
both sample and blank round bottomed flasks for 1 hour. After reflux, allow both the round 
bottomed flasks to cool. Titrate the samples using 0.5 N HCl with phenolphthalein indicator. The 
disappearance of pink indicates the end point.  
 
Final Test report 
Parameter Observation 
Color Yellowish  
Smell Characteristic 
Touch Greasy 
Appearance Turbid 
 
 
S.No Parameter 
Mean (n=3) SD 
1 Loss on Drying at 105 °C (%) 8.03 ± 1.09 
2 Total Ash (%)  0.788  ± 0.37 
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S.No Specific Test MRK 
1 pH  6 
2 Refractive index  1.48 
3 Iodoine value (mg I2/g) 101 
4 
Saponification Value  (mg of KOH to saponify 1gm of 
fat) 
205 
 
 
Reference:  
1. India Pharmacopeia I Volume I, Government of India, Ministry of Health and Family 
welfare, Indian Pharmacopeia commission, 2014. 
2. Pharmacopoeial Laboratory for Indian Medicine (PLIM) Guideline for standardization 
and evaluation of Indian medicine which include drugs of Ayurveda, Unani and Siddha 
systems. Department AYUSH .Ministry of Health & Family Welfare, Govt. of India   
3. Indian standard methods of sampling and test for oils and fats Indian standard institution 
New Delhi 47-50. 1964 
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Phyto chemical analysis of Mega rajanga kirutham 
Sample Preparation 
Mega rajanga kirutham (MRK) was extracted with hexane and the extract was subjected 
to the following analysis 
Test for Alkaloid- Mayer's reagent 
To the test drug about 2ml of Mayer's reagent was added and was observed for the 
presence of alkaloids. Appearance of dull white precipitate indicates the presence of alkaloids. 
Test for flavonoid 
To 0.1ml of the test sample about 5 ml of dilute ammonia solution were been added 
followed by addition of few drops of conc. Sulfuric acid. Appearance of yellow color indicates 
the presence of Flavonoids. 
Test for Glycosides -Borntrager‟s Test 
Test drug is hydrolysed with concentrated hydrochloric acid for 2 hours on a water bath, 
filtered and the hydrolysate is subjected to the following tests. To 2 ml of filtered hydrolysate, 3 
ml of choloroform is added and shaken, choloroform layer is separated and 10% ammomia 
solution is added to it. Pink colour indicates presence of glycosides. 
Test for Triterepnoids 
To the test solution 2ml chloroform was added with few drops of conc. Sulphuric acid 
(3ml) at the side of the test tube. An interface with a reddish brown coloration is formed if 
terpenoids constituent is present. 
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Test for Steroids - Salkowski test 
To the test solution 2ml of chloroform was added with few drops of conc. Sulphuric acid 
(3ml), and shaken well. The upper layer in the test tube was turns into red and sulphuric acid 
layer showed yellow with green fluorescence. It showed the presence of steroids. 
Test for Carbohydrates - Benedict‟s test 
To 0.5 ml of test drug about 0.5 ml of Benedic‟s reagent is added. The mixture is heated 
on a boiling water bath for 2 minutes. A characteristic coloured precipitate indicates the presence 
of sugar. 
Test – Phenol- Lead acetate test 
The test sample is dissolved in of distilled water and to this 3 ml of 10% lead acetate 
solution is added. A bulky white precipitate indicates the presence of phenolic compounds. 
Test for tannins  
About 0.5ml of test sample is boiled in 20 mL of distilled water in a test tube and then 
filtered. The filtration method used here is the normal method, which includes a conical flask and 
filter paper. The 0.1% FeCl3 is added to the filtered samples and observed for brownish green or 
a blue black coloration, which shows the presence of tannins 
Test for Saponins 
The test drugs were shaken with water vigorously for 10 mins , copious lather formation 
indicates the presence of saponins. 
Test for Proteins (Biuret Test) 
Biuret test: Equal volume of 5% solution of sodium hydroxide and 1% copper sulphate 
were added. Appearance of pink or purple colour indicates the presence of proteins and free 
amino acids. 
Test of Coumarins 
 1 ml of extract, 1 ml of 10% sodium hydroxide was added. The presence of coumarins is 
indicated by the formation of yellow color. 
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Test for Anthocyanin 
About 0.2 ml of the extract was weighed in separate test tube, 1ml of 2N Sodium hydroxide 
was added, and heated for 5 minutes at 100 ± 2°C. Observed for the formation of bluish green 
color which indicates the presence of anthocyanin. 
Reference 
Brain KR, Turner TD. The Practical Evaluation of Phytopharmaceuticals. Bristol:Wright- 
Scientechnica; 1975:36-45 
RESULTS 
 Test for Alkaloid- Mayer's reagent 
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Test for flavonoid 
  
Test for Glycosides -Borntrager‟s Test 
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Test for Steroids - Salkowski test 
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 Test for Carbohydrates - Benedict‟s test 
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 Test – Phenol- Lead acetate test 
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 Test of Coumarins 
  
  
Test for Anthocyanin 
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PHYTOCOMPONENTS MRK 
ALKALOIDS - 
FLAVONOIDS + 
GLYCOSIDES - 
STEROIDS + 
SUGAR + 
TRITEREPNOIDS + 
COUMARINS + 
PHENOLS + 
TANNINS - 
SAPONINS - 
PROTEINS + 
ANTHOCYANIN - 
 
+   Indicates positive 
- Indicates Negative 
 
Quantitative estimation of phytoconstituents of Mega rajangakritham 
Determination of total Phenol content 
 The total phenol content was determined using Folin–Ciocalteu reagents with analytical 
grade Gallic acid as the standard. 1 ml of sample was added to deionized water (10 ml) and 
Folin–Ciocalteu phenol reagents (1ml). After 5 minutes, 20% sodium carbonate (2 ml) was 
added to the mixture. After being kept in total darkness for 1 hr, the absorbance was measured at 
750 nm using a spectrophotometer. Amounts of total Phenol was calculated using Gallic acid 
calibration curve. The results were expressed as Gallic acid equivalents (GAE) mg/g of dry plant 
matter. 
Reference 
Ganesh N. Sh 
arma K, Nitin S, Jyotsana S. Phytochemical screening and estimation of Total Phenolic Content 
in AeglemarmelosSeeds. Int J PharmaClinc Res.2011; 3(2): 27-29.  
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Total Flavonoid 
Total flavonoid content in the drug  MRK was determined using aluminum chloride method . In 
this method Quercetin was used as standard and flavonoid contents were measured as 
quercetinequivalent. For this purpose, the calibration curve of quercetin was drawn. 1ml of 
standard or sample MRK was taken into 10ml volumetric flask, containing 4ml of distill water. 
0.3ml of 5%NaNO2 added to the flask. After 5min, 0.3ml 10%AlCl3 was added to the mixture. 
At the 6th min add 2ml of 1M NaOH was added and volume made up to 10ml with distills water. 
The absorbance was noted at 510nm using UV-Visible spectrophotometer. 
Reference 
Olajire A. A and Azeez L Total antioxidant activity, phenolic, flavonoid and ascorbic acid 
contents of Nigerian vegetables., 2011; 2(2) 022-029,African Journal of Food Science and 
Technology 
Phyto- constituents MRK 
Total phenols                         
 (GAE mg/gm) 
0.934 ± 0.04 
Total flavanoids 
 (Quercetin mg/gm) 
2.82 ± 0.42 
 
Mean with 3 replicates ± SD. 
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Anti inflammatory activity of Mega rajanga kirutham 
In-vitro Anti-Inflammatory Activity by Protein (Albumin) denaturation Assay 
Project ID  : NRS/AS/0025/02/2017 
Institute   : National Institute of Siddha 
Sample Name  : Mega rajangakritham 
Sample ID   : MRK  
Sample Stock prepared using Hexane  
Albumin Denaturation Assay Procedure 
In-vitro anti-inflammatory activity Mega rajangakritham (MRK) was studied using albumin 
denaturation technique. The reaction mixture consisted of bovine serum albumin (5% aqueous solution) 
and test sample MRK at varying concentration ranges from 100 to 500 mcg/ml and standard diclofenac 
sodium at the concentration of100 mcg/ml of final volume. pH was adjusted by using a small amount of 1N 
Hydrochloric acid. The samples were incubated at 37°C for 20 min and then heated at 57°C for 3 min. After 
cooling the sample, 2.5 ml of phosphate buffer solution was added into each test tube. Turbidity developed 
was measured spectrophoto-metrically at 660 nm, for control distilled water was used instead of test 
sample while product control tests lacked bovine serum albumin. The experiment was performed in 
triplicate. 
The Percentage protection from denaturation is calculated by using the formulae 
 
Statistical analysis 
Results are expressed as Mean ± SD. The difference between experimental groups was compared by 
One-Way Analysis Of Variance (ANOVA) followed by Dunnet Multiple comparison test 
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Preparation of Test and control 
 
Absorbance of reaction mixture – Test Sample 
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Absorbance of reaction mixture – Control and Standard 
 
Absorbance Range of test and standard at Trial 1 
 
Absorbance Range of test and standard at Trial 2 
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Absorbance Range of test and standard at Trial 3 
 
FINAL RESULT 
Concentration in 
µg/ml 
Absorbance 
Control 
0.917  ± 0.020 
MRK 100 0.61  ± 0.098 
MRK 200 0.503 ± 0.076 
MRK 300 0.406  ± 0.040 
MRK 400 
0.296  ± 0.080 
MRK 500 0.203  ± 0.045 
Diclofenac sodium                
(100 µg) 
0.023  ± 0.011 
Each value represents the mean ± SD. N=3 
Concentration in 
µg/ml 
Percentage Inhibition of Protein 
Denaturation 
MRK 100 
25.18  ± 13.2 
MRK 200 36.89  ± 8.97 
MRK 300 47.46  ± 4.49 
MRK 400 59.34  ± 10.9 
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MRK 500 
69.54  ± 7.22 
Diclofenac sodium                
(100 µg) 
89.22  ± 2.83 
Each value represents the mean ± SD. N=3 
Result Analysis 
The result obtained from the present clearly indicates that the test drug MRK was effective in inhibiting heat 
induced albumin denaturation. Maximum percentage inhibition of about 69.54 % was observed at 500 
μg/ml when compare to that of the Diclofenac sodium, a standard anti-inflammatory agent with the 
maximum inhibition 89.22 % at the concentration of 100 μg/ml. 
Conclusion 
From the result of the study it was concluded that the test drug MRK possess promising anti-inflammatory 
property in protein denaturation assay. 
Reference 
1. G.Leelaprakash, S.MohanDass. In-vitro anti-inflammatory activity of methanol extract of 
enicostemmaaxillare. Int. J. Drug Dev. & Res., 2011, 3 (3): 189-196. 
2. M. V. Anoop, A. R. Bindu . In-vitro Anti-inflammatory Activity Studies on Syzygiumzeylanicum (L.) 
DC Leaves. International Journal of Pharma Research & Review, August 2015; 4(8):18-27. 
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Anti microbial activity of Mega rajanga kirutham 
Purpose: Anti- Microbial Profiling 
Project Id : NRS/AS/0025/02/2017 
Total Sample : 01  
Sample ID :  MRK 
Institute : National Institute of Siddha, Chennai 
Disc-diffusion method:  
The antibacterial activities of the sample MRK were carried out by disc diffusion method.  
The concentrations of the test compounds were used at the concentration of 500, 1000, 2000 µg. 
The target microorganisms were cultured in Mueller–Hinton broth (MHB). After 24 h the 
suspensions were adjusted to standard sub culture dilution. The Petri dishes containing Muller 
Hinton Agar (MHA) medium were cultured with diluted bacterial strain.Diamond's mediumused 
for incubation ofTrichomonasvaginalis. Disc made of Whatman No.1, diameter 6 mm was pre-
sterilized and was maintained in aseptic chamber.Each concentration was injected to the sterile 
disc papers. Then the prepared discs were placed on the culture medium.Standard drug 
Ciprofloxacin (5µg) for anti-bacterial /Metronidazole (5µg) for Trichomonasvaginalisand 
Fluconazole (25µg) was used as a positive reference standard to determine the sensitivity of each 
microbial species tested. Then the inoculated plates were incubated at 37
o 
C for 24 h (Bacterial) - 
72 hr (Fungal).The diameter of the clear zone around the disc was measured and expressed in 
millimeters as its anti-microbial property. The results were depicted in Table. 
Organisms used for Anti-Bacterial Activity 
s.no organisms 
1.  E-Coli 
2.  Staphylococcus aureus 
3.  TrichomonasVaginalis 
4.  Candida albicans 
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5.  Aspergillusniger 
 
Zone of Inhibition data of Anti-Microbial activity  
Sample 
Code E-Coli 
Staphylococcus 
aureus 
Trichomonas
Vaginalis Candida albicans Aspergillusniger 
Concentra
tion 
500 
µg 
1000 
µg 
200
0  
µg 
500 
µg 
1000 
µg 
200
0  
µg 
50
0 
µg 
10
00 
µg 
200
0  
µg 
500 
µg 
1000 
µg 
2000  
µg 
500 
µg 
1000 
µg 
200
0  
µg 
MRK 
- 2 4 - 4 8 - 3 6 - - 3 - - - 
Ciprofloxa
cin  
(10µg) 24 19 NA NA NA 
Metronida
zole (5µg) 
NA NA 
22 
NA NA 
Fluconazol
e (25µg) NA NA NA 20 17 
-  =  Not active  
- NA= Not Applicable 
Conclusion 
From the results of the present study it was concluded that the sample MRK was effective 
against TrichomonasVaginalis,Staphylococcusaureus,E-Coli,Candida albicans and not active 
againstAspergillusniger 
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Anti-Bacterial Evaluation of MRK 
Anti- Microbial Effect of MRK against Staphylococcus aureus 
    
 
 
Anti- Microbial Effect of MRK against E-Coli 
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Anti- Microbial Effect of MRK against TrichomonasVaginalis 
 
Anti- Microbial Effect of MRK against Candida albicans 
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Anti- Microbial Effect of MRK against Aspergillusniger 
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Anti-Oxidant activity of Mega rajanga kirutham 
Project Report 
Project Id: NRS/AS/0025/02/2017 
Total Sample: 01 
Sample :Mega rajangakritham 
Sample ID: MRK 
Institute : National Institute of Siddha, Chennai, Tamil Nadu, India 
Purpose: Characterization 
DPPH (2, 2-Diphenyl 1-2 picrylhydrazyl) Assay 
 
The antioxidant activity of test drug sample MRK was determined using the 2,2-diphenyl 
1-2 picrylhydrazyl (DPPH) free radical scavenging assay . Sample MRK was mixed with 95% 
methanol to prepare the stock solution in required concentration (10mg/100ml or 100μg/ml). 
From the stock solution 1ml, 2ml, 4ml, 6ml 8ml and 10ml of this solution were taken in five test 
tubes and by serial dilution with same solvent were made the final volume of each test tube up to 
10 ml whose concentration was then10 μg/ml, 20 μg/ml, 40μg/ml, 60 μg/ml, 80 μg/ml and 100 
μg/ml respectively. Ascorbic acid were used as standard was prepared in same concentration as 
that of the sample extract by using methanol as solvent. Final reaction mixture containing 1 ml of 
0.3 mM DPPH methanol solution was added to 2.5 ml of sample solution of different 
concentrations and allowed to react at room temperature. Absorbance in the presence of test 
sample MRK at different concentration of (10 µg, 20 µg, 40 µg, 60 µg, 80 µg and 100 µg/ml) 
was noted after 15 min incubation period at 37
0
C. Absorbance was read out at 517 nm using 
double-beam U.V Spectrophotometer by using methanol as blank. 
% scavenging = [Absorbance of control - Absorbance of test sample/Absorbance of control] 
X 100 
The effective concentration of test sample MRK required to scavenge DPPH radical by 
50% (IC50 value) was obtained by linear regression analysis of dose-response curve plotting 
between %inhibition and concentrations 
Reference 
Badami, Omprakash, DongrSH,Suresh B. In-vitro Antioxidant property of  
SolanumPseudocapsicum leaf extract. Indian J Pharmacol.2005; 37:251-252. 
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Nitric Oxide Radical Scavenging Assay 
The concentrations of test sample MRK are made into serial dilution from 10−100 μg/mL 
and the standard gallic acid. Griess reagent was prepared by mixing equal amounts of 1% 
sulphanilamide in 2.5% phosphoric acid and 0.1% naphthylethylenediaminedihydrochloride in 
2.5% phosphoric acid immediately before use. A volume of 0.5  mL of 10  mM sodium 
nitroprusside in phosphate buffered saline was mixed with 1  mL of the different concentrations 
of the test drug (10−100  μg/mL) and incubated at 25°C for 180  mins. The test drug MRK was 
mixed with an equal volume of freshly prepared Griess reagent. Control samples without the test 
drug but with an equal volume of buffer were prepared in a similar manner as was done for the 
test samples. The absorbance was measured at 546  nm using a Spectra Max Plus UV-Vis 
microplate reader (Molecular Devices, GA, USA). Gallic acid was used as the positive control. 
The percentage inhibition of the test drug MRK and standard was calculated and recorded. The 
percentage nitrite radical scavenging activity of the test drug MRK and gallic acid were 
calculated using the following formula: 
 
Reference 
B. N. Panda, A. B. Raj, N. R. Shrivastava, and A. R. Prathani, “The evaluation of nitric oxide 
scavenging activity of Acalyphaindica Linn Root,” Asian Journal Research Chemistry, vol. 2, 
no. 2, pp. 148–150, 2009.  
ABTS Assay 
This assay carried out for the purpose of evaluating the anti-oxidant potential of test drug 
MRK against 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) or ABTS radicals 
The ABTS radical cation method was modified to evaluate the free radical-scavenging effect of 
one hundred pure chemical compounds. The ABTS reagent was prepared by mixing 5  mL of 
7  mM ABTS with 88  μL of 140  mM potassium persulfate. The mixture was then kept in the 
dark at room temperature for 16  h to allow free radical generation and was then diluted with 
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water (1  :  44, v/v). To determine the scavenging activity, 100  μL ABTS reagent was mixed 
with 100  μL of test sample (10-100μg/ml) and was incubated at room temperature for 6  min. 
After incubation, the absorbance was measured 734  nm.  100% methanol was used as a 
control.Gallic acid with same concentrations of test drug MRK was measured following the same 
procedures described above and was used as positive controls. The antioxidant activity of the test 
sample MRK was calculated using the following equation: The ABTS scavenging effect was 
measured using the following formula: 
 
Reference 
N. Pellegrini, M. Ying, and C. Rice-Evans, “Screening of dietary carotenoids and carotenoid-rich 
fruits extract for antioxidant activities applying 2,2′-azobis (3-ethylbenzothine-6-surfonic acid) 
radical cationdecolorization assay,” Methods in Enzymology, vol. 299, pp. 384–389, 1999. 
Results 
Percentage inhibition of test drug MRK on  
DPPH radical scavenging assay 
 
Concentration 
(μg/ml) 
% Inhibition of  
Ascorbic Acid 
% Inhibition of 
MRK 
10 μg/ml 38.15 ±  3.395 7.778 ±  2.222 
20 μg/ml 50.37 ±  7.398 16.67 ±  1.925 
40 μg/ml 61.11 ±  6.186 23.7 ±  1.697 
60 μg/ml 70.74 ±  9.45 29.63 ±  3.395 
80 μg/ml 80.37 ±  2.313 35.56 ±  1.925 
100 μg/ml 88.15 ±  0.6415 41.85 ±  3.395 
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  Data are given as Mean ± SD (n=3) 
IC50 Values for DPPH radical scavenging Assay by MRK and standard. 
Test Drug / Standard IC50 Value  DPPH  Assay ±  SD (μg /ml)   
ASCORBIC ACID 23.55 ±  10.9 
MRK 121 ±  12.15 
Data are given as Mean ± SD (n=3) 
Percentage inhibition of test drug MRK on  
Nitric Oxide radical scavenging assay 
 
Concentration 
(μg/ml) 
% Inhibition of  
MRK 
% Inhibition of 
Gallic Acid 
10 μg/ml 6.069 ±  2.168 31.07 ±  2.621 
20 μg/ml 19.61 ±  3.658 41.14 ±  0.6014 
40 μg/ml 26.9 ±  4.21 52.94 ±  1.203 
60 μg/ml 32.46 ±  6.831 60.58 ±  1.804 
80 μg/ml 43.22 ±  9.679 67.18 ±  7.678 
100 μg/ml 55.03 ±  7.536 82.81 ±  0.6014 
  Data are given as Mean ± SD (n=3) 
IC50 Values for Nitric Oxide radical scavenging assay 
byMRK and standard. 
Test Drug / Standard IC50 Value  NO Assay  
±  SD (μg /ml)   
MRK 40.41  ±  2.46 
GALLIC ACID 93.74 ±  16.24 
Data are given as Mean ± SD (n=3) 
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Percentage inhibition of test drug MRK on  
ABTS radical scavenging assay 
Concentration 
(μg/ml) 
% Inhibition of  
MRK 
 
% Inhibition of 
Gallic Acid 
10 μg/ml 13.97 ±  3.772 22.57 ±  3.772 
20 μg/ml 20.78 ±  3.281 37.6 ±  4.341 
40 μg/ml 27.58 ±  3.873 46.56 ±  5.298 
60 μg/ml 36.89 ±  1.24 66.96 ±  2.236 
80 μg/ml 44.76 ±  1.86 77.35 ±  3.281 
100 μg/ml 55.86 ±  3.772 88.45 ±  1.24 
   Data are given as Mean ± SD (n=3) 
IC50 Values for ABTS radical scavenging assay 
By MRK and standard. 
Test Drug / Standard IC50 Value  ABTS  Assay ±  
SD (μg /ml)   
MRK 42.48  ±  1.45 
GALLIC ACID 89.18 ±  2.81 
Data are given as Mean ± SD (n=3) 
Conclusion  
From the results of the present investigation it was concluded that the siddha formulation MRK 
has promising anti-oxidant activity in the estimated test. 
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Percentage inhibition ofSTD on ABTS radical scavenging assay 
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Percentage inhibition ofMRK on ABTS radical scavenging assay 
 
Triplicate 1 
 
Triplicate 2 
 
Triplicate 3 
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Percentage inhibition ofSTD on DPPH radical scavenging assay 
 
Triplicate 1 
 
Triplicate 2 
 
Triplicate 3 
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Percentage inhibition ofMRK on DPPH radical scavenging assay 
 
Triplicate 1 
 
Triplicate 2 
 
Triplicate 3 
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Percentage inhibition ofSTD on NO radical scavenging assay 
 
Triplicate 1 
 
Triplicate 2 
 
Triplicate 3 
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Percentage inhibition ofMRK on NO radical scavenging assay 
 
Triplicate 1 
 
Triplicate 2 
 
Triplicate 3 
135 
 
GCMS Analysis of Mega Rajanga Kirutham 
GCMS- Analysis Report 
GCMS (Clarus 500 Perkin – elmer (Auto system XL)), NIST Ver.2.1 MS data library 
Specification: 
Start Time (min)   End Time(min)   Start m/z  End m/z Scan   Speed 
2.50   18.00   50.00   650.00    2000 
Sample Inlet Unit: GC 
 GC-MS Plays a key role in the analysis of unknown components of plant origin. GC-MS 
ionizes compound and measures their mass numbers. Ionization method includes EI (Electron 
Ionization). The EI method produces ions by colliding thermal electrons emitted from a filament 
with sample gas molecules. This method provides high stability in ionization and obtained mass 
spectra show good reproducibility. The EI method provides good result for quantitative analysis 
as well. Quantitative analysis with GC-MS, in which only ions specific to the compounds are 
measured, is highly selective method without interfering components. Gas chromatography 
Technique involves the separation of volatile components in a test sample using suitable 
capillary column coated with polar or non-polar or intermediate polar chemicals. Elite-1 column 
(100% Dimethyl polysiloxane) is a non-polar column used for analysis of phyto-components. 
Elite -5 column (5% phenyl and 95% methyl polysiloxane) is an intermediate column and also 
used for the estimation of Phytochemical. An inert gas such as hydrogen or nitrogen or helium is 
used as a carrier gas .The compounds of test sample is evaporated in the injection port of the GC 
equipment and segregated in the column by absorption and adsorption technique with suitable 
GC programme. 
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GC-MS CHROMATOGRAM OF MRK 
 
Peak Report of MRK 
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TLC and HPTLC ANALYSIS OF MEGA RAJANGA KIRUTHAM 
TLC Analysis Report  
Project ID  : NRS/AS/0025/02/2017 
Institute   : National Institute of Siddha 
Sample Name  : Mega rajangakritham 
Sample ID   : MRK  
TLC Analysis 
Test sample MRK was subjected to thin layer chromatography (TLC) as per conventional one 
dimensional ascending method using silica gel 60F254, 7X6 cm (Merck) were cut with ordinary 
household scissors. Plate markings were made with soft pencil. Micro pipette were used to spot 
the sample for TLC applied sample volume 10-micro liter by using pipette at distance of 1 cm at 
5 tracks. In the twin trough chamber with different solvent system Ethyl acetate: Methanol: 
Water (100:13.5:10) After the run plates are dried and was observed using visible lightShort-
wave UV light 254nm and light long-wave UV light 365 nm 
 
Sample Spotting 
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Visible         Short UV    Long UV 
 
Reference 
Lukasz Komsta, Monika Waksmundzka-Hajnos, Joseph Sherma . Thin Layer Chromatography 
in Drug Analysis .CRC Press, Taylor and Francis. 
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High Performance Thin Layer Chromatography Analysis 
HPTLC method is a modern sophisticated and automated separation technique derived 
from TLC. Pre-coated HPTLC graded plates and auto sampler was used to achieve precision, 
sensitive, significant separation both qualitatively and quantitatively. High performance thin 
layer chromatography (HPTLC) is a valuable quality assessment tool for the evaluation of 
botanical materials efficiently and cost effectively. HPTLC method offers high degree of 
selectivity, sensitivity and rapidity combined with single-step sample preparation. In addition it 
is a reliable method for the quantitation of nano grams level of samples. Thus this method can be 
conveniently adopted for routine quality control analysis. It provides chromatographic 
fingerprint of phytochemicals which is suitable for confirming the identity and purity of 
medicinal plant raw materials.  
Chromatogram Development 
It was carried out in CAMAG Twin Trough chambers. Sample elution was carried out 
according to the adsorption capability of the component to be analysed. After elution, plates were 
taken out of the chamber and dried. 
Scanning 
Plates were scanned under UV at 366nm. The data obtained from scanning were brought 
into integration through CAMAG software. Chromatographic finger print was developed for the 
detection of phytoconstituents present in each extract and Rf values were tabulated.
 
Reference 
1. Wagner H. Plant Drug Analysis. A thin Layer chromatography Atlas.2nd ed. Heidelberg: 
Springer-Verlag Belgium; 2002:305, 227.  
HPTLC Chromatographic condition  
Sample   : MRK 
Derivatization Solvent : Anisaldehyde 
Stationary phase  : Silica gel GF254 
Mobile phase  : Chloroform: Hexane: Methanol (6:3:1)  
Scanning wavelength  : 366 nm 
Sample concentration  : 10mg/ml  
Applied volume             : 5 µl  
Application mode          : CAMAG HPTLC 
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TLC Chromatogram 
 
 
 
HPTLC CHROMATOGRAM OF MRK 
 
Peak Table of HPTLC finger printing of MRK 
 
146 
 
 
 
 
 
 
 
 
DISCUSSION 
 
 
 
 
 
 
 
 
 
147 
 
 
DISCUSSION 
 Vellai noi which affect the women, commonly and frequently in reproductive age group. 
It is one of the sexually transmitted disease. The signs and symptoms of vellai noi are correlated 
with Leucorrhoea in modern medicine.  
 40 cases of vellai noi were diagnosed based on clinical symptoms and vaginal smear. All 
the cases were treated in outpatient department of Ayothidoss pandithar hospital, NIS, 
Tambaram, Sanastorium, and Chennai-47. 
 The various siddha & modern methods of examination of the diseases were carried out 
and the data were recorded in the proforma. 
 The trial medicine selected for internal treatment is Mega rajanga kirutham. The day 
before starting the treatment with the trial drug “Mega rajanga kirutham” , Purgation was given 
with Meganatha kuligai-2 in hot water. Next day the patient was advised to take rest. Third day 
onwards the trial drug Mega rajanga kirutham-4ml twice a day before food was given 
continuously for 9 days. From the next day onwards the patient was under drug holiday for 9 
days. Then another 9 days trial medicine was given to the patient continuously. 
 Before starting the treatment careful detailed history was taken and recorded for the 40 
selected cases.  
 Laboratory investigation was done periodically for all the cases and vaginal smear were 
done for all the cases before and after treatment. 
 The biochemical, pharmacological studies of the trial drug was done in the laboratories 
and the results were documented. 
Gender distribution: 
 Though vellai noi affects both sexes, only 40 female patients were selected for this 
dissertation. In our hospital, female cases were recorded more than the male cases. So the sexual 
dominance was not studied.  
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Age distribution:  
Among 40 cases, 50% of cases were in the age between 21-30years, 45% of cases, 
between 31-40 years, only 5% of cases were in the age between 41-54years. So the occurrence of 
disease is found mostly in 21-30 years age group.  (Fig: 1) 
Marital status:  
All the 40 cases in this study were married. Married females were more affected than 
unmarried because; it is a sexually transmitted disease. (Fig: 2) 
Paruvakaalam:  
 Among 40 patients, 65% of cases were affected in Munpani kaalam. 35 % in Pinpani 
kaalam. (Fig: 3) 
Thinai:  
 72.5% of the cases were coming from Neithal nilam, 25% came from Marytham. Only 
2.5% were coming from Kurini. Maximum No of cases were from the Neithal nilam. Because 
Vellai noi is a Pitha disease, and people who are living in sea sour (Neithal nilam) are more 
prone to pitha disease. (Fig: 4) 
Diet factors:  
 Among 40 cases, 97.5% cases were Non-vegetarians. Only 2.5% were vegetarians. Most 
of the cases were found in non-vegetarian category. In non-vegetarian people, body heat is 
increased so it may be produce pitha disease. (Fig: 5) 
Socio-economic Status: 
Among 40 cases, 45% of cases were belongs to poor class, 40% were brlonging to middle 
class. Only 12.5 % were in rich people. So this disease was found mostly in poor class people 
due to poor socio-economic stage, poor hygiene and ignorance of treatment. (Fig: 6) 
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Family history: 
 Among 40 cases, 90% of cases were not found any family history; only 10% of cases had 
family history of vellai noi. (Fig: 7) 
Kaalam: 
 Among 40 cases, 72.5% of patients were affected in vatha kaalam (age up to 33years). 
27.5% of patients were affected in Pitha kaalam (34 to 66 years).  (Fig: 8) 
Habit: 
 All the 40 cases do not have any bad habits like Pan, Snuff etc. 
Thegi: 
 Among 40 cases, 37.5% of patients are Pitha thegi, and 30% are Vatha thegi, 32.5% are 
Thontha thegi. Most of the cases were Pitha thegi category; they are more prone to pitha disease. 
(Fig: 9) 
Educational Status: 
 Among 40 cases, 40% of patients are illiterate, 27.5% are middle school completed, 20% 
are High school completed and 12.5% are Degree holder. Illiterate people were mostly affected, 
due to poor hygiene, ignorance of treatment. (Fig: 10) 
Body built: 
 Among 40 cases, 55% of patients were under weight. 27.5% were Normal weight and 
17.5% were Obese. (Fig: 11) 
Occupation: 
 Among 40 cases, 50% of patients were in daily wages. 37.5% of patients were 
housewives. Only 12.5% of patients were in sedentary work. (Fig: 12) 
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Treatment History: 
 Among 40 cases, 45% of patients had allopathic treatment for Leucorrhoea. 20% of 
patient‟s dose not had any treatment for leucorrhoea. 17.5% of patients had siddha treatment, 
7.5% had Ayurvedhic and 10% had Homeopathic treatment for the same illness. (Fig: 13) 
Clinical history:  
 100% of patients had whitish/yellowish discharge per vagina, Low back pain, vulval 
irritation, and Dyspareunia. 97.5% had Pruritus vulva, 95% had lower abdominal pain and 75% 
had Dysuria. (Fig: 19) 
Disturbances of Vatham: 
 All the 40 cases were affected with Abanan, Viyanan, Samanan and Devathathan.  
 Affected abanan produce vaginal discharge.  
Affected viyanan produce low back pain and lower abdominal pain.  
Affected devathathan produce tiredness and general weakness of upper limb and lower 
limb. (Fig: 14) 
Disturbances of Pitham:  
 Among 40 cases, 50% of patients were affected with Anarpitham, 20% of cases were 
affected with Ranjaga pitham. Only 5% of cases were affected with Alosaga pitham. 
 Affected anarpitham produce loss of appetite and ranjaga pitham produce Anaemia. (Fig: 
15) 
Disturbances of Kabam:  
 Among 40 cases 100% of patients were affected with Avalambagam and santhigam.  
 Affected santhigam produce Low back pain. (Fig: 16) 
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Changes in Kosangal: 
 Among 40 cases, 100% of patients were affected with Annamaya kosam and Manomaya 
kosam. 80% of patients were affected with piranamaya kosam. 55% of cases were affected with 
Anandhamaya kosam. 
 Affected Annamaya kosam indicates loss of appetite, general weakness, and tiredness.  
 Affected Manomaya kosam indicates Stress due to increased vaginal discharge. 
 Affected piranamaya kosam indicates low back pain and weakness in both upper limb 
and lower limb.  
 Affected Ananthamaya kosam indicates Disturbed Sleep due to pruritus vulva. (Fig: 17) 
Seven Udal thathukkal: 
 Among 40 cases 100% of patients were affected with saaram and suronitham. 30% of 
patients were affected with enbu. 20% of patients were affected with senneer. 
Affected saaram indicates general weakness and tiredness.  
Affected suronitham indicates excessive vaginal discharge. 
Affected enbu indicates low back pain both upper limb and lower limb pain. (Fig: 18) 
Neerkkuri and Neikkuri:  
 55% of case of Neikkuri showed pitha neer, 25% showed kaba neer and 20% of cases 
showed slowly spread shape. Most of the neikkuri showed pitha neer because it indicates 
increased pitham in these patients. 
Special investigation:  
 VDRL, vaginal smear tests were done in all cases before treatment.  All the cases had 
negative VDRL test. 
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 Among 40 cases only 15 cases were Wet test positive for Trichomonas vaginalis. Another 
25 cases were symptomatically treated with this trial drug. After treatment among 15 positive 
cases, 10 cases were turned to negative result. (Fig: 20) 
Results after treatment: 
 66% of cases showed negative result for Trichomonas vaginalis. Symptomatically among 
40 cases 50% of cases showed good result 40% of cases showed moderate improvement. Only 
10% of cases showed poor result. (Fig: 21) 
Chemical Analysis:  
The chemical study of the trial drug reveals Calcium, Carbonate, Iron, Zinc, Magnesium, 
Alkaloid and Tannic acid. 
Pharmacological study:  
 The pharmacological study reveals the trial drug have Anti inflammatory, Anti microbial 
and Anti oxidant activity in In vitro study. 
 Physico-chemical, Phyto chemical, GCMS, TLC, and HPTLC has also be done for trial 
drug.  
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STATISTICAL ANALYSIS 
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Statistical analysis for Clinical study 
 All collected data were entered into MS Excel software using different columns as 
variable and rows as patients. SPSS software was used to perform statistical analysis. Basic 
descriptive statistics include frequency distributions and cross-tabulations were performed. The 
quantity variables were expressed as Mean + Standard Deviation and qualitative data as 
percentage. A probability value of <0.05 was considered to indicate as statistical significance. 
Paired„t‟ test was performed for determining the significance between before and after treatment. 
 Paired Sample Statistics (Symptoms score before and after treatment) 
Variable Obs Mean±std „t‟ Value p Value 
Before treatment 40 6.65±0.53 17.13 <0.0001 
After treatment 40 1.57±1.75 
The Mean ± Standard deviation of symptom score at before and after treatment were 
6.65±0.53 and 1.57±1.75 respectively which is highly significant. (t value = 17.13, p = 0.0001). 
 Paired Sample Statistics (Total cell count before treatment and after treatment) 
Variable Obs Mean±std „t‟ Value p Value 
Before treatment 40 7710±2104 1.97 0.054 
After treatment 40 7242±1598 
The Mean ± Standard deviation of TC count at before and after treatment were 
7710±2104 and 7242±1598 respectively which is moderately significant. (t value =1.97, p = 
0.054). 
Paired Sample Statistics (LDL before and after treatment) 
Variable Obs Mean+Std „t‟ Value p Value 
Before treatment 40 81.675±16.03 2.3316 0.0125 
After treatment 40 2.598±16.43 
 
The Mean ± Standard deviation of LDL at before and after treatment were 81.675±16.03 
and 2.598±16.43 respectively which is moderately significant. (t value =2.3316, p = 0.0125). 
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Summary 
 The Aim of the study is to evaluate the efficacy of Mega rajanga kirutham in Vellai noi. 
 The protocol of this study has been submitted to IEC of NIS on 26-8-2015 and then 
approval was got from IEC for conducting this clinical study. The IEC NO is NIS/IEC 
9/2014-15/8-26.08.2015. 
 This Clinical study was registered in Clinical Trial Regisry of India on 7-3-17. And the 
CTRI NO is CTRI/2017/03/008025. 
 In the period of seven months, 250 cases were screened for this clinical study.  Only 17 
cases were identified as Trichiomoniasis by using Wet test, all the other cases were 
Negative, but the clinical symptoms are nearly correlated with Trichomoniasis. So as per 
our HOD guidance I had taken other negative cases with clinical symptoms for this study. 
 For this clinical study, 40 cases were selected based on the inclusion and exclusion 
criteria. All the cases were treated in OPD of Department of Maruthuvam, Ayothidoss 
pandithar hospital, National institute of Siddha, Chennai-47. 
 Clinical diagnosis of vellai noi was done by siddha and modern methodology. 
 Blood, Urine Investigations and Vaginal smear test were carried out before and after 
treatment and data were recorded in the Lab investigation Form. 
 The day before starting treatment with the trial drug “Mega rajanga kirutham”, purgation 
was given with Meganatha kuligai-2 in hot water at early morning.  
 The second day, after purgative therapy the patient was advised to take rest. Third day 
onwards the trial drug “Mega rajanga kirutham -4ml twice a day, before food was given 
continuously for 9 days.  
 From the next day onwards the patient was under drug holiday for 9 days. Then another 9 
days trial medicine was given to the patient continuously. 
 During the study period , there were no adverse reactions reported 
 The chemical analysis of the trial drug reveals Calcium, Carbonate, Iron, Zinc, 
Magnesium, Alkaloid and Tannic acid. 
 The pharmacological study reveals the trial drug have Anti inflammatory, Anti microbial 
and Anti oxidant activity in In Vitro studies. 
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 Physico-chemical, Phyto chemical, GCMS, TLC, and HPTLC has also be done for trial 
drug. There is no harmful chemical was identified. 
 Statistical analysis: There is significant difference between clinical symptoms score of 
before and after treatment (p<0.0001). 
 The improvements of the patients were observed and clinical assessments were noted in a 
weekly progress chart. Observation of both clinical and laboratory parameters before and 
after treatment ensures the efficacy of the trial drug.  
 The outcome of this study reveals that out of 17 positive cases, 10 cases showed negative 
result for Trichomonas vaginalis in after treatment, 2 cases were withdrawal from this 
study andsymptomatically among 40 cases, 50% of cases showed good result 40% of 
cases showed moderate improvement. Only 10% of cases showed poor result. 
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CONCLUSION 
A. Clinical study reveals that the trial drug showed good improvement in 50% of cases. 
Moderate improvement in 40% of cases. Poor improvement in 10% of cases. There 
were no adverse effects found inall treated cases during the course of the treatment.  
Hence the drug is effect in the treatment of Leucorrhoea. 
B. The Pharmacological study revealed the trial drug had Anti inflammatory, Anti 
microbial and Anti oxidant activity.  
C. Physico chemical, Phyto chemical, GCMS, TLC and HPTLC analysis showed 
phytoconstituents which is responsible for therapeutic action. 
D. Because of the encouraging clinical and laboratory results, the study may be extended 
with the same drug in more number of cases, in treating Vellai noi successfully.  
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Summary   the efficacy of MEGA RAJANGA KIRUTHAM (prepared from 
herbal constitutents) in patients with Vellainoi(Leucorrhoea). 
In this trial 40 patients will be recruited and the trial drug 
will be administered 4 ml twice a day for a period of 9 days 
twice a month. During the trial period if any AE/SAE/SUSAR 
will be noticed and referred to pharmacovigilancedept in NIS 
and further management will also be given in NIS OPD /IPD. 
The entire trial will be monitored by the research monitoring 
committee of NIS. During this trial all the safety efficacy 
parameters will be recorded in the CRF. After completion of 
the trial all the study related data will be analysed 
statistically. The out come of this trial will be published in 
Indian  Journal of Medical Research.   
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDOSS PANDITHAR HOSPITAL 
DEPARTMENT OF   MARUTHUVAM 
 
           Clinical Evaluation of Siddha drug “MEGA RAJANGA KIRUTHAM” (Internal) in “VELLAI NOI 
(LEUCORRHOEA)    FORM l - SCREENING AND SELECTION PROFORMA 
OP NO:                        NAME: ……………………                         AGE: ……GENDER: … 
OCCUPATION: ……………………………   
 ADDRESS: 
CONTACT NO:              
INCLUSION CRITERIA  
 Age:21-45 yrs                                                                                                   Yes / No 
 Married female                                                                              Yes / No 
 Patient having the symptoms of whitish or yellowish discharge per vagina,   Yes / No                                 
 Pruritis vulva, vulval irritation, dysuria, abdominal pain, low backache           Yes / No 
 Patient willing to cooperate for vaginal swab examination                        Yes / No           
 Patient willing to undergo routine blood investigation           Yes / No 
 Positive Wet test for Trichomonas vaginalis                                                     Yes / No 
 Patient  willing to participate in trial and signing in consent form          Yes /No 
 
EXCLUSION CRITERIA:  
 History of Diabetes mellitus        Yes / No 
 History of Bacterial vaginosis/Vulvovaginal candidiasis                             Yes / No 
 History of STD (Syphilis,HIV,gonorrhoea)                             Yes / No 
 History of non specific leucorrhea                                                       Yes / No                                                                                 
 Pregnancy and lactation                    Yes / No                                                                                 
 History of Malignancy                                                                                 Yes / No 
 
 ADMITTED TO TRIAL  
              YES           NO  
   
                           If Yes Serial NO: 
Date:        
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                           Signature of the HOD:   
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   NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
                                                 AYOTHIDOSSPANDITHARHOSPITAL  
                                                   DEPARTMENT OF MARUTHUVAM 
 Clinical evaluation of siddha drug“MEGA RAJANGA KIRUTHAM” (Internal) in “VELLAI NOI 
(LECORRHOEA )”  FORM II- CASE RECORD FORM 
1. STUDY NO -----------                       2. OP/IP NO ------------------           REG NO:  
3.  NAME ---------------------------        4. . Age (years): ________    Height: ____ m Weight: ______ Kg5) 
5. Educational Status: 
1) Literate        2) Illiterate   
6. Occupation:                                           
7. Marital Status:   1.Married             2 .Unmarried 
If married;     Gravidity                            Parity 
Dyspareunia -    Present                          Absent 
8. Complaints and Duration:   
________________________________________________________________________ 
________________________________________________________________________ 
________________________________________________________________________ 
MENSTRUAL HISTORY 
 1.Age at menarche _______ year 
 2. Regularity of cycle     Regular                              Irregular  
      3. Length of cycle [Days] 
      4. Duration of flow [Days]  
      5. Dysmenorrhoea started at age _______ years 
     6. Presence of abdominal pain other than around the time of menstruation 
 
1. Yes                     2.No 
GYNAECOLOGICAL HISTORY 
1. Amount and onset of the discharge_________________________ 
2. Colour_________________  
3. Odour:                         1.Yes                              2.No 
4. Consistency 
MEDICAL/SURGICAL HISTORY 
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Diabetes mellitus:       1.Yes                             2.No 
 Bacterial vaginosis/vulvovaginal candidiasis: 1.Yes                    2.No 
STD (syphilis, HIV, gonorrhoea):1.Yes                            2.No 
Malignancy 1. Yes                    2.No 
FAMILY HISTORY 
              Whether this problem runs in family?     1. Yes                2.No            
              If yes, mention the relationship of affected person(s) 
        1._________________ 
                                               2._________________ 
                                               3._________________ 
DIETARY STYLE     
  1.Pure vegetarian                                 2.Non-vegetarian               
BOWEL HABITS & MICTURITION: 
             Historyof habitual constipation              1.Yes               2.No                                                       
             History of frequent diarrhoea                  1.Yes              2.No                                                         
  History of frequent dysuria                               1.Yes               2.No                        
7. THEGI: [TYPE OF BODY CONSTITUTION]   
Vatham predominant  Kabam predominant  
Pitham predominant  Thondha udal  
 
8. NILAM: [LAND WHERE PATIENT LIVED MOST]  
Kurinji               Mullai                 Marutham             Neithal              Palai   
(Hillyterrain)   (Forest)                     (Plains)         (Coastalbelt)         (Aridregions)     
9.KAALAM:[SEASON] 
Kaarkalam           Pinpanikalam      
Koothirkalam   Ilavenil  
Munpanikalam   Muthuvenil 
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10. GUNAM:[CHARACTER] 
Sathuvam                        Rasatham                       Thamasam    
DAY OF ASSESSMENT   :    
                       0
th
 day                   9
th
day                       18
th
 day              27
th
 day 
SIDDHA SYSTEM OF EXAMINATION: 
1. ENVAGAI THERVU: [EIGHT-FOLD EXAMINATION] 
I.NAADI: [PULSE PERCEPTION] 
 
 
 
 
 
 
 
 
 
 
II.NAA:[TONGUE] 
 0
th
 day 9
th
 day 18
th
 day 27
th
 day 
Date     
Colour normal/ Red 
pale/yellow 
normal/ Red 
pale/yellow 
normal/ Red 
pale/yellow 
normal/ Red 
pale/yellow 
Taste Sweet/Sour/ 
Pungent/ 
Bitter/None 
Sweet/Sour/ 
Pungent/ 
Bitter/None 
Sweet/Sour/ 
Pungent/ 
Bitter/None 
Sweet/Sour/ 
Pungent/ 
Bitter/None 
Coating Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Fissure Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Saliva Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased/ 
Decreased 
Dryness Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Glossitis Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Baldnes
s 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
 0
th
 day 9
th 
day 18
th 
day 27
th
 day     
Date     
Vali     
Azhal     
Iyyam     
Vali Azhal     
Azhal vali     
Iyya vali     
Vali Iyyam     
Azhal 
Iyyam 
    
Iyya Azhal     
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III.NIRAM: [COMPLEXION]    
0
th
 day 9
th
 day 18
th
 day 27
th
 day 
Date    
Dark/pale/ 
Yellow tinted/ 
whitish brown 
Dark/pale/ 
Yellow tinted/ 
whitish brown 
Dark/pale/ 
Yellow tinted/ 
whitish brown 
Dark/pale/ 
Yellow tinted/ 
whitish brown 
 
IV.MOZHI: [VOICE] 
0
th
 day 9
th
 day 18
th
 day 27
th
 day 
Date    
Medium/ 
High/ 
Low pitched 
Medium/ 
High/ 
Low pitched 
Medium/ 
High/ 
Low pitched 
Medium/ 
High/ 
Low pitched 
V.VIZHI: [EYES] (Lower palpebral conjunctiva)     
0
th
 day 9
th
 day 18
th
 day 27
th
 day 
Date    
normal/Red 
pale/yellow 
Normal/Red 
pale/yellow 
normal/Red 
pale/yellow 
normal/Red 
pale/yellow 
   
VI. MALAM:[BOWEL HABITS / STOOLS] 
 0
th
 day 9
th
 day 18
th
 day 27
th
 day 
Date     
Colour Dark/pale/ 
yellow/ 
Red 
Dark/pale/ 
yellow/ 
Red 
Dark/pale/ 
Yellow/ 
Red 
Dark/pale/ 
yellow/ 
Red 
Consistency Solid/ 
Semisolid 
/Watery 
Solid/ 
Semisolid/
Watery 
Solid/ 
Semisolid/ 
Watery 
Solid/ 
Semisolid/ 
Watery 
stool  bulk                          Normal/
Reduced 
Normal/ 
Reduced 
Normal/ 
Reduced 
Normal/ 
Reduced 
Constipation   Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Diaarhoea Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
 
VII.MOOTHIRAM: [URINE EXAMINATION]  
    
Neerkkuri 0
th
 day 9
th
 day 18
th
 day 27
th
 day 
Date     
Niram[Colour]   Yellow/ 
Red/ 
White/ 
Straw 
coloured/ 
Crystal clear 
Yellow/ 
Red/ 
White/ 
Straw 
coloured/ 
Crystal clear 
Yellow/ 
Red/ 
White/ 
Straw 
coloured/ 
Crystal clear 
Yellow/ 
Red/ 
White/ 
Straw 
coloured/ 
Crystal clear 
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Manam[Odour] Present/ 
Absent 
 Present/ 
Absent 
Present/ Absent Present/ Absent 
Nurai[Froth] Nil/ 
Reduced/ 
Increased 
Nil/ 
Reduced/ 
Increased 
Nil/ 
Reduced/ 
Increased 
Nil/ 
Reduced/ 
Increased 
Edai[Sp.gravit]                                Normal/ 
Increased/ 
Reduced  
Normal/ 
Increased/ 
Reduced  
Normal/ 
Increased/ 
Reduced  
Normal/ 
Increased/ 
Reduced  
Enjal[Deposits] Present/ 
Absent 
Present/ 
Absent 
Present/ Absent Present/ Absent 
Volume   Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
 
Neikkuri  0
th
 day 9
th
 day 18
th
 day 27
th
 day 
Date     
Serpentine fashion at___mints at___ mints at___ mints at___ mints 
Annular/Ringed 
fashion 
at___mints at___ mints at___ mints at___ mints 
Pearl beaded 
fashion    
at___mints at___ mints at___ mints at___ mints 
Mixed fashion at___mints at___ mints at___ mints at___ mints 
Other fashion at___mints at___ mints at___ mints at___ mints 
 
VIII. SPARISAM: [PALPATORY PERCEPTION] 
0
th
 day 9
th
 day 18
th
 day 27
th
 day 
Date    
Warmth/Hot/ 
cold/ Sweat 
Warmth/Hot/co
ld/ Sweat 
Warmth/Hot 
/cold/ Sweat 
Warmth/Hot/ 
cold/ Sweat 
 
2. IYMPORIGAL:[SENSORY ORGANS] 
 0
th
 day 9
th
 day 18
th
 day 27
th
 day 
Date     
 Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Mei [Skin]     
Vaai[Buccal 
cavity]  
    
Kan [Eyes]     
Mooku[Nose]     
Sevi [ear]     
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3. IYMPULANGAL: [MOTOR ORGANS] 
 0
th
 day 9
th
 day 18
th
 day 27
th
 day 
Date     
 Normal/  
Affected      
Normal/  
Affected   
Normal/  
Affected      
Normal/  
Affected      
Kai [upperlimb]     
Kal [lowerlimb]     
 
Vai[Buccal cavity]     
Eruvai  
[excretory organ] 
    
Karuvai[Reporduc-
tive organ] 
    
4. KOSAM: [SHEATHS] 
  
 
0
th
 day 9
th
 day 18
th
 day 27
th
 day 
Date     
 Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Annamaya kosam 
 
    
PranamayaKosam     
Manonmayakosam 
 
    
Vingyanamaya kosam     
Anandhamaya kosam     
 
5. MUKKUTRAM: [AFFECTION OF THREE HUMORS 
A) VATHAM:    
 0
th
 day 9
th
 day 18
th
 day 27
th
 day 
Date     
 Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Praanan     
Abaanan      
Samaanan     
Udhaanan     
Viyaanan     
Naahan     
Koorman     
Kirukaran     
Devathathan     
Dhananjeyan     
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B) PITHAM: 
 0
th
 day 9
th
 day 18
th
 day 27
th
 day 
Date     
 Normal/ 
Affected 
Normal/ 
Affected 
Normal/ 
Affected 
Normal/ 
Affected 
Anarpitham                  
Prasakam     
Ranjakam     
Aalosakam     
Saathakam     
C) KABAM: 
 0
th
 day 9
th
 day 18
th
 day 27
th
 day 
Date     
 Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Avalambagam     
Kilethagam     
Pothagam     
Tharpagam      
Santhigam     
 
6. SEVEN DHATHUS: [SEVEN SOMATIC COMPONENTS]  
 0
th
 day 9
th
 day 18
th
 day 27
th
 day 
Date     
 Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Saaram[chyme]     
Senneer[Blood]     
Oon[Muscle]     
Kozhuppu[Fat]     
Enbu[Bones]     
Moolai[Bone marrow]     
Sukkilam/Suronitham  
[Genital discharges] 
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7. SYSTEMIC EXAMINATION: 
 0
th
 day 9
th
 day 18
th
 day 27
th
 day 
Date     
CardioVascular System  
 
    
Respiratory  System    
 
    
Gastrointestinal System 
 
    
Genit urinary system     
8. GENERAL EXAMINATION: 
 0
th
 day 9
th
 day 18
th
 day 27
th
 day 
     
Date     
Height (cms)     
Weight (kg)     
Temperature(°F)     
Pulse rate (per min)     
Heart rate (permin)     
Respiratory rate(per min)     
Blood pressure(mm/Hg)     
Pallor     
Jaundice     
Cyanosis     
Lymphadenopathy     
Pedal edema     
Clubbing     
Jugular vein pulsation     
 
9. CLINICAL SYMPTOMS: 
 0
th
 day 9
th
 day 18
th
 day 27
th
 day 
Date     
Profuse, thin, creamy, 
whitish/yellowish discharge  
    
Purities vulva     
Vulval irritation     
Dysuria     
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Abdominal pain     
Low backache     
Dyspareunia     
 
Date: 
Station: 
Signature of the Investigator: 
 
Signature of the Lecturer:                                                               Signature of the HOD 
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDOSSPANDITHARHOSPITAL 
DEPARTMENT OF MARUTHUVAM 
 
 Clinical Evaluation of Siddha drug “MEGA RAJANGA KIRUTHAM” (Internal) 
“VELLAI NOI (LEUCORRHOEA)” 
FORM III   LABORATORY INVESTIGATION FORM 
1. OP/IP No: ________                          2 .S. No:                                  3.Reg no:  
  
BLOOD INVESTIGATION 
Before 
treatment 
Date: 
After 
treatment 
Date: 
NORMAL VALUES 
HB (gms %)   11-15 
T.RBC(milli/cu.mm)   3.5-5.5 
ESR (mm) 
½ hr.   2-6 
1 hr.   4-8 
T.WBC (cu.mm) 
 
  
 
4000-11,000 
 
 
DIFFERENTIAL 
COUNT (%) 
Polymorphs   40-75 
Lymphocytes   20-35 
Monocytes   2-10 
Eosinophils   1-6 
Basophils   0-1 
Blood glucose (mg/dl) 
Fasting   80-120 
PP   <130 
Random   <140 
Lipid profile (mg/dl) 
Serum cholesterol   150-250 
HDL   30-60 
LDL   Upto 130 
VLDL   40 
TGL   Upto 160 
RFT (mg/dl) 
Blood urea 
 
 16-50 
Serum creatinine 
 
 0.6-1.2 
Serum Uric acid 
 
 2.5-7.5 
LFT (mg/dl) 
Total bilirubin   0.2-1.2 
Direct bilirubin   0.1-1.2 
Indirect bilirubin   0.2-0.7 
Serum total protein   6-8 
Serum Albumin   3.5-5.5 
Serum globulin   2-3.5 
Serum fibrinogen    
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Serum calcium   9-11 
Serum phosphorous   2-5 
SGOT   IU/L   0-40 
SGPT  IU/L   0-35 
Alkaline phosphatase  
IU/L 
  80-290 
  
 URINE INVESTIGATION 
Urine investigation Before TMT(with Date) After TMT (With Date) 
Albumin   
Fasting sugar   
PP sugar   
Random Sugar   
Deposits   
Bile salts   
Bile pigments   
Urobilinogen 
  
MICROBIOLOGY 
         SEROLOGY 
 
Before treatment  Date: 
After treatment Date: 
 
          VDRL  
 
 
 
 
SPECIAL INVESTIGATION 
 
WET TEST FOR 
TRICHOMONAS VAGINALIS 
Before treatment 
Date: 
After treatment 
 Date: 
 
  
 
 
 
 
Date: 
Station: 
 
Signature of the Investigator: 
Signature of the Lecturer:                                                                             Signature of the HOD 
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDOSS PANDITHAR HOSPITAL 
                                         DEPARTMENT OF   MARUTHUVAM 
Clinical Evaluation of Siddha drug “MEGA RAJANGA KIRUTHAM” (Internal) in 
“VELLAI NOI (LEUCORRHOEA)” 
FORM IV -DRUG COMPLIANCE FORM 
S. NO: ---------   OPD/IPD NO: --------------- NAME: -----------------------        REG NO:  
Name Of The Drug: Mega rajanga kirutham-4 ml bid before food 
 
DAY DATE MORNING EVENING 
 
DAY1    
DAY2    
DAY3    
DAY4    
DAY5    
DAY6    
DAY7    
DAY8    
DAY9    
DAY 10-18             DRUG HOLIDAY  
DAY19    
DAY20    
DAY21    
DAY22    
DAY23    
DAY24    
DAY25    
DAY26    
DAY27    
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDASS PANDITHAR HOSPITAL 
DEPARTMENT OF   MARUTHUVAM 
Clinical Evaluation of Siddha drug “MEGA RAJANGA KIRUTHAM” (Internal) in 
“VELLAI NOI (LEUCORRHOE)” 
FORM V- PATIENT INFORMATION SHEET 
Name of the Principal Investigator: Dr.S.SANTHANA KITTU (PG Student)                                                 
Name of the Institution                   :  National Institute of siddha, TambaramSanatorium                            
                                                              Chennai-47. 
               I Dr.S.Santhana kittu studying M.D (Siddha) in National Institute of Siddha, 
Chennai. I am doing a clinical trial on the study of Vellai noi (Leucorrhoea due to 
Trichomonas vaginalis).It is the most common easily curable Sexually transmitted 
disease. The factors like increasing age,illiteracy,low socioeconomic status,high 
parity,induced abortion & place of delivery are all contributing factors for occurrence of 
vaginal discharge.It includes symptoms of Profuse, thin, creamy whitish/yellowish 
discharge ,Vulval irritation,Pruritis vulva,Dysuria,Abdominal pain,Low 
backache,Dyspareunia.This condition is being treated in NIS with many siddha 
formulations. As a part of M.D(S) research programme and developing new efficacious 
medicine, I have proposed to study the drug Mega rajanga kirutham for treating this 
condition. This formulation has been mentioned in siddha literature and empirical 
evidence with contemporary tools is required for documentation. You can receive 
medicines free of cost. The duration of treatment period is 27 days. You have to visit NIS 
9 days once and collect drugs for 9days. The diagnosis tests will be carried out free of 
cost .We will assess the effect of treatment after completion of 27days of treatment using 
clinical and lab parameters. 
               In this regard, I need to ask you few questions. I will maintain confidentiality of 
your comments and data obtained from you. There will be no risk of disclosing your 
identity and no physical, psychological or professional risk is involved by taking part in 
this study. 
               Taking part in this study is voluntary. No compensation will be paid to you for 
taking part in this study. You can choose not to answer any specific question. There is no 
specific benefit for you if you take part in the study, but you will be under our clinical 
monitoring and specific attention will be given for your health. Taking part in the study 
may be of benefit to the community, as it may help us to develop medicine for Vellai noi. 
In case of any adverse symptoms like severe low back pain, increased profuse white 
discharge during the treatment shall be reported to me and care will be taken in NIS for 
relief. You can withdraw from the study at the midst of treatment period, if you are not 
interested to continue and you will receive our usual treatment without condition. 
              The information collected in this study, will remain between you and me as a 
principal investigator.  I will not write your name on different forms which sent to 
different investigating/analysis sections and I will use a code instead given by the 
principal investigator. Only the principal investigator will know the key to this code 
which will be kept in safe custody. If you agree to be a participant in this study, you will 
be screened as per the study protocol.  
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              If you wish to find out more about this study before taking part, you can ask me 
all the questions you want or contact Dr,Santhana kittu, PG student cum principal 
investigator of this study, attached to the National Institute of Siddha, Chennai (Mobile 
phone no:9952410979). You can also contact the Chairman/Member-secretary of Ethics 
committee, National Institute of Siddha, Chennai – 600047, Tel no: 91-44-22411611, for 
rights and participation in the study. 
 
 
§¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ, ¦ºý¨É 47 
  «§Â¡ò¾¢¾¡º÷ ÀñÊ¾÷ ÁÕòÐÅÁ¨É 
¦Åû¨Ç §¿¡öì¸¡É º¢ò¾ ÁÕó¾¢ý (§Á¸Ã¡ƒ¡í¸ ¸¢Õ¾õ)  ÀÃ¢¸Ã¢ôÒò ¾¢È¨Éì 
¸ñ¼È¢Ôõ ÁÕòÐÅ ¬öÅ¢ü¸¡É ¾¸Åø ÀÊÅõ. 
 
FORM V- ¾¸Åø ÀÊÅõ 
 
Ó¾ý¨Á ¬Ã¡öîº¢Â¡Ç÷ ¦ÀÂ÷ :  Dr. º¢.ºó¾É¸¢ðÎ  
 ¿¢ÚÅÉò¾¢ý ¦ÀÂ÷                  :  §¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ 
                                                  ¾¡õÀÃõ º¡Éð§¼¡Ã¢Âõ 
                                                  ¦ºý¨É 47 
 
              Dr. º¢.ºó¾É¸¢ðÎ. ¬¸¢Â ¿¡ý §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨ÉÂ¢ø Àð¼ §ÁüÀÊôÒ 
ÀÂ¢ýÚ ÅÕ¸¢§Èý. ¦Åû¨Ç §¿¡ö ±ýÛõ §¿¡Â¡Ìõ ±Ç¢¾¢ø Ì½ôÀÎò¾ìÜÊÂ ´Õ 
À¡øÅ¢¨É §¿¡Â¡Ìõ. þó§¿¡Â¡ÉÐ «¾¢¸ÀÊÂ¡É ¦Åû¨Ç ¸º¢×,À¢ÈôÒÚôÀ¢ø 
«Ã¢ôÒ,º¢Ú¿£÷ ±Ã¢îºø,ÓÐÌ ÅÄ¢, Ò½÷îº¢ ÅÄ¢ §À¡ýÈ ÌÈ¢Ì½í¸¨Çò §¾¡üÚÅ¢ìÌõ. 
þó§¿¡öìÌ §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨ÉÂ¢ø ÀÄ º¢ò¾ ÁÕóÐ¸û ÀÂýÀÎò¾ôÀðÎ 
ÅÕ¸¢ýÈÐ. º¢ò¾ ÁÕòÐÅ Àð¼ §ÁüÀÊôÀ¢ø, ¬öÅ¢ý ´Õ ÀÌ¾¢Â¡¸ Ò¾¢Â ÁÕóÐ¸¨Ç 
ÀÂýÀÎòÐõ §¿¡ì¸¢ø(§Á¸Ã¡ƒ¡í¸ ¸¢Õ¾õ)  ±ýÛõ ÁÕó¾¢¨É þó§¿¡öìÌ ÅÆí¸ 
ÀÃ¢óÐ¨Ã ¦ºö¸¢§È¡õ. þó¾ ÁÕó¾¢ý ¦ºöÓ¨È, «Ç×, «ÛÀ¡Éõ ÁüÚõ ÁÕòÐÅ 
ÀÂý¸û «¨ÉòÐõ «í¸£¸Ã¢ì¸ôÀð¼ º¢ò¾ ÁÕòÐÅ áÄ¢ø ÜÈôÀðÎûÇÐ. ±ó¾Å¢¾ 
¸ð¼½ÓÁ¢ýÈ¢ ¾¡í¸û þó¾ ÁÕó¾¢¨É ¦ÀüÚì¦¸¡ûÇÄ¡õ. þó¾ ¬öÅ¢ø ÁÕóÐ 
¯ð¦¸¡ûÙõ ¸¡Äõ 27 ¿¡ð¸û ¬Ìõ. 9 ¿¡û¸ÙìÌ ´ÕÓ¨È §¾º¢Â º¢ò¾ 
ÁÕòÐÅÁ¨ÉìÌ §¿Ã¢ø ÅóÐ ÁÕó¾¢¨É ¦ÀüÚì¦¸¡ûÇ §ÅñÎõ. þó¾ ¬ö× 
ºõÀó¾Á¡É ¬öÅ¸ ÀÃ¢§º¡¾¨É¸û ¸ð¼½Á¢ýÈ¢ ¦ºöÂôÀÎõ. 27 ¿¡ð¸û ÁÕóÐ 
¯ð¦¸¡ûÙõ ¸¡Äõ ÓÊó¾ À¢ÈÌ §¿¡öì¸¡É ÌÈ¢Ì½í¸û ÁüÚõ ¬öÅ¸ 
ÀÃ¢§º¡¾¨É¸û þÅüÈ¢ý ÓÊ×¸Ç¢ý «ÊôÀ¨¼Â¢ø ÁÕó¾¢ý ÀÃ¢¸Ã¢ôÒò¾¢Èý 
¸ñ¼È¢ÂôÀÎõ.  
        
 þó¾ ¬ö× ºõÀó¾Á¡¸ º¢Ä §¸ûÅ¢¸¨Ç ¾í¸Ç¢¼õ §¸ð¸ þÕì¸¢§Èý. 
¾í¸Ç¢¼Á¢ÕóÐ ¦ÀÈôÀÎõ ¸ÕòÐì¸û ÁüÚõ ÌÈ¢ôÒ¸û «¨ÉòÐõ ¿õÀ¢ì¨¸Â¡¸ 
À¾¢× ¦ºöÂôÀÎõ.þó¾ ¬öÅ¢ø ¾í¸¨Ç ¯ðÀÎò¾¢ì¦¸¡ûÅ¾¢ý ãÄõ ±ó¾ Å¨¸Â¢Öõ 
À¡¾¢ôÒìÌûÇ¡¸ Á¡ðË÷¸û ±É ¯Ú¾¢ «Ç¢ì¸¢§Èý. 
        
 ±ó¾Å¢¾ ÅüÒÚò¾ÖÁ¢ýÈ¢, þó¾ ¬öÅ¢ø Àí§¸ü¸×õ, þó¾ ¬ö× ºõÀó¾Á¡¸ 
§¸ð¸ôÀÎõ §¸ûÅ¢¸ÙìÌ À¾¢ø ÜÈ×õ ¾í¸ÙìÌ ÓØ Í¾ó¾¢Ãõ «Ç¢ì¸ôÀÎ¸¢ÈÐ. 
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þó¾ ¬öÅ¢ø Àí§¸üÀ¾üÌ ±ó¾ ºýÁ¡ÉÓõ ÅÆí¸ôÀ¼Á¡ð¼¡Ð.  ¬É¡ø, ¬ö× 
ÓØÅÐõ ±ÉÐ §ÁüÀ¡÷¨ÅÂ¢Öõ, ¾í¸û ¯¼ø¿Äý ÌÈ¢ò¾ ¾É¢ ¸ÅÉò¾¢Öõ ¬ö× 
§Áü¦¸¡ûÇôÀÎõ. ¦Åû¨Ç §¿¡öì¸¡É Ò¾¢Â ÁÕó¾¢ý ÀÃ¢¸Ã¢ôÒò¾¢È¨É ºã¸ò¾¢üÌ 
¯½÷òÐõ Å¨¸Â¢ø þó¾ ¬ö× §Áü¦¸¡ûÇôÀÎ¸¢ÈÐ. þó¾ ¬öÅ¢ø, ÁÕóÐ 
¯ð¦¸¡ûÙõ ¸¡Äò¾¢ø º¢ÄÕìÌ Á¢¸ 
 «¾¢¸ÀÊÂ¡É ¦Åû¨Ç ¸º¢× , ¾¡í¸ÓÊÂ¡¾  ÓÐÌÅÄ¢ §À¡ýÈ Á¡ÚÀð¼ 
ÌÈ¢Ì½í¸û ¦¾¡¼÷óÐ þÕìÌõ Àðºò¾¢ø, Ó¾ý¨Á ¬Ã¡öîº¢Â¡ÇÃ¡É ±ýÉ¢¼õ 
¦¾Ã¢Å¢ì¸ôÀðÎ, §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨ÉÂ¢ø «¾üì¸¡É ¾£÷× ÅÆí¸ôÀÎõ. þó¾ 
¬öÅ¢¨Éò ¦¾¡¼Ã ¾í¸ÙìÌ Å¢ÕôÀõ þø¨Ä¦ÂÉ¢ø, ±ô¦À¡ØÐ §ÅñÎÁ¡ÉÖõ 
¬öÅ¢ý þ¨¼Â¢ø Å¢Ä¸¢ì¦¸¡ûÇ×õ, þõÁÕòÐÅÁ¨ÉÂ¢ø ÅÆí¸ôÀÎõ 
þó§¿¡öì¸¡É ÅÆì¸Á¡É ÁÕóÐ¸¨Ç ¦ÀüÚì¦¸¡ûÇ×õ «È¢×Úò¾ôÀÎ¸¢È£÷¸û. 
        
 þó¾ ¬öÅ¢ø §º¸Ã¢ì¸ôÀÎõ Å¢ÀÃí¸û «¨ÉòÐõ ¾í¸ÙìÌõ Ó¾ý¨Á 
¬Ã¡öîº¢Â¡ÇÃ¡É ±ÉìÌõ þ¨¼Â¢ø þÃ¸º¢ÂÁ¡¸ ¨Åì¸ôÀÎõ. §¸ûÅ¢ À¾¢ø 
ÅÊÅò¾¢ø ¾í¸Ç¢¼õ §¸ûÅ¢¸û §¸ð¸ôÀÎõ. «¨ÉòÐô ÀÊÅí¸Ç¢Öõ ¾í¸Ç¢ý ¦ÀÂ÷ 
¾Å¢÷ì¸ôÀðÎ ¬öÅ¡ÇÃ¡ø ¾í¸Ùì¦¸É ¾É¢ì ÌÈ¢Â£Î ÅÆí¸ôÀÎõ. «ó¾ì ÌÈ¢Â£Î 
¬öÅ¡ÇÕìÌ ÁðÎ§Á ¦¾Ã¢ó¾¾¡¸ þÕìÌõ. ¿£í¸û þó¾ ¬öÅ¢ø Àí§¸ü¸ 
Å¢ÕôÀôÀð¼¡ø, ¾¢ð¼ Å¨Ã× ÀÊ §¾÷× ¦ºöÂôÀÎÅ£÷¸û. 
         
 ¿£í¸û þó¾ ¬öÅ¢ø Àí§¸üÌõ Óý, þó¾ ¬öÅ¢¨Éô ÀüÈ¢Â §ÁÖõ Å¢ÀÃí¸û 
¦ÀÈ §ÅñÎ¦ÁÉ Å¢ÕôÀôÀð¼¡ø, þó¾ ¬öÅ¢ý Ó¾ý¨Á ¬Ã¡öîº¢Â¡Ç÷ ÁüÚõ 
§¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨É, Àð¼ §ÁüÀÊôÒòÐ¨È Á¡½Å¢  Dr º¢.ºó¾É¸¢ðÎ ¬¸¢Â 
±ý¨É 9952410979 ±ýÈ ±ñ½¢ø ¦¾¡¼÷Ò ¦¸¡ûÇÄ¡õ. §ÁÖõ, ¿£í¸û þó¾ 
¬öÅ¢ø, ¯í¸ÇÐ Àí§¸üÒ ÁüÚõ ¯Ã¢¨Á ÀüÈ¢ ¦¾Ã¢óÐ ¦¸¡ûÇ §¾º¢Â º¢ò¾ 
ÁÕòÐÅÁ¨É, ¾¨ÄÅ÷/¦ºÂüìÌØ ¯ÚôÀ¢É÷ «Å÷¸¨ÇÔõ 91-44-22411611 ±ýÈ 
±ñ½¢ø ¦¾¡¼÷Ò ¦¸¡ûÇÄ¡õ.   
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDOSS PANDITHAR HOSPITAL 
DEPARTMENT OF   MARUTHUVAM 
 
Clinical Evaluation of Siddha drug “MEGA RAJANGA KIRUTHAM” (Internal) in 
VELLAI NOI (LEUCORRHOEA)” 
FORM VI –INFORMED CONSENT FORM 
 “I have read the foregoing information, or it has been read to me. I have had the 
opportunity to ask questions about it and any questions I have asked have been answered to my 
satisfaction.  
            I   consent voluntarily to participate in this study and understand that I have the right to 
withdraw from the study at any time without in any way it affecting my further medical care”. 
           "I have received a copy of the information sheet/consent form". 
Date: 
Signature of the participant 
In case of illiterate participant 
  “I have witnessed the accurate reading of the consent form to the potential participant, 
and the individual has had the opportunity to ask questions. I confirm that the individual has 
given consent freely.”                                                   
 
Date: 
 
 Signature of a witness                                            Left thumb Impression of the Participant     
(Selected by the participant bearing no connection with the survey team)      
 Date:    
Station: 
 Signature of participant:                                                 
Signature of the Investigator: 
Signature of the Lecturer:                                                          Signature of the HOD 
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                      §¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ 
«§Â¡ò¾¢¾¡º ÀñÊ¾÷ ÁÕòÐÅÁ¨É, ¦ºý¨É - 47. 
Àð¼ §ÁüÀÊôÒ ÁÕòÐÅòÐ¨È 
   
¦Åû¨Ç §¿¡öì¸¡É º¢ò¾ ÁÕó¾¢ý (§Á¸Ã¡ƒ¡í¸ ¸¢Õ¾õ) ÀÃ¢¸Ã¢ôÒò ¾¢È¨Éì 
¸ñ¼È¢Ôõ ÁÕòÐÅ ¬öÅ¢ü¸¡É ¾¸Åø ÀÊÅõ  
                      
                        FORM  VI-  ´ôÒ¾ø ÀÊÅõ 
 
                ¿¡ý §ÁüÜÈ¢Â  ¾¸Åø  ÀÊÅò¨¾ ÀÊòÐ «øÄÐ ÀÊì¸ §¸ðÎ ¦¸¡ñ§¼ý. 
-Ð ¦¾¡¼÷À¡É Å¢Çì¸í¸¨ÇÔõ §¸ðÎ ¦¾Ã¢óÐ ¦¸¡ñ§¼ý. ±ó¾ Å¢¾ ÅüÒÚò¾Ä¢ýÈ¢, 
±ý ¦º¡ó¾ Å¢ÕôÀò¾¢ý §ÀÃ¢ø ±ý¨É -ó¾ ¬Ã¡öîº¢ìÌ ¯ðÀÎò¾ ±ý ÓØÁÉ§¾¡Îõ 
ÍÂ¿¢¨É§Å¡Îõ ºõÁ¾õ ¦¾Ã¢Å¢ì¸¢ý§Èý. ±ÉìÌ Å¢ÕôÀÁ¢øÄ¡¾ Àðºò¾¢ø þó¾ 
¬Ã¡öîº¢Â¢ø þÕóÐ ±ý¨É ±ô§À¡Ð §ÅñÎÁ¡É¡Öõ Å¢ÎÅ¢òÐ ¦¸¡ûÙõ ¯Ã¢¨Á¨Â 
¦ÀüÚû§Çý ±ýÀ¨¾Ôõ «È¢§Åý. 
 
 
   
§¾¾¢:                                                                             
þ¼õ:                                                                              
                                                                                º¡ðº¢ì¸¡Ã÷ ¨¸¦Â¡ôÀõ: 
                                                                                ¦ÀÂ÷: 
¨¸¦Â¡ôÀõ:                                                              ¯È×Ó¨È :                                                                                       
¦ÀÂ÷     : 
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDOSS PANDITHAR HOSPITAL 
DEPARTMENT OF   MARUTHUVAM 
 
Clinical Evaluation of Siddha drug “MEGA RAJANGA KIRUTHAM” (Internal) in 
“VELLAI NOI (LEUCORRHOEA )” 
FORM VII-WITHDRAWAL FORM 
1. SERIAL NO OF THE CASE: …………………   
2. OP / IP NO: ......................................    
3. NAME: ……………………………    4.AGE: …………       5.GENDER: .................                           
6. DATE OF TRIAL COMMENCEMENT: ………………... 
7. DATE OF WITHDRAWAL FROM TRIAL: …………….. 
8. REASONS FOR WITHDRAWAL: 
Long absence at reporting:              Yes/ No 
Irregular treatment:                          Yes/ No 
Shift of locality:                                    Yes/No 
Increase in severity of symptoms:    Yes/No 
Development of severe adverse drug reactions:  Yes/No 
Date:          
Station: 
 
Signature of the Investigator: 
Signature of the Lecturer:                                                   Signature of the HOD: 
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Please note:  i.  All consumers / patients and reporters information will remain confidential. 
                          ii. It is requested to report all suspected reactions to the concerned, even if  it 
does not have complete data, as soon as possible. 
Peripheral Center code:     State:  
1. Patient / consumer identification (please complete or tick boxes below as appropriate) 
Name  Father name 
 
Patient / Record No. 
Ethnicity  Occupation 
Address  
Village / Town 
Post / Via 
District / State    
Date of Birth / Age: 
 
Sex:     Male / 
Female  
Weight : 
Degum: 
 
2. Description of the suspected Adverse Reactions (please complete boxes below) 
Date and time  of 
initial observation 
 Season: 
Description of 
reaction   
 
 Geographical area: 
 
 
 
Reporting Form for Suspected Adverse Reactions to Siddha Drugs 
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3. List of all medicines / Formulations including drugs of other systems used by the patient 
during the reporting period: 
Medicine Daily 
dose 
Route of 
administration 
& Vehicle - 
Adjuvant 
Date  Diagnosis for 
which medicine 
taken  Starting Stopped 
Siddha 
 
 
 
 
     
Any other 
system of 
medicines 
 
 
     
 
4. Brief details of the Siddha Medicine which seems to be toxic : 
Details Drug – 1 Drug – 2 Drug – 3 
a) Name of the medicine    
b) Manufacturing unit and 
batch No. and date 
   
c) Expiry date    
d) Purchased and obtained 
from 
   
e) Composition of the 
formulation / Part of the 
drug used 
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b) Dietary Restrictions if any 
c) Whether the drug is consumed under Institutionally qualified medical supervision or used as 
self medication.  
d) Any other relevant information. 
5. Treatment provided for adverse reaction: 
 
6. The result of the adverse reaction / side effect / untoward effects (please complete the boxes 
below) 
Recovered:           Not 
recovered: 
 Unknown: Fatal: If Fatal 
Date of death: 
Severe:   Yes   /   No. Reaction abated after drug stopped or dose reduced: 
 
Reaction reappeared after re introduction: 
 
 
Was the patient admitted to hospital? 
If yes, give name and address of 
hospital 
 
 
7. Any laboratory investigations done to evaluate other possibilities?  If Yes specify:  
 
8. Whether the patient is suffering with any chronic disorders? 
Hepatic    Renal    Cardiac    Diabetes    Malnutrition    
 
Any Others  
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9. H/O previous allergies / Drug reactions:  
 
10. Other illness (please describe): 
 
11. Identification of the reporter: 
Type (please tick):  Nurse / Doctor / Pharmacist / Health worker / Patient / Attendant / 
Manufacturer /                                                                      
                                Distributor / Supplier / Any others (please specify) 
Name: 
 
Address: 
 
Telephone / E – mail if any : 
 
 
Signature of the reporter:       Date: 
Please send the completed form to:  
           The Director 
            National Institute of Siddha, 
                                                           (Pharmacovigilance Regional Centre For Siddha Medicine), 
                                                           Tambaram Sanatorium, Chennai-600 047. 
                                                            (O) 044-22381314       Fax : 044 – 22381314 
        Website : www.nischennai.org  
        Email: nischennaisiddha@yahoo.co.in   
Name & address of the RRC-
ASU / PPC-ASU 
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* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * ** * * * *  
This filled-in ADR report may be sent within one month of observation /occurrence of ADR   
 
 
 
Date:                                                                              
Station:  
 
 
 
Signature of the Investigator: 
Signature of the Lecturer:                                                             
 
          
 
Date:      
Station: 
 
Signature of the Investigator: 
 
Signature of the Lecturer:                                                       Signature of the HOD 
Who Can Report?     
 Any Health care professionals like Siddha Doctors /  Nurses / Siddha 
Pharmacists / Patients etc.  
What to Report?  
 All reactions,  Drug interactions,  
Confidentiality  
 The patient’s identity will be held in strict confidence and protected to the 
fullest extent.  
 Submission of report will be taken up for remedial measures only not for 
legal claim  
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